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ABSTRACT: 
 
Aim: The chemokine system not only coordinates leukocyte migration in immunity 
and inflammation, but it is also implicated in the pathogenesis of many human 
diseases, including cancer. The expression of chemokines and their receptors is altered 
in many malignancies and leads to aberrant chemokine receptor signalling. Emerging 
evidence indicates that the tumour microenvironment has critical roles in all aspects 
of cancer biology, including growth, angiogenesis, metastasis and progression. One of 
the important representatives of this system are the chemokine ligand CXCL12 and its 
receptor, CXCR4 as they are most commonly found on human and murine cancer cells. 
Our aims are to study and understand if there are any differences in activation of 
signalling molecules in the downstream signalling cascades in CXC- chemokine 
receptors in different cell types, and to identify the importance of different effector 
proteins in migration of cells; the two proteins of interest include Protein Kinase C 
(PKC) and arrestins.  
 
Methodology: Experimentation was undertaken in MCF-7 breast cancer cells and 
Jurkat leukemic T-lymphocytes which both naturally express the chemokine receptor 
CXCR4. Small molecule inhibition and protein overexpression was used in chemotaxis 
and calcium release assays to measure cellular responses. Immunocytochemistry was 
used to determine the effect of protein blocking and protein overexpression on 
receptor internalisation, protein localisation and the formation of cellular structures 
associated with migration.  
 
Results: Inhibition of PKC has no effect on Jurkat cell migration, but it blocks MCF-7 
cell migration showing that there is a difference in the usage of PKC in different cell 
types. Arrestin 3 is important for migration in both suspension Jurkat cells and 
adherent breast cancer MCF-7 cells. 
 
Conclusion: Our study shows that CXCL12-induced migration may be arrestin 3 
mediated. We have also shown that activation of signalling molecules needed for 
CXCL12-induced migration can differ between different cell lines. Overall, the research 
in this thesis has identified potential signalling molecules that can be targeted to 
interfere with migration of cells.    
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ABBREVIATIONS: 
 
7TMRs 7 transmembrane receptors 
Ab Antibody 
ADP Adenosine diphosphate 
AML  Acute myelogenous leukaemia  
ANOVA Analysis of variance 
Arr2 siRNA Arrestin 2 siRNA 
Arr3 siRNA  Arrestin 3 siRNA  
ASK1 Apoptosis signalling kinase 1  
ATCC American Type Culture Collection 
AT1AR Angiotensin-II type 1a receptor  
ATP Adenosine triphosphate  
BRAK Breast and kidney-expressed chemokine  
BRET Bioluminescence resonance energy transfer  
BSA Bovine serum albumin 
Ca2+ Calcium ions 
CCL C-C motif chemokine receptor ligand 
CCR C-C motif chemokine receptor 
CHO.CCR5 Chinese hamster ovary cells, CCR5 stably transfected 
CO2 Carbon dioxide 
c-Src Cellular sarcoma non-receptor tyrosine kinase 
Crk Proto-oncogene c-Crk 
CXCL C-X-C motif chemokine receptor ligand 
CXCR C-X-C motif chemokine receptor 
DAG Diacylglycerol 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethyl sulfoxide 
EC50 Concentration at which 50% if an effect occurs 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor  
EGFP Enhanced green fluorescent protein  
ER Endoplasmic reticulum  
ERK Extracellular signal-regulated kinase  
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FAK Focal adhesion kinase  
FCS Foetal calf serum 
Gα G-Protein α subunit 
Gβγ G-Protein βγ subunit 
GDP Guanosine diphosphate 
GTP Guanosine triphosphate 
GEF Guanine nucleotide exchange factor 
GFP Green fluorescent protein  
GPCR G-Protein coupled receptor 
Grb2 Growth factor receptor-bound protein 2 
GRK G-protein couple receptor kinase 
GTP Guanosine triphosphate  
HEK293 Human embryonic kidney 293 cells 
HIV Human immunodeficiency virus 
HSCs Hematopoietic stem cells  
IC50 Concentration at which 50% inhibition occurs 
IP3 Inositol triphosphate  
IRS-1 Insulin receptor substrate-1  
IL Interleukin  
JAK Janus kinase 
JNK c-Jun N-terminal kinase  
MAPK Mitogen activated protein kinase 
MAP2K/MEK/MKK  MAPK kinase  
MAPKKK/MAP3K MAPK kinase 
MCF-7 Michigan Cancer Foundation-7 (breast cancer cell line) 
MKP7 MAPK phosphatase 7 
MMP Matrix metalloproteinases  
mRNA Messenger ribonucleic acid  
NFκB Nuclear factor kappa-light-chain-enhancer of activated B cells 
p38 p38 mitogen activated protein kinase 
PAK p21-activated kinase 
PAR-2 Protease-activated receptor-2 
PBL Peripheral blood lymphocyte 
PBS Phosphate buffered saline  
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PBMC Peripheral blood mononuclear cell 
pEGFP.C2 Plasmid DNA coding enhanced green fluorescent protein 
fused to C terminus 
pArr2.EGFP Plasmid DNA coding arrestin 2 fused to EGFP protein 
pArr3.EGFP Plasmid DNA coding arrestin 3 fused to EGFP protein 
pA2-Mut.EGFP Plasmid DNA coding arrestin 2-mutant fused to EGFP protein  
pH Pleckstrin homology  
PI Phosphoinositide 
PI3K Phosphoinositide 3-kinase 
PIP2 Phosphatidylinositol 4,5-biphosphate  
PKA Protein kinase A 
PKC Protein kinase C 
PKD Protein kinase D 
PLC Phospholipase C 
PMA Phorbol 12-myristate 13-acetate  
PTX Pertussis toxin  
Pyk-2 Proline-rich kinase-2 
Rac Ras-related C3 botulinum toxin substrate  
RAF Rapidly accelerated fibrosarcoma  
Ras Rat sarcoma GTPase 
Rho Ras homology GTPase 
RhoA Ras homolog gene family, member A 
RLuc Renilla Luciferase  
RPMI Roswell Park memorial institute medium 
RT-PCR Reverse transcription polymerase chain reaction  
SDF-1α Stromal cell-derived factor 1α 
SEM Standard error of the mean 
siRNA Small interfering ribonucleic acid 
STAT Signal transducer and activator of transcription 
TKs Tyrosine kinases  
TNFα Tumour necrosis factor alpha  
TPA 12-O-tetradecanolphorbol-13-acetate 
VEGF Vascular endothelial growth factor  
WT Wild type  
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CHAPTER 1: Introduction 
 
1.1. Introduction  
 
Tumour metastasis is the major cause of death in cancer patients who have suffered 
from a primary solid tumour. Recent evidence has shown that chemotactic signalling 
plays an important role in tumour invasion and spreading [1–3]. Studies have shown 
that selected chemokine receptors are often upregulated in a large number of common 
human cancers, including those of breast, lung, prostrate, colon and melanoma [4–8]. 
It is now believed that chemokines and their receptors play key roles in cancer cells 
migration and metastasis to different organs as they share similarities with leukocyte 
trafficking to sites of inflammation, including adherence of cells to endothelium, 
extravasation and migration from blood vessels [3,9]. Infiltrating leukocytes are not the 
only cells that respond to chemokine gradients in cancers; cancer cells can express 
chemokine receptors and respond to chemokine gradients [4,10].  
 
Investigation of chemokines and their receptors, and also the downstream signalling 
pathways that they couple to, may give us a better understanding of how and why 
particular chemokines contribute to cancer growth and metastasis [11]. Understanding 
the intracellular signal transduction events for specific receptors will help to identify 
therapeutic targets and to stop migration of cells, hence stop cancer cells to 
metastasize. Metastatic tumours generally have poor prognosis, as they are usually 
difficult to treat with current therapies. The molecular mechanisms underlying 
metastasis are still poorly understood due to complex network of chemokines and their 
receptors. The need for novel and specific anti-migratory therapies to treat chronic 
inflammatory and metastatic diseases is great. Therefore, a greater understanding of 
signal transduction events triggered by chemokine receptor activation is vital. 
 
CXCR4 is the chemokine receptor that is most commonly found in cancer cells [2,12]. 
It is found in tumour cells from at least 23 different types of human cancers of 
epithelial, mesenchymal and haematopoietic origin [1]. CXCR4 expression is generally 
a characteristic of malignant epithelial cell, as its expression is usually low or absent on 
normal breast, ovarian and prostate epithelia [1,4,13]. CXCR4 makes an interesting 
system to study not only due to its expression in numerous inflammatory diseases and 
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cancers but also its relevance to HIV research as a co-receptor to CC- chemokine 
receptor, CCR5 [14,15]. CXCL12 is a homeostatic chemokine and is a known ligand for 
CXCR4 [2]. It is found constitutively expressed in several organs such as lung, liver, 
skeletal muscle, bone marrow and also at sites of metastasis in breast and thyroid 
cancer, neuroblastoma and haematological malignancies [4,16,17].  
 
The binding of CXCL12 to CXCR4 initiates divergent signalling pathways downstream 
of ligand binding. This usually results in a variety of responses, including chemotaxis, 
increase in intracellular calcium and gene transcription [11,18]. Although the 
chemokine system has been heavily studied over the last two decades and is considered 
to be highly promising drug targets for immunological and inflammatory diseases, 
current studies have not yet resulted in many new therapeutics. This is likely due to a 
complexity of the chemokine system, that is characterised by redundancy, pleiotropy 
and differences among species [19].  
 
1.2. G-Protein Coupled Receptors (GPCRs)  
 
G-protein coupled receptors (GPCRs,) also known as 7 Transmembrane Receptors 
(7TMRs), represent the largest family of membrane receptors. GPCRs mediate most of 
our cellular responses to hormones, neurotransmitters and environmental factors, and 
so they have been comprehensively studied over these past three decades due to their 
great potential as therapeutic targets for a broad spectrum of diseases [20]. GPCRs in 
vertebrates are commonly divided into 5 families based on their sequence and 
structural similarity [21]: rhodopsin (family A), secretin (family B), glutamate (family 
C), adhesion and Frizzled/Taste2. The rhodopsin family is the largest and most diverse 
family, and the members are characterised by conserved sequence motifs [20]. It is 
apparent that they share similarities in structures, with the exception of functionally 
unique conserved motifs, but the level of sequence homology is relatively low [22], 
resulting in individual GPCRs having unique combinations of signal-transduction 
activities involving multiple G-protein subtypes, and G-protein-independent signalling 
pathways and complex regulatory processes [20].  
 
G-proteins, also known as guanine nucleotide-binding proteins, are coupled to the 
receptor through its C-terminus segment and the third intracellular loop [23]. G-
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proteins are important signal transducing molecules in cells, known to function as 
molecular switches inside cells, and there are two classes of G-proteins; the first class 
function as monomeric small GTPases, while the second class function as 
heterotrimeric G-protein complexes [24]. Heterotrimeric G-proteins are the molecular 
switches that turn on intracellular cascades in response to the activation of the GPCRs 
by extracellular stimuli, hence, they have a crucial role in defining the specificity and 
temporal characteristics of the cellular response [25]. All GPCRs couple to 
heterotrimeric G-proteins (Gα, Gβ/Gγ subunits), which become activated upon ligand 
binding and transduce signals via a wide range of intracellular molecules. Studying the 
ability of GPCRs to activate selective signalling pathways according to the 
conformation stabilised by bound ligands and the duration of GPCR signalling is often 
important and a more complex concept in the GPCR field [26].  
 
GPCRs identify many extracellular signals and transduce them to heterotrimeric G-
proteins, which further transduce these signals intracellularly to appropriate 
downstream effectors. These receptors play an important role in various signalling 
pathways, including chemotactic migration, by processing complex but subtle 
physiological environments and transduce signalling into intracellular responses such 
as cell survival and/or proliferation, chemotaxis, intracellular calcium release and gene 
transcription [2,27]. 
 
1.3. Chemokines and chemokine receptors  
 
Chemokines are a family of chemotactic cytokines and can be induced by inflammatory 
cytokines, growth factors and pathogenic stimuli [28–30]. Chemokine signalling is 
involved in gene transcription, in cell invasion, motility, survival and can coordinate 
cell movement during inflammation and homeostatic transport of haematopoietic 
stem cells (HSCs) and leukocytes such as lymphocytes and dendritic cells [1,31]. 
Directed cell migration of cells that express the appropriate chemokine receptor occurs 
along a chemokine gradient, causing them to move towards a high concentration of 
chemokines [32–34]. Chemokines compromise a superfamily of about 50 human 
ligands and there are at least 20 seven-transmembrane-domain chemokine receptors, 
belonging to the family Class A G-protein coupled receptors (GPCRs) [29,35].  
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Chemokines and their receptors have been divided into four families on the basis of 
the pattern of first two cysteine residues that are within the amino terminus in the 
ligands; CXC-, CC, C- and CX3C- [1]. They have been classified as being ‘homeostatic’ – 
controls leukocyte navigation during immune surveillance, and ‘inflammatory’ – 
controls cell recruitment to sites of infection and inflammation [36]. Chemokines are 
key regulators of leukocyte migration that ensure localisation  of cells to tissues, 
depending on their activation state and inflammatory state of the tissue [37]. The 
profile of chemokine-receptor expression on an individual cell is determined by its 
family, stage of differentiation, and microenvironmental factors such as chemokine 
concentration, presence of inflammatory cytokines and hypoxia [1].  
 
Most chemokines bind to multiple receptors and the same receptor may bind to more 
than one chemokine; for example, CXCL12 binds to CXCR4 and ACKR3 (also known as 
CXCR7), and CCL3 binds to CCR1, CCR2 and CCR5 [1,2]. Differences in cytoplasmic 
signalling are governed by factors such as the number of phosphorylation sites the 
receptor expresses [15]; for example, CCR5 possesses 7 sites while CXCR4 possesses 21. 
Comparisons and distinctions between the structures and functions of different 
chemokines and GPCR families are important for identifying cell-, receptor- or family- 
specific signalling. This information can then be used to identify therapeutic targets for 
inflammatory diseases and cancers where specific chemokine receptors are known to 
be involved. Different chemokines can elicit other important cellular responses [38,39] 
and/or activate different pathways to elicit a particular response [40,41]. 
 
Chemokines have an important role in the development and maintenance of innate 
and adaptive immunity [12]. Chemokines and their receptors play a key role in 
development and homeostasis as well as in several inflammatory diseases and cancers. 
Chemokines also have a role in embryonic development [42,43]; current research 
involves chemokine receptor CXCR4 in the maternal decidualized stromal cells [44].  
 
Chemokine receptors are critical regulators of cell migration in terms of immune 
surveillance, inflammation and development [45].They share a seven transmembrane-
spanning α-helix architecture, separated by alternating intracellular and extracellular 
loop regions, that accommodates signal propagation from across biological membranes 
[20,46].  
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Most tumours express chemokine receptor CXCR4 at higher levels than normal 
corresponding tissue (table 1); other receptors include CCR6 and CX3CR1 which are 
overexpressed in colorectal and pancreatic cancer [47,48], CXCR2 and CCR10 in 
melanoma [49,50] and CXCR6 in prostate cancer [51].  
 
Table 1.1: Expression of CXC chemokine receptor 4 (CXCR4) in cancer metastasis 
 
The expression of CXCR4 on malignant epithelial cells implies that the CXCR4/CXCL12 
pathway plays an important role in directing the metastasis of CXCR4+ tumour cells to 
organs that express CXCL12, which include lymph nodes, lungs, liver and bones [2]. 
Several CXCR4+ cancers metastasize to the bones and lymph nodes in a CXCL12-
dependent manner, in which, the bone marrow can provide a protective environment 
for tumour cells [9,64].  
 
Due to high levels of expression of CXCR4 in cancer cells coupled with the fact that 
CXCR4 in cancer metastasis leads to a poor prognosis, the CXCR4/CXCL12 signalling 
axis serves as an attractive target for cancer metastasis therapy, hence, using and 
understanding CXCR4 as a model system is important and interesting.  
 
 
Cancer cell type Site of metastasis References 
Breast Lung, Lymph Node [4,52] 
Prostate Bone [53] 
Non-small cell lung Pleural Space [54] 
Ovarian Peritoneum [13,55] 
Pancreas Liver, Lung [56] 
Melanoma Lymph Node [57] 
Neuroblastoma Bone, Bone Marrow [58] 
Oesophageal Lymph Node, Bone 
Marrow 
[59] 
Colorectal Liver [60] 
Osteosarcoma Lung [61] 
Renal Adrenal Glands, Bone [62] 
Gastric Peritoneum [63] 
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1.4. Activation of chemokine receptors 
 
Upon activation by a chemokine ligand, the GPCR chemokine receptor undergoes a 
conformational change and activates the G-proteins. Heterotrimeric G-proteins are 
composed of three subunits; α, β and γ, and their switching function depends on the 
ability of the G-protein α subunit (Gα) to cycle between an inactive GDP-bound 
conformation that is primed for interaction with an activated receptor, and an active 
GTP-bound conformation that can modulate the activity of downstream effector 
proteins [25]. Conformational changes in the cytoplasmic domains of the receptor and 
activation of G-proteins  leads to  the dissociation of G-protein subunits β/γ (Gβγ) 
dimer from Gα [65]. Both these subunits complexes then act upon their downstream 
effectors and thereby initiate intracellular signalling processes, such as changes in the 
cytoskeleton and transcription of genes involved in cell migration and survival [66]. 
Protein kinase C (PKC), phosphoinositide 3-kinase (PI3K), Rho and mitogen-activated 
protein kinase (MAPK) are amongst the examples of proteins that may be activated by 
chemokine receptors [66,67]. One of the major functions of chemokines is lymphocyte 
trafficking, and one of the pathways that mediates this process involves PI3K activation. 
PI3K can be activated by both Gα and Gβγ subunits. PI3K activation can result in the 
phosphorylation of several focal adhesion components such as proline-rich kinase-2 
(Pyk-2), focal adhesion kinase (FAK), paxilin and adaptor protein, proto-oncogene c-
Crk (Crk), which has been found to play a role in mediating cell migration [2].  
 
Receptor desensitisation and internalisation by agonist-dependent phosphorylation of 
the C-terminal tail of the GPCR by G-protein receptor kinases (GRKs) then occurs to 
refract from continued stimuli [68]. Receptor phosphorylation subsequently promotes 
binding of arrestin, which sterically block further interaction with G-proteins and 
mediate receptor internalisation  through clathrin coated pits [69]. Endocytosis of a 
GPCR can lead to either lysosomal degradation or recycling back to the cell surface and 
resensitisation [11]. After signal propagation, the GTP of Gα-GTP is hydrolysed to GDP 
and Gα becomes inactive (Gα-GDP), which leads to its re-association with the Gβγ 
dimer to form the inactive heterotrimeric complex [27].  
 
There are many classes of Gα subunits and some examples include GSα (G stimulatory), 
Giα (G inhibitory), GOα (G other), Gqα and G12/13α and they behave differently in the 
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recognition of the effector molecule but share a similar mechanisms of activation 
[70,71]. As discussed in section 1.2, GPCRs have been best characterised with respect to 
signalling through  heterotrimeric G-proteins, primarily involving Giα subunit (figure 
1.1) [11]. With the use of pertussis toxin (PTX), it has been shown that most CXCR4 
activation is dependent on activation of Giα proteins as PTX, which ADP-ribosylates 
Giα, specifically inhibits GPCR/Giα coupling [66]. Giα proteins mainly inhibit adenylate 
cyclase and transduce signals through tyrosine kinases such as Src [72]. 
 
 
Figure 1.1 (Adapted from O’Hayre et al. (2008) [11]): Simplified overview of GPCR signalling which 
represents the most upstream events after receptor activation common to all GPCRs. Receptor 
activation and signalling via heterotrimeric G-proteins, which were activated by exposing important 
motifs such as the DRY motif (TM-III) [73], followed by desensitisation through GRKs and arrestins. 
GPCRs may have complex regulatory processes by numerous unique combinations of signal-
transduction involving multiple G-protein subtypes, and G-protein-independent signalling pathways 
via downstream effectors such as GRKs and arrestins. 
 
Chemokine activity is often determined by measuring the transient increase in 
cytosolic free calcium [74]. Ligand stimulation results in an increase in intracellular 
calcium, which is not only achieved via Gqα, but also via the dimeric complex, Gβγ. Gβγ 
subunits are crucial for the activation of many chemokine-induced pathways. Gβγ 
triggers PLC activation and formation of inositol triphosphate (IP3) and diacylglycerol 
(DAG), resulting in mobilisation of calcium from intracellular stores ultimately leading 
to the regulation of processes such as gene transcription, cell migration and cell 
adhesion [70]. The other major Gβγ activated pathway is PI3Kγ [72]. There is growing 
23 
 
evidence that Gβγ are responsible for signalling to chemotaxis downstream of various 
chemokine receptors [75–78]. 
 
The signalling and physiological response downstream of receptor activation can vary, 
depending on chemokine/receptor combination, the cell type and pathophysiological 
state [38,39]. Chemokine receptors have also recently been shown to be able to 
transduce signal through G-protein-independent pathway, for example, the arrestin-
dependent pathway, through the formation of signalling scaffolds that can lead to 
specific and independent cellular responses [79–81], hence the precise downstream 
events leading to signalling are still poorly understood despite extensive study of 
chemokines and chemokine receptors.  
 
As discussed above, malignant cells from different cancer types have different profiles 
of chemokine-receptor expression, but CXCR4 is most commonly found. Upon 
activation of chemokine receptor CXCR4, a number of signalling pathways are 
activated leading to a variety of biological responses [82] and they can happen via both 
G-protein signalling [66] and G-protein-independent signalling involving other 
proteins such as arrestins and Janus kinases (JAK) [83,84]. Other than emerging 
evidences showing CXCR4 is involved in inflammation and cancer [12], the complexity 
in regulation of CXCR4 signalling makes CXCR4 an interesting system to study and 
understand. 
 
1.5. CXCR4/CXCL12 in cancer metastasis  
 
The involvement of chemokines and their receptors in cancer, particularly metastasis, 
has been firmly established [1,4,85] and this is not surprising as tumour metastasis 
shares many similar features with normal cell migration and leukocyte trafficking 
[10,85,86]. Chemokines and their receptors provide directional cues for leukocytes or 
tumour cells for migration and metastasis [87]. The role of chemokines and their 
receptors in cancer may involve providing directional cues for migration, shaping the 
tumour microenvironment and/or providing growth signals (figure 1.2) [88–90].  
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Figure 1.2 (Adapted from Koizumi et al. (2007) [9]): A simplified example of molecular mechanisms 
of CXCR4/CXCL12 signalling axis that promotes the development of peritoneal carcinomatosis. 
Gastric tumour cells that express CXCR4 are preferentially attracted to the peritoneum cavity where 
CXCL12 is produced abundantly. CXCL12 produced in a paracrine manner may also shape tumour 
microenvironment for the gastric tumour cells to grow and survive [9,91,92].  
 
CXCR4 selectively binds to CXC chemokine, CXCL12, which is also known as Stromal 
Cell Derived Factor 1 (SDF-1) [21,30]. CXCR4 and CXCL12 play an important 
homeostatic function by mediating the homing of progenitor cells to the bone marrow 
and regulating their mobilisation into peripheral tissues upon injury or stress [93]. 
CXCR4 has been intensively studied in different autoimmune diseases, including 
rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis, and cancers 
as it is overexpressed in more than 23 cancers and it is involved in leukocyte chemotaxis 
in inflammatory conditions [3,94,95]. In malignant cancerous tumours, signalling by 
CXCR4 might be transiently increased by factors such as hypoxia [96], vascular 
endothelial growth factor (VEGF) [97] and oestrogen [98].  
 
Mukarami et al. (2002) and Cardones et al. (2003) have demonstrated that 
overexpression of CXCR4 in luciferase-expressing B16 murine melanoma cell results in 
enhanced lung metastasis following tail-vein injection in wild-type mice [99,100]. 
Under stress conditions, endothelial CXCL12 may trigger the arrest of circulating cells 
by activating adhesion molecules in a manner analogous to the process described in 
leukocytes [50]. Several groups have shown that CXCL12 stimulates cancer cell 
proliferation [100,101], migration and invasion [102,103].  
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Following binding of CXCL12, CXCR4 activates several key migratory pathways, 
proliferative, and survival signalling pathways, including MAPK pathway, PI3K-Akt 
pathway, and JAK/STAT pathway [104–106]. There is emerging evidence that in 
addition to their role in signal termination, arrestins are able to function as signal 
transducers by activating pathways such as Akt, PI3K and MAPK and also, to act as 
scaffolds for a number of signalling molecules, resulting in chemotaxis [107–109]. 
 
Although there is numerous research on chemokines and chemokine receptors in 
cancer and tumour metastasis, the exact mechanisms of action are not well understood, 
and the underlying complexity of the chemokine network makes it difficult to 
characterise them. Considering some of these complexities, it may be crucial to 
elucidate more precise mechanisms, and thus enable the development of better cancer 
therapeutics to stop migration of cells.  
 
1.6. Downstream signalling transduction via CXCR4/CXCL12 signalling axis 
 
Upon CXCL12 binding to the CXCR4 receptor, signalling is transduced by activation of 
the heterotrimeric G-proteins, which is composed of Gα, Gβ and Gγ subunits. As 
discussed previously in section 1.4, both Gα and Gβγ complexes subsequently induce 
chemokine signalling and regulate a wide variety of downstream pathways that 
ultimately lead to the physiological responses, such as chemotaxis [110]. Chemokine 
receptor signalling in migration and survival/proliferation occurs through the class IB 
PI3Kγ, which activates Rac and subsequently PAK (p21-activated kinase). Activation of 
FAK, pyk2 and other tyrosine kinases are also important in this process [111]. Anti-
apoptotic signalling, transcription of growth and proliferation-related genes, and 
transcription of matrix metalloproteinases (MMPs) involved in migration and 
remodelling the microenvironment are all transduced downstream from Akt, 
extracellular signal-regulated kinase (ERK), PKC and tyrosine kinase, such as Src, 
activation [70,112]. CXCR4 signalling has also been shown to involve the Ras-activated 
signalling pathway, several src-related kinases such as Src, Lyn, Fyn and Lck, T-cell 
activating molecule ZAP-70, and vav and small GTPases [2].  
 
Signal transduction is terminated by phosphorylation of the receptor at its cytoplasmic 
tail by GRKs and subsequent receptor desensitisation and internalisation. The GTP is 
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rapidly hydrolysed to GDP resulting in re-association of the receptor and the trimeric 
G-protein complex; the inactive form of the α-subunit (Gα-GDP) is regenerated, thus 
allowing reassociation with a Gβγ dimer to form the “resting” G-protein, which can 
again bind to a GPCR and await activation.  
 
As discussed previously , there are different classes of Gα subunits; GSα, Giα, GOα, Gqα 
and G12/13α. Giα G-proteins  inhibit adenyl cyclase as well as activate the Src family of 
tyrosine kinases while GSα subunit stimulates adenyl cyclase [2,66]. Giα has also been 
shown to stimulate MAPK activation whereas G12α is associated with low molecular 
weight G-proteins  such as Rho and Ras [71,113].  
 
Gqα family acts via PLC, and activate phosphatidylinositol-specific phospholipases, 
which hydrolyse phosphatidylinositol 4,5-bisphosphate (PIP2) to generate two second 
messengers, IP3 and DAG. IP3 and DAG increase the intracellular concentrations of 
free calcium and activate a number of protein kinases, including PKC and MAPK 
[70,114,115].   
 
Researchers have shown that CXCR4 may not just be limited to Giα, but CXCR4 can 
also couple to Gqα, GOα and GSα [116,117]. Following CXCL12 binding, CXCR4 promotes 
the recruitment of GRKs that induce site-specific phosphorylation at the C-terminus, 
which results in binding of arrestins to the phosphorylated receptor [66]. Arrestin 
recruitment leads to the uncoupling of CXCR4 from G-protein and it induces receptor 
internalisation [84]. Other than GRKs, PKC has also been observed to directly 
phosphorylate the CXCR C-tail in different serine residues leading to receptor 
desensitisation and  internalisation [66,68,118]. In addition to their classical role as 
signal terminators, the recruitment of arrestins to CXCR4 also serves as a scaffold for a 
number of downstream effectors, MAPK and ERK, and can function as a signal 
transducer itself by activating pathways such as Akt, PI3K and NF-κB, which can lead 
to numerous cellular responses such as cell migration [81,109].  
 
CXCL12-induced migration is mediated by PI3K and as discussed previously, PI3K can 
be activated by Gβγ and also Gα subunits [70]. PI3K activation can result in 
phosphorylation of several focal adhesion components such as pyk-2, Crk-associated 
substrate (p130Cas), FAK, paxillin, Nck, Crk and Crk-L, activating intracellular 
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signalling cascades [111,119]. PI3K can also lead to the activation of serine-threonine 
kinase Akt, which has been found to play a key role in tumour cell survival [120]. Other 
than Akt, both p38 and ERK1/2 have also been implicated in tumour cell survival and 
CXCL12 can promote cell survival through PI3K and MAPK cascades without cell cycle 
progression [121]. Genes associated with cell survival can be up-regulated upon CXCL12 
exposure via post-translational inactivation of the cell death machinery and an 
increased transcription of cell survival-related genes [122].  
 
Activation of the JAK/STAT pathway by CXCR4 has been proposed to be G-protein-
independent, where CXCL12 induces the transient association of JAK2 and JAK3 with 
CXCR4 and leads to the activation and nuclear translocation of a number of STAT 
proteins [83,123].  
 
GPCR oligomerization has been hypothesised to play a role in modulating GPCR 
signalling, and both CXCR4 homodimers and heterodimers have been reported [124]. 
The functional consequences of homo- or heterodimerization are currently poorly 
understood. However, homodimerization of CXCR4 has been suggested to be 
necessary to result in JAK/STAT signalling pathway as well as in enhancement of 
response to CXCR4 to CXCL12 [66,116]. Even though there are still gaps in knowledge 
of oligomerization of CXCR4, it should be considered that oligomerization may be a 
way of regulating signalling while also allowing for alternative signalling pathways 
upon activation [125].  
 
Given the complex role CXCR4 plays in diverse processes from development to cancer 
metastasis, CXCR4 is a very intriguing therapeutic target. Due to the intricacy of the 
roles and network of chemokines and its chemokine receptors, a detailed basic 
understanding of chemokine-receptor activation is still lacking, even though ample 
body of work has been done in delineating potential pathways that mediate specific 
effect, including chemotaxis. Understanding the downstream signalling cascades of 
CXCR4 upon CXCL12 activation leading to chemotaxis should provide insight into 
potential therapeutic targets in this pathway.  
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1.6.1. Downstream effector: Protein Kinase C (PKC) 
 
Protein kinase C (PKC) is a family of protein kinase enzymes that are involved in 
controlling the function of other proteins through the phosphorylation of hydroxyl 
groups of serine and threonine amino acid residues on these proteins, which is a 
fundamental component of cell signalling resulting in crucial roles in most signal 
transduction cascades [126,127]. PKC activation is dependent on the generation of 
second messengers DAG and calcium ions, and play important roles in several signal 
transduction cascades including cell growth and proliferation and also immunological 
regulation [128–130].  
 
The PKC family consists of 15 isoforms in humans and the isoforms are divided into 
three subfamilies, based on their second messenger requirements [131]. The three 
subfamilies consist of (i) conventional (or classical – α, βI, βII, γ), which require calcium 
ions, DAG and phosphatidylserine for activation, (ii) novel (δ, ε, η, θ), which require 
only DAG and not calcium ions for activation and (iii) atypical (ζ, ι, λ), which require 
neither calcium ions nor DAG for activation [130].  
 
All PKCs consists of a regulatory domain and a catalytic domain hitched together by a 
hinge region. The catalytic region is highly conserved among the different isoforms, 
and the regulatory region results in the second messenger requirement differences 
between the isoforms, which are usually similar within the classes [132].  
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Figure 1.3 (Adapted from Steinberg et al. (2008) [132]): Domain structure of PKC isoforms 
- showing autoinhibitory pseudosubstrate (PS) segment, C1 domains, C2 domains and kinase core; the 
activation loop, turn motif, and hydrophobic motif phosphorylation sites are indicated. Crystal 
structures of C1B, C2 and kinase domains are also shown above.  
 
Figure 1.3 shows the domain structure of different PKC isoforms. PKCs have a 
conserved kinase domain and more variable regulatory domains. All PKC regulatory 
domains have a pseudosubstrate motif amino terminal to the C1 terminal [132]. 
 
As a tool for activating PKC, phorbol esters, derived from oil of the seed of the plant 
Croton tiglium, are much more potent than DAG: they bind PKC with a higher affinity 
than DAG, and are not readily metabolised [133]. In conventional and novel PKCs, 
tandem C1 domains are the molecular sensors of phorbol 12-myristate 13-acetate 
(PMA)/DAG whereas in single atypical PKC, C1 domain does not bind DAG and PMA 
[134]. The C2 domains function as calcium-dependent phospholipid binding modules 
in conventional PKCs but not in novel PKCs as novel PKCs do not bind calcium. This 
difference in C2 domain structure reflects the distinct pharmacology in conventional 
and novel PKC isoforms [132]. PKCs are regulated by two distinct mechanisms: by 
phosphorylation, which regulates the active site as well as the subcellular localisation  
of the enzyme and by second messengers, which promote PKC’s membrane 
association, resulting in pseudosubstrate exposure [135]. Understanding the structural 
determinants that dictate PKC isoform-specific differences is important in studying 
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protein-protein interactions, cellular signal transduction and downregulation of 
receptors [132,136].  
 
PKC are central components in intracellular networks that regulate a vast number of 
cellular processes including migration [137], and one example is that PKCε regulates 
neuroblastoma cell motility. Downregulation of PKCε by siRNA suppresses both basal 
and 12-O-tetradecanoylphorbol-13-acetate (TPA) induced migration [138]. Another 
study linked PKC to regulation of the actin cytoskeleton, thereby affecting cellular 
migration and indicating that integrins are crucial mediators both upstream and 
downstream of PKC in inducing morphological changes [139].  
 
The choice of ligand for receptor activation depends on the cell type and its 
receptor/signalling pathway signature. Hence, studying PKC activation in 
chemokine/receptor signalling cascades may be important in understanding the 
downstream signalling cascades which would lead to cell growth and/or proliferation, 
gene transcription and regulation of immunological responses [126,136]. Studying PKC 
signalling and the role of PKC in chemokine/receptor systems can be done by using 
small molecule inhibitors to see how phosphorylation by these enzymes would affect 
different processes; examples of inhibitors that were used are included in table 1.2.  
 
Agonist binding to a chemokine receptor activates catalytic cascades of intracellular 
mediators which greatly amplify the response to an extracellular stimulus. This then 
causes functional uncoupling of the heterotrimeric G-protein from the receptor and 
rapid homologous desensitisation  consequently occurs [140]. On a molecular level, 
phosphorylation of ligand-occupied receptors by GRKs or by second messenger 
activated kinases such as PKC, have been shown to attenuate receptor interaction with 
G-proteins [141,142]. Recently, it has been revealed that there is increased 
phosphorylation of Ser339 of CXCR4 following CXCL12 stimulation [143]. Increased 
phosphorylation of Ser339 was also observed following epidermal growth factor (EGF) 
or phorbol ester treatment, suggesting that this may be a potential PKC 
phosphorylation site. GRK2 [14,144] and GRK6 [145,146] have been implicated in the 
involvement of phosphorylation of CXCR4 upon CXCL12 activation. However, GRK2 
has also been suggested to negatively regulate CXCR4 downstream signal transduction, 
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possibly via MAPK [147]. These data imply that there may be multiple kinases 
regulating CXCR4 in response to CXCL12 stimulation.  
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Table 1.2: Small-molecule active site inhibitors  
 
Compound Type of Inhibitor Determination of binding IC50 References 
GF109203X Conventional, Novel PKC 
inhibitor 
Non-selective bisindolylmaleimide inhibitor which has 
been used effectively in platelets, Swiss 3T3 fibroblasts and 
macrophages. 
α – 8.4 nM 
βI – 18 nM 
δ – 210 nM 
ε – 132 nM  
ζ – 2.8 µM 
(10 µM ATP) 
[148,149] 
Staurosporine Conventional, Novel PKC 
inhibitor 
Non-selective indolocarbazoles inhibitor which is also a 
model apoptosis inducer. 
cPKC & PKCε – 11 – 
32 nM 
[150] 
Rottlerin Conventional, Novel PKC 
inhibitor 
Non-selective mitochondrial uncoupler that depolarises the 
mitochondrial membrane potential, reduces cellular ATP 
levels. Although there was extensive published 
documentation to support the use of rottlerin as a selective 
PKCδ inhibitor, there has been more controversy in the 
literature over this claim.  
α, β, γ – 30 – 42 µM 
δ – 3 – 6 µM  
ε, η, ζ – 80 – 100 µM 
 
[151,152] 
CID755673 PKD inhibitor Blocks PKD-mediated protein transport. PKD1 – 180 nM 
PKD2 – 280 nM 
PKD3 – 227 nM 
PKC - >10 µM  
[153,154] 
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1.6.2. Downstream effector: Arrestins 
 
Arrestins are a small family of proteins important for regulating signal transduction 
from GPCRs [109,155]. In response to ligand stimulation, GPCRs activate heterotrimeric 
G-proteins as discussed above. GRK phosphorylation would then occur to prepare the 
activated receptor for arrestin binding [156,157]. Arrestin binding to the receptor blocks 
further G-protein-mediated signalling and targets receptors for internalisation  [158]. 
Other than the classical role as signal terminators, arrestins can also act as signalling 
scaffolds for cytoskeletal signalling molecules and redirect signalling to alternative G-
protein-independent pathways [152,153]. Plasma membrane translocation of arrestins 
to activated receptors and its signalling capabilities even without G-protein-receptor 
complex strongly suggest the existence of specific receptor conformation for arrestin 
binding [161,162].  
 
Arrestins are highly flexible proteins that can assume several distinct conformations, 
and in receptor-bound conformation, arrestins have a higher affinity for a subset of 
partners which explains how receptor activation regulates arrestin-dependent 
signalling via arrestin recruitment to GPCRs [163]. Arrestin family contains four 
members; the two visual subtypes found in retinal photoreceptors are arrestin 1 and 
arrestin 4 and the two non-visual subtypes are arrestin 2 and arrestin 3 (also known as 
β-arrestin-1 and -2), which are ubiquitously expressed in all cells [164].  
 
Studying the regulation of intracellular signalling pathways is important as this 
mechanism regulates aspects of cell motility, chemotaxis and apoptosis but it is still 
poorly understood. The mechanism may involve recruitment, activation and 
scaffolding of cytoplasmic signalling complexes via two multifunctional adaptor and 
transducer molecules, arrestins 2 and 3 [109]. According to numerous studies, there are 
two hypotheses regarding the requirement for arrestins in chemotaxis; firstly, 
desensitisation and recycling of chemotactic receptors which are essential for 
maintaining polarity and secondly, arrestins serve as signalling scaffolds to localise 
molecules involved in cytoskeletal reorganisation [165–167].  
 
Growth factors, neuropeptides, peptides, hormone and proteases promote cell 
migration through the activation of their cognate GPCRs or receptor tyrosine kinases 
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[168]. Chemotaxis  mediated by 2 different Gqα-coupled receptors, the protease-
activated receptor-2 (PAR-2) and the angiotensin-II type 1a receptor (AT1AR), were 
shown to be arrestin-dependent [169,170]. In both examples, arrestin-dependent 
chemotaxis does occur independent of G-protein coupling.  
 
According to several studies, arrestins may also trigger signal transduction, including 
the activation of Src family tyrosine kinases [108], PI3K/Akt [171], insulin receptor 
substrate-1 (IRS-1) [172], RhoA [173,174] and NFκB [175–178]. In recent years, there is 
emerging evidence that arrestins serve as scaffolds for numerous signalling networks, 
including the MAPK pathway [179]. The new paradigm implies that arrestins not only 
mediate desensitisation of G-protein signalling, but also act as a signal transducer. An 
example of an arrestin-dependent signalling system is activation of MAPK, ERK 
[169,170]. Studies indicate that arrestins can sequester active ERK1/2 at the leading 
edge during PAR2-induced cell migration [180]. It is implied that this facilitates specific 
phosphorylation of proteins involved in chemotaxis, but such targets have not been 
identified.  
 
Similarly, it has been demonstrated that arrestin 3 scaffolds c-Jun N-terminal kinases 
1/2 (JNK1/2) with its upstream kinases MKK4 and MKK7, which phosphorylate 
different residues in its activation loop [181]. Activation of p38 signalling cascades is 
also arrestin-dependent, although a direct scaffolding complex of arrestin and p38 has 
not yet been established [182–184]. CXCL12-induced chemotactic response, which is 
arrestin-dependent, is sensitive to p38 inhibitors [182] but these data only show some 
cellular functions regulated by arrestins involving p38, even though direct arrestin-
dependent p38 phosphorylation is not documented. There are a few hypotheses as how 
arrestins act as scaffold proteins: they form a discrete signalling module, they localise 
the grouped components to specific areas in the cell and they insulate the active kinases 
from de-phosphorylation by phosphatases [109]. Arrestin-mediated activation of ERK 
appears to be linked to the function of arrestins in mediating endocytosis of receptors 
in clathrin-coated pits, for example, arrestin scaffolded signalling complex has been 
implicated in internalisation with class B receptors such as AT1AR and ultimately is 
found in endocytic vesicles together with the receptor [185].  
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Figure 1.4 (Adapted from Lefkowitz et al. (2005) [109]): Signal transduction by GPCR. (A) Classical 
pathway where the active form of the receptor stimulates G-proteins and is rapidly phosphorylated 
by GRKs, which leads to arrestin recruitment and termination of signal by desensitisation. (B) New 
theory on the role of arrestins which not only mediate desensitisation of G-protein signalling but also 
act as signal transducers. Another theory of arrestins’ new role is arrestin as a scaffolding protein (not 
shown in diagram).  
 
The requirement of arrestins in chemotaxis downstream of multiple receptors suggests 
that arrestins play a key role in apoptosis [186–189], inflammation [81,179,190] and 
mediating cell migration [169,174,191,192]. Arrestins can sequester MAPK but a specific 
role for arrestin-dependent sequestration of MAPKs in chemotaxis has not been 
identified. Arrestins are versatile, regulators of receptor desensitisation, trafficking and 
signalling through their ability to interact with numerous binding components (figure 
1.4) [193], but there is still a number of unresolved questions regarding arrestins’ 
functions that needs to be addressed. It is crucial to determine the different biological 
roles of GPCR-arrestin conformations and how those are regulated via other signalling 
mechanisms.  
 
1.6.3. Downstream effector: Mitogen Activated Protein Kinases (MAPK) 
 
Mitogen activated protein kinases (MAPKs) are highly conserved family of 
serine/threonine protein kinases involved in a variety of important cellular processes 
[194]. MAPK networks are important for the transmission of extracellular signals into 
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appropriate intracellular responses. They are evolutionarily conserved kinase modules 
that link extracellular signals to the machinery that controls fundamental cellular 
responses such as growth, proliferation, differentiation, migration and apoptosis 
[195,196]. Therefore, dysregulation of theses cascades may be involved in the induction 
and progression of diseases such as cancer, diabetes, autoimmune diseases and 
developmental abnormalities [197–199].  
 
MAPK pathways are comprised of a three-kinase core modules consisting of a MAPK 
kinase (MAPKKK or MAP3K) that phosphorylates and activates MAPK kinase (MAP2K, 
MEK or MKK) that in turn phosphorylates and dramatically increases the activity of 
one or more MAPKs [200]. Conventional MAPKs include the ERK1/2, the JNK1-3, the 
p38 isoforms (p38α, β, γ, and δ) and ERK5 [200,201]. A broad range of extracellular 
triggers including mitogens, cytokines, growth factors and environmental stressors 
stimulate the activation of one or more MAPKKKs via the receptor-dependent or -
independent mechanisms [194]. While most MAPKKK, MEK and MAPKs display a 
strong preference for one set of substrates, there is significant cross-talk in a stimulus 
and cell-type dependent manner [201,202]. 
 
Abnormalities in the MAPK signalling are important in the development and 
progression of cancer [203–208]. Many MAPK pathways participate in stress signalling, 
and generally, stress comes in many forms, including hypoxia, detachment from 
substrate, inflammation and metabolic stress, and thus, large input of the network is 
important for sensing and processing stress signals [195]. This shows that there is an 
emergence in importance for stress-activated kinases in cancer, inflammation, DNA 
damage response and apoptosis [202,204].  
 
ERK1/2 cascade is the best studied and first MAPK pathway elucidated which is 
dysregulated in approximately one-third of all human cancers [195,209]. In the 
ERK/MAPK pathway, ERK1/2 is activated upon phosphorylation by MEK1/2, which is 
activated when phosphorylated by activator, Raf (Raf-1, B-Raf and A-Raf) (figure 1.5) 
[195,210].  
 
37 
 
 
Figure 1.5 (Adapted from CST Signalling Technology ‘MAP Kinase Signalling Resources’): An 
overview of MAPK signalling. Schematic representation of the MAPK cascades showing a range of 
extracellular triggers leading to the phosphorylation of the three core kinases and consequently result 
in signalling of cellular processes including growth, proliferation, differentiation, motility and 
apoptosis [195,210]. 
 
ERK/MAPK pathway is activated by a wide variety of receptors involved in growth and 
differentiation including receptor tyrosine kinases (TKs), integrins and ion channels 
and this pathway is activated by GPCRs using different set of adaptors and binding 
proteins including, Ras, Rap1 (GEF proteins), Raf (MAPKKK), MEK1/2 (MAPKK) and 
ERK (MAPK) as some examples (figure 1.5) [210,211]. Activated ERK can regulate targets 
in the cytosol and also translocate to the nucleus where it phosphorylates a variety of 
transcription factors regulating gene expression [195].  
 
Studies into the mechanisms of oncogenic B-Raf signalling, a member of the Raf kinase 
family of growth signal transduction protein kinases, have highlighted novel 
mechanisms by which Raf kinases activate MEK/ERK signalling which differs from the 
classical Ras pathway [212]. B-Raf isoform is mutated at a high frequency in human 
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cancer, and mutation of V600E drastically elevates B-Raf kinase activity and its ability 
to activate the ERK pathway [212,213], but this does not apply to all cases.  
 
Wan et al. (2004) studies showed that a few mutations do not elevate B-Raf kinase 
activity but they are able to activate MEK/ERK signalling [214]. This shows the 
specificity of the signalling and also, led to the discoveries that B-Raf heterodimerizes 
with Raf-1 and can signal through Raf-1 [213,215]. This indicates intricate complexities 
in MAPK signalling network, and hence, huge gaps of knowledge in this area to be 
filled.  
 
Activated Raf activates MEK1/2 by phosphorylating serine 218 and 222 in the activation 
loop, and they are activated by specific Raf isoforms [216,217]. Activated ERKs 
phosphorylate numerous cytoplasmic and nuclear targets, including kinases, 
phosphatases, transcription factors and cytoskeletal proteins, and these signalling 
depends on the particular cell type with high specificity and reliability [218,219]. These 
factors may be linked to temporal differences in the strength and localisation of ERK 
within the cell [220].  
 
Accumulating evidence have suggested that affecting ERK pathway can be a potential 
therapeutic drug target for cancer development and progression, particularly Ras, Raf 
and MEK [203,207]. PD98059 is a potent MEK inhibitor (IC50 = 2-7 µM), and it acts by 
binding to the inactivated form of MEK, and therefore preventing its phosphorylation 
by cRAF or MEK kinase [221]. It inhibits cell growth and proliferation in acute 
myelogenous leukaemia (AML) cell lines [222]. Activating ERK pathway not only play 
a role in cell proliferation, but it also potentially plays key roles in angiogenesis, cell 
migration, invasion and metastasis [223,224]. A study by Sharma et al. (2003) 
suggested that there is evidence of cross talk activation between MAPKs, in particular 
between ERK1/2 and p38, in co-ordinating cellular migration and proliferation in 
epithelial corneal wound healing and possibly general wound healing [225]. 
 
p38 MAPKs are members of the MAPK family that are activated by a variety of 
environmental stresses and inflammatory cytokines. p38 is required for the expression 
of tumour necrosis factor alpha (TNFα) and interleukin-1 (IL-1) during inflammatory 
responses, and characterisation of the function of p38 has been facilitated by using 
39 
 
SB203580, an anti-inflammatory drug that is a p38 inhibitor [226,227]. The p38 MAPK 
signalling pathway allows cells to interpret a wide range of external signals and respond 
appropriately by generating a plethora of different biological effects, and this diversity 
and specificity in cellular outcomes depends on the activation and regulation of core 
kinases, cross talk between signalling pathways and the nature of p38 MAPK substrates 
[228–230]. In addition to modulating cell survival, p38 MAPK is an interesting target 
to study tumour metastasis as there are literature supporting that p38 MAPK plays an 
essential role in modulation of cell migration and invasion [202]. 
 
SB203580 is a selective p38 MAPK inhibitor with IC50 values of 50 and 500 nM for p38 
and p38β2 respectively [231]. SB203580 is a pyridimyl imidazole compound that is 
widely used due to its specificity in binding p38α and p38β but not p38δ and p38γ 
[232]. A great interest has developed in p38 inhibitors as they have been shown to have 
significant therapeutic benefits in inflammation such as arthritis, gastritis and 
pulmonary inflammation [233–235]. The recruitment process is a cascade of events, 
and hence intervening at one step will inevitably affect downstream events. This 
creates possibilities to investigate p38 MAPK signalling cascades, which may result in 
subsequent signalling events such as chemotaxis, using p38 inhibitors. Cara et al. 
(2001) suggested that there is a role of p38 MAPK in neutrophil chemotaxis and that 
p38 may be involved in the regulation of actin assembly [236]. Chemokines induce 
morphological changes in leukocytes that include rearrangement of cytoskeleton, to 
execute chemotaxis and there are literature showing the p38 inhibition may cause 
significant reduction effects upon downstream events of neutrophil emigration and 
chemotaxis [237–239].  
 
Another study [240] suggested that p38 MAPK is a key signalling molecule for Ras, 
particularly H-Ras, induced cell motility. Ras is a protein superfamily of small GTPases 
and its expression has been suggested as a marker for tumour aggressiveness of breast 
cancer, including degrees of invasion [241,242]. Cancerous mutations in MAPK 
pathways have been shown to frequently affect Ras and B-Raf in the extracellular signal 
regulated kinase pathway [195]. The specific function of p38 MAPK depends on cell 
type, stimuli and also the isoform that is activated. The p38 MAPK pathway is usually 
activated in response to diverse stimuli and mediated by components upstream of  p38, 
and in this case, it is H-Ras [202,240].  
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As discussed previously, there is emerging evidence that show expanding roles of 
arrestins as scaffolds and adapters in GPCR signalling and trafficking and one of the 
signalling pathways that falls into this category is MAPK pathway which involves 
interaction with molecules such as Src, Raf, ERK, apoptosis signal-regulating kinase 1 
(ASK1) and JNK3 [180,183]. Arrestins function as MAPK scaffolds, bringing three 
components of MAPK signalling modules, such as JNK3, MKK4 and ASK1 (figure 1.6) 
[243]. All four arrestins were found to interact with these MAPK components but only 
arrestin 3 was needed for JNK3 phosphorylation, and interestingly, phosphorylated, 
active JNK3 can only be detected in association with arrestin 3 and is excluded from 
the nucleus [179,243]. These findings show that arrestin-activated kinase is only found 
in the cytoplasm [244].  
 
 
Figure 1.6 (Adapted from De Wire et al. (2007) [179]): Arrestins scaffolds for signalling. The 
arrestin scaffold for c-Jun N-terminal kinase (JNK) 3 activation. JNK3 and apoptosis signalling kinase 1 
(ASK1) bind to arrestin 3 directly, whereas MAPK kinase 4 (MKK4) binds indirectly. Willoughby et al. 
(2005) recently showed that there is a possibility of fourth partner in this signalling module, MAP 
kinase phosphatase 7 (MKP7) and seem to be a negative regulator in an arrestin signalling module 
[245]. 
 
Metastatic cancer occurs through the orchestrated proliferation, migration, adhesion 
and differentiation of cells and MAPKs have been suggested to play a role in the 
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development and progression of cancer [202,229,240].The role of MAPKs in cancer is 
as pleiotropic as cancer itself, and there are studies that demonstrate the involvement 
of MAPKs in migration of cells [205,236] but the downstream signalling cascades after 
MAPK phosphorylation are still poorly understood.  
 
1.7. Actin remodelling in migration of cells  
 
Chemotaxis is a directed movement of a cell toward a chemical signal, and it requires 
a chemoattractant, which interacts with a cell surface receptor, to coordinate cell 
polarisation and motility in the direction towards the higher chemoattractant ligand 
concentration gradient [246]. Chemotactic signals then implicate in rearrangement of 
the actin cytoskeleton, leading to the formation of a leading edge, de-adhesion of the 
trailing edge and subsequent migration toward the chemoattractant [32,33]. Cell 
migration is a highly integrated and intricate multistep process which contributes to 
tissue repair and regeneration, and also drives disease progression in cancer [32,63]. 
Chemotaxis requires polarization of the cell such that it is actively moving in one 
direction the cell must effectively be sending opposing signals to each pole [34,247].  
 
Actin assembly events involve nucleation, uncapping, severing and bundling of 
filaments, and for the cell to move along a substrate, there must be a certain amount 
of traction exerted, which is accomplished through the formation and disassembly of 
focal contacts at the leading edge and contractile forces of myosins bound to actin 
filaments [248,249]. The proteins that regulate all these events must be tightly 
controlled, including arrestins that are involved in spatial regulation of actin assembly 
and bundling proteins [81].  
 
Actin cytoskeletal reorganisation and cell migration requires arrestins to act  
downstream of numerous receptors, which led to a great deal of interest in the 
mechanism by which arrestins can regulate these processes [81]. In addition to their 
classical, canonical role of arrestins as signal terminators in GPCR signalling, arrestins 
also act as signalling scaffolds, helping to localise molecules involved in cytoskeletal 
reorganisation and trigger cellular responses resulting in migration and chemotaxis as 
mentioned previously [81,179].  
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Cancer cells and immune cells both migrate toward a chemoattractant and upon 
binding of the ligand to its chemokine receptor, this would consequently lead to 
downstream signalling events, resulting in migration of cells. Arrestins have been 
hypothesised to regulate receptor turnover and hence, affect actin assembly. At the 
high end of chemokine concentration gradient, the cell will be surrounded and thus 
experiencing a uniform concentration of chemokine. At these high concentrations, 
arrestin mediated desensitisation and internalisation aid in receptor turnover [81]. As 
the cell moves along a gradient, the concentration of chemokine ligands gets lower and 
only receptors closest to the gradient will then be activated. At these concentrations, 
arrestin mediated actin assembly would then dominate, allowing the cell to move 
toward the source of the chemoattractant [18]. As the concentration of chemokine 
increases, cells may stop migrating due to loss of the ability to elaborate extensions or 
when they reach a region of uniform attractant, causing a loss of directional cue for the 
cell to migrate towards [250].  
 
 
Figure 1.7 (Adapted from Aman et al. (2009) [250]): Cell migration towards 
chemoattractant. (a) Cellular extensions are polarized in the direction of migration in response to a 
gradient chemoattractant, usually chemokine or growth factor ligands (blue). (b) Cells stop migrating 
when they lose the ability to elaborate extensions (left) or they reach a region of uniform attractant 
(right).  
 
PAR2 and AT1AR are two GPCR examples that have been demonstrated to promote the 
formation of arrestin scaffolds containing key actin assembly proteins [174,180]. These 
studies support a model where active arrestin signalling is involved in chemotaxis and 
showing actin assembly within a cell is the driving force behind directed cell movement 
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and can be regulated, both directly and indirectly, by various proteins [251]. Scott et al. 
(2006) have also identified that actin-bundling protein filamin as a novel arrestin 
binding partner, which suggest multifaceted roles for arrestins in actin assembly and 
cytoskeletal reorganisation and ultimately leads to migration of cells [251]. 
Additionally, proteins that are commonly associated with actin assembly include PI3K, 
RhoA, cofilin and these components can also be regulated by arrestins [170,174,186].  
 
Various studies have suggested that arrestin-dependent ERK1/2 activation is important 
for actin reorganisation and/or chemotaxis, and the role of filamin in filapodia 
formation is well established [251,252]. There are also studies suggesting that myosin 
binds actin filaments at the back of migrating cells, stabilising polarity by inhibiting 
protrusion formation while at the leading edge, myosin is important for sensing 
changes. They can also help in promoting traction, through contractile forces exerted 
on the extracellular matrix and helping the cell moves along its substrate [253–256].  
 
The identification of actin-binding and regulatory proteins as arrestins-binding 
partners suggests that arrestins scaffolding function is important for actin 
reorganisation, and ultimately resulting in cell migration. Research into the molecular 
basis of cell migration has progressed rapidly over the past few years, and even though 
key regulatory molecules have been identified, mechanisms of how cells migrate are 
still poorly established, for example, how cells establish and maintain their polarity and 
how cells recognise their targets [32]. Emerging evidence showing the involvement of 
arrestins in actin cytoskeleton reorganisation complicates the studying of spatially 
segregated component processes across the cell [18,81]. There are so many gaps of 
knowledge regarding this area that is yet to be explored to further understand the 
molecular mechanisms of migration of cells.  
 
1.8. Concluding remarks  
 
The dysregulation of migration is causative to numerous diseases and understanding 
why this is happening is critical for the identification of potential therapeutic targets 
for these diseases. The chemokine receptor CXCR4 is directly linked to inflammatory 
and metastatic diseases, but it is also widely characterised intra- and extracellularly, 
together with CCR5, due to its involvement as a co-receptor in HIV viral entry [15,257]. 
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This makes CXCR4 a particularly good model system in which the specifics of cell 
migration can be determined with numerous cell lines available which endogenously 
express CXCR4 (Jurkat, MCF-7 cells). Even though there is a large amount of research 
which has been undertaken over the last decade to establish signalling events 
governing pathways downstream of activated CXCR4, there are still so many 
unresolved areas to be explored.  
 
There is evidence, as mentioned previously, that support that PKC phosphorylation, 
other than GRK2 phosphorylation, triggers signalling events upon chemokine receptor 
activation, but whether they directly affect migration of cells is still unknown. There 
are a large number of diverse inhibitors available for use to study the downstream 
signalling upon CXCR4/CXCL12 activation. Investigation of CXCR4 signalling using 
cell permeable small molecule inhibitors enables us to study and identify potential 
targets and to map out the possible pathways that may lead to migration of cells. The 
inhibitors can be used to clarify cell specific type from receptor specific type events and 
to identify targets which may have an effect in migration of cells.   
 
The other proteins of interest are arrestins, which are known to be involved in cell 
migration via chemokines/chemokine receptors signalling but the molecular 
mechanisms of this signalling event have not been well characterised. Knockdown and 
overexpression of proteins in this case can reveal potential drug targets and to further 
understand the role of these proteins in downstream signalling cascades, resulting in 
migration of cells.  
 
Studying migration of cells is important because in cancer, metastatic tumours have 
poor prognosis, as they are usually difficult to treat with current therapies. 
Understanding how chemokine/chemokine receptor influence cells to migrate and 
how tumour metastasize would create possibilities to beneficial therapeutic targets and 
help combat different diseases. This thesis will outline interactions of proteins of 
interest in CXCL12-induced signalling events upon CXCR4 activation.   
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1.9. Research objectives  
 
Pharmacological disruption of chemokine receptor mediated processes represents a 
path to therapeutic intervention in many diseases. Even though chemokines and their 
receptors have been of interest for over a decade, there is still lack of understanding of 
chemokine receptor mediated signalling. CXCR4 signalling events are still poorly 
understood due to the large number of protein interactions which may potentially be 
involved.  
 
The introduction demonstrated the possible proteins that may be involved in CXCR4 
signalling event, which may lead to migration of cells, such as PKC and arrestins. PKC 
and arrestins are involved in chemokine/chemokine receptor signalling event but the 
relationship between them are still not clearly defined. Identifying if these events occur 
simultaneously and/or are dependent on the specifics of the chemokine receptor 
signalling, for example, if they are receptor or cell type specific, is critical. By using 
small molecule inhibitors to disrupt protein signalling and comparing effects in 
downstream signalling cascades, this may give understanding of chemokine receptor 
signalling and the potential to identify novel receptor specific targets for disruption of 
chemokine receptor function.  
 
In order to achieve this, the experimentation that was undertaken included:  
 
CHAPTER 3: Chemokines have redundant actions on target cells and promiscuous 
receptor usage [258]. The interaction of chemokines with their receptors is 
characterised by considerable promiscuity, however, some groups have found different 
receptor signalling and trafficking responses to individual chemokines, suggesting that 
there may be biased signalling [259,260].  
 
Hypothesis: We hypothesised that different chemokines illicit different signalling 
pathway responses in different cell types.  
 
Research undertaken: Characterisation of CXCR4 by investigation into the 
chemotactic responses stimulated by various chemokines which would result in 
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signalling events in suspension leukemic T-lymphocytes Jurkat cells and adherent 
breast cancer MCF-7 cells.  
 
CHAPTER 4: Woerner et al. (2005) showed that there was increased phosphorylation 
of Ser339 following SDF stimulation and that increased phosphorylation of Ser339 was 
also observed following phorbol ester treatment [143], suggesting that this may be a 
potential PKC phosphorylation site of CXCR4.  
 
Hypothesis: We hypothesised that PKC phosphorylation contributes to CXCL12-
induced migration in different cell types.  
 
Research undertaken: Investigation and determination of the role of PKC in CXCL12-
induced migration in Jurkat and MCF-7 cells to see if there is a difference in effects in 
different cancer cell lines. Comparison of effects of PKC inhibition in different 
chemokine receptors and different cell lines – to see whether they are cell-type or 
receptor-type specific.  
 
CHAPTER 5: Over the past few years, it has been increasingly appreciated that 
arrestins not only play a role in desensitisation of activated GPCRs but they have also 
emerged as multifunctional adaptor/scaffold proteins that dynamically assemble a 
wide range of multiprotein complexes in response to stimulation of most 7TMRs [261]. 
Arrestins are not only required for the desensitisation of several chemokine receptors, 
including CXCR4, but they have been found to help orchestrate the cellular signals to 
chemotactic signals [14,18,144].  
 
Hypothesis: We hypothesised that arrestins is important in CXCL12-induced 
migration in different cell types.  
 
Research undertaken: Exploring the role of arrestins in CXCR4/CXCL12 signalling 
axis as they have been shown to be essential regulators in chemotaxis, but the 
mechanisms of their involvement in this particular signalling axis are still not yet 
established. Here, knockdown and overexpression of arrestins by using DNA plasmids 
were undertaken to confirm the role of arrestins in cell signalling events, including 
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migration, of Jurkat and MCF-7 cells in relation to CXCL12-induced migration via 
CXCR4 chemokine receptor.  
  
48 
 
CHAPTER 2: Materials and methods 
 
2.1. Cell lines and tissue culture 
 
2.1.1. Acute monocytic leukaemia cell line THP-1 
 
THP-1 cells were originally obtained from the peripheral blood of a one-year old male 
donor with acute monocytic leukaemia [262]. THP-1 cells have been shown to be good 
study models as they endogenously express a number of human chemokine receptors. 
THP-1 cells were obtained from American Type Culture Collection (ATCC) 
(Teddington, UK) and were cultured using RPMI (Corning, Biosera) supplemented 
with 10% v/v Foetal Calf Serum (FCS) (Invitrogen), 100 µM non-essential amino acids 
(Gibco) and 2 mM glutamine (Invitrogen).  
 
2.1.2. Leukemic T-cell lymphoblasts Jurkat 
 
Jurkat cells are T lymphocytes originally derived from one-year old male with acute T 
cell leukaemia [263]. They have been proven to be useful and good model systems to 
study as they express various chemokine receptors susceptible to viral entry, 
particularly HIV. This cell line is a suitable transfection host, and it has high expression 
of CXCR4. Jurkat cells were obtained from American Type Culture Collection (ATCC) 
(Teddington, UK) and were cultured using RPMI (Corning, Biosera) supplemented 
with 10% v/v FCS (Invitrogen), 100 µM non-essential amino acids (Gibco) and 2 mM 
glutamine (Invitrogen).  
 
2.1.3. CHO.CCR5 stably transfected Chinese Hamster Ovary fibroblasts 
 
Chinese Hamster Ovary (CHO) cells have proven to be easy to culture and are relatively 
large in size, which makes them good specimens for microscopy. CHO.CCR5 cells were 
acquired from Professor J. McKeating (Nuffield Department of Medicine, Oxford). 
CHO cells were transfected with pcDNA3 encoding Human CCR5 and selected for 
stable expression in 10% FCS DMEM (Corning, Biosera) with 2 mM glutamine in the 
presence of selective aminoglycoside antibiotic G418 (Invitrogen) (400 µg/mL). 
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CHO.CCR5 cells were cultured in complete DMEM (10 % FCS, 100 µM non-essential 
amino acids and 2 mM glutamine) supplemented with 400 µg/ mL G418 (Invitrogen) 
to ensure continued expression of CCR5.  
 
2.1.4. Human breast adenocarcinoma cell line MCF-7 
 
MCF-7 cells are a widely studied epithelial cancer cell line derived from breast 
adenocarcinoma [264]. It is the best characterised and most widely use of all the human 
breast cancer cell lines.  MCF-7 cells can be used to study various pathways that are 
involved in cell migration, including PI3K and MAPK involvement. MCF-7 cells were 
cultured in DMEM (Corning, Biosera) supplemented with 10% v/v FCS (Invitrogen), 
100 µM non-essential amino acids (Gibco) and 2 mM glutamine (Invitrogen). 
 
2.1.5. Routine tissue culture procedures for cell lines  
 
Both adherent and suspension cell lines were cultured in 75 cm2 flasks (Corning) in a 
humidified atmosphere at 37oC with 5% CO2. At 80-95% confluence, adherent cells 
were removed from the flask by adding PBS (1.5 mM potassium phosphate monobasic, 
3 mM potassium phosphate dibasic, 150 mM NaCl; pH 7.2) supplemented with 2.5 mM 
EDTA and incubating them for 5 – 10 minutes at 37oC with 5% CO2. Flasks were then 
gently agitated to suspend cells. Cells were centrifuged at 1800g for 5 minutes and 
resuspended in relevant growth medium after which cell density was determined 
microscopically with the use of a haemocytometer. Cells were then used for 
experimentation or passaged by reducing cell density by 80-90% and continued 
culturing. The suspension cell line, THP-1, was cultured for 3 days or until cell density 
reached 6 X 104/ mL at which point cell density was reduced to 2 X 104/ mL by removal 
of suspended cells and addition of fresh media. Jurkat cells was cultured for 2 days or 
until cell density reached 1 X 106/ mL at which point cell density was reduced to 1 X 105/ 
mL by removal of suspended cells and addition of fresh RPMI. Where cells were to be 
cryopreserved, 1 X 106 cells were centrifuged, resuspended into 1 mL of 10% v/v DMSO 
in FCS and transferred into cryotubes. To prevent damage by freezing these cryotubes 
were first wrapped in tissue and chilled to -80oC for at least 24 hours before long term 
storage in liquid nitrogen at -196oC. 
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2.2. Small molecule and oligomeric inhibitors 
 
A complete list of the small molecule and protein inhibitors is detailed below. 
 
Table 2.1. PKC inhibitors  
Inhibitor Supplier Stock Conc/ 
Vehicle 
Working Conc 
GF109203X Tocris 23.5 mM DMSO 5 µM 
Staurosporine  Tocris 100 µM water 10 nM  
Rottlerin Tocris 2 mM ethanol  4 µM 
CID755673 Tocris 4.6 mM ethanol  11 µM 
 
Table 2.2. Kinase inhibitors 
Inhibitor Supplier Stock Conc/ 
Vehicle 
Working Conc 
PD98059 Abcam 25 mM DMSO 25 µM 
SB203580  Tocris 25 mM DMSO 10 µM 
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2.3. Chemokine ligands 
 
A complete list of the chemokine ligands used is detailed below. 
 
Table 2.3. Chemokine ligands used for experiments; CF- calcium flux, CTX – 
chemotaxis assays, IF- immunofluorescence, FC- flow cytometry, WHA – wound 
healing assays. Note: All chemokine ligands stock was made up in purified water  
 
Chemokines Supplier Chemokine 
receptor 
Concentrations 
used 
CCL1 (I-309) PeproTech CCR8 10 nM CTX 
CCL2 (MCP1) PeproTech CCR2 0.01 – 100 nM CTX 
CCL3 (MIP-1α, 
isoform D26A) 
CCL3 (2-70) - a gift from 
L. Czaplewski (British 
Biotech) [265]  
CCR1, CCR5 100 nM CF 
1 nM CTX 
100 nM IF 
CCL5 
(RANTES) 
PeproTech CCR1, CCR3, 
CCR5 
0.01 – 100 nM CTX 
CCL8 (MCP2) PeproTech CCR2, CCR5 1 nM CTX 
CCL23 (MIP-3) PeproTech CCR1 10 nM CTX 
CXCL8 (IL-8) A gift from K. Schmitz 
(TU Darmstadt) [266] 
CXCR1, CXCR2 50 nM CF 
CXCL11 (IP-9) PeproTech CXCR3 0.01 – 100 nM CTX 
CXCL12 (SDF1-
α) 
PeproTech CXCR4, 
ACKR3 
10 nM CF 
0.001 – 10 nM CTX 
10 nM IF 
15 nM FC 
10 nM WHA 
CXCL12 N-His 
Tag (SDF1, 
isoform a) 
A gift from K. Schmitz 
(TU Darmstadt) 
CXCR4 1 – 500 nM CF 
0.01 – 500 nM CTX 
CXCL14 
(BRAK) 
PeproTech Orphan 
receptor 
0.001 – 300 nM 
CTX 
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2.4. Antibodies 
 
A complete list of primary and secondary antibodies is detailed below. 
 
Table 2.4. Primary and secondary antibodies used for experiments;                              
IF -Immunofluorescence, FC- Flow Cytometry, WB- Western Blot 
 
Primary Antibody Supplier Assay use Dilution factor 
HEK/1/85a/7a rat 
monoclonal 
A gift from J.A. 
McKeating 
(Oxford) 
IF 1:100  
CXCR4 (125G5): sc-12764 Santa Cruz 
Biotechnology 
IF 1:100 
Human CXCR4 Antibody  R&D systems  FC 1:2000 
β-Arrestin-1/2 Antibody 
(H-290): sc-28869 
Santa Cruz 
Biotechnology 
WB 1:100-1:1000 
β-Arrestin-1/2 Antibody 
(21-B1): sc-53781 
Santa Cruz 
Biotechnology 
WB 1:100 – 1:1000 
β-Arrestin-1/2 (A-1): sc-
74591 
Santa Cruz 
Biotechnology 
WB 1:500  
β-Actin (C4): sc-47778 Santa Cruz 
Biotechnology 
WB 1:1000 
 
Secondary Antibody Supplier Assay use Dilution factor 
Goat anti-mouse FITC  Sigma- Aldrich IF 1:1000 
Goat anti-mouse TRITC Sigma- Aldrich IF  1:1000 
Goat anti-mouse IgG 
(H+L), F(ab’)2 fragment, 
CF 647 
Sigma- Aldrich FC 1:200  
Anti-mouse IgG 
horseradish peroxidase  
Sigma- Aldrich WB 1:5000 
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2.5. Plasmid DNA 
 
The pEGFP arrestin 2/3 plasmids were produced by cloning relevant arrestin DNA into 
HindIII/ ApaI digested pEGFP-N1 plasmids (Clontech, Saint-Germain-en-Laye, France) 
as described and validated and were a gift from E. Kelly (Bristol). In addition to pEGFP 
arrestin 2 and pEGFP arrestin 3 plasmids, arrestin 2 mutant (arrestin 2-V53D) plasmid 
was made by point mutation, where the valine residue was substituted for an aspartic 
acid as described [267]. pEGFP.C2 plasmids (Clontech) were used as mock transfection 
controls. 
 
Figure 2.1: Mammalian arrestin 2 amplified by PCR and cloned into HindIII/ApaI digested pEGFP-N1 
(Clontech). DNA plasmids were gift from E. Kelly (Bristol).  Arrestin 2 insert can be excised by HindIII/ 
ApaI digestion. EGFP is on the C-terminal end of arrestin 2 [268].  
 
The CXCR4 coding sequences without a stop codon were amplified using sense and 
antisense primers harbouring unique HindIII and BamHI sites. The fragments were 
then subcloned in frame into HindIII/BamHI sites of a humanized form of Renilla 
Luciferase (hRluc)-N3 vector as described and validated [269]. The arrestin3/GFP10 
construct was prepared from the vector pcDNA3.1-GFP10. CXCR4-RLuc3 and h-
arrestin3-GFP10 plasmids were kindly provided by N. Heveker (Montreal). 
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2.5.1. Preparation of plasmid DNA from bacterial colonies 
 
Chemically competent E. coli DH5Αf1 (Invitrogen) were transformed with the required 
plasmid DNA to allow amplification of plasmids. 50 µL of E. coli DH5Αf1 were thawed 
in iced-water and gently broken down with a pipette to form homogenous slurry. 1-5 
µg of the relevant plasmid DNA construct was added to the E. coli and incubated for 
30 minutes in the iced-water bath. Transformation was then induced by heat shocking 
the bacteria at 42oC for 90 seconds before 2 minutes incubation in iced-water. 1 mL of 
pre-warmed Lennox Broth (LB) was added to the heat shocked E. coli before incubation 
in rotary shaker at 37oC, 200 rpm for 2 hours. 25 µL of the resulting bacterial broth was 
spread on prepared LB agar plates containing kanamycin (ThermoFisher Scientific) 
(100 µg/ mL) or ampicillin (ThermoFisher Scientific) (100 µg/ mL) and grown, upside-
down, overnight at 37oC. Viable colonies were picked then incubated overnight in 20 
mL LB containing kanamycin (ThermoFisher Scientific) (100 µg/ mL) or ampicillin 
(ThermoFisher Scientific) (100 µg/ mL). The cultured bacterial broth was then frozen 
down at -80oC or used for plasmid amplification described below.  
 
2.5.2. Amplification of plasmid DNA 
 
Plasmid DNA was purified using the Qiagen MIDI kit (Qiagen). The relevant 
transformed DH5Αf1 strain was grown overnight and the bacterial broth was 
centrifuged at 6000g for 10 minutes. The supernatant was removed and 4 mL of P1 
buffer containing RNAse was added to resuspend the pellet. 4 mL of P2 buffer was 
added to the suspension then agitated sufficiently to turn the solution a uniform blue 
before incubation for 5 minutes at room temperature. 4 mL of P3 buffer was added to 
precipitate protein then the solution was centrifuged at 6000g for 10 minutes. 
Supernatant was then filtered through an activated Qiagen column and flushed with 
10 mL QC wash buffer. Plasmid DNA was then eluted from the column with 5 mL QF 
elution buffer. 3.5 mL of propan-2-ol was added to the eluent to precipitate DNA during 
centrifugation for 1 hour at 6000g. The supernatant was removed, and the pellet 
washed in ethanol before being dried and dissolved in 500 µL deionised water. Plasmid 
DNA purity was determined by gel electrophoresis after digestion with HindIII/ EcoRI 
restriction enzymes (Promega). Plasmid DNA concentration was determined by 
Nanodrop spectrometer system (ThermoFisher Scientific).  
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2.6. Electroporation transfection  
 
2.6.1. Electroporation transfection of plasmid DNA 
 
Cells were counted and centrifuged to give 3 X 106 cells per tube. Cells were 
resuspended in 250 µL HEPES buffered electroporation solution (HEPES 20 mM, NaCl 
137 mM, KCl 5 mM, Dextrose 6 mM, Na2HPO4 0.7 mM, pH 7.5) to which 5 µL t-RNA 
(Sigma Aldrich) and 2 µg plasmid DNA was added in 0.2 cm transfection cuvette 
(Sigma Aldrich) before electroporated, using AMAXA Nucleofector 2b (Lonza), at the 
relevant setting (X-005 for Jurkat cells). 500 µL of simple RPMI was added to the 
mixture in the cuvette and the contents were incubated at room temperature for 10 
minutes. The solution was removed with a pipette and transferred to pre-incubated 9.5 
mL T-25 flasks (Corning) containing relevant growth media. Cells were incubated for 
24 hours before assessment of transfection by flow cytometry.  
 
2.6.2 Electroporation transfection of siRNA  
 
Scrambled siRNA (Dharmacon) was used as a negative control and it has the same 
nucleotide composition but not the same sequence as the test siRNA. Scrambled siRNA 
is used to distinguish sequence-specific silencing from non-specific effects. Scrambled 
siRNA can be used as a negative control as it is designed to not target any known gene 
in the cell. Stock concentration of 2 µM scrambled siRNA diluted in 1X siRNA 
suspension buffer was made up and used in working concentrations of 50 nM in 
transfection assay. 5 nmol ARRB1 and ARRB2 ON-TARGETplus siRNA reagents 
(Dharmacon) were prepared using Dharmacon siRNA resuspension protocol as stock 
concentration of 20 µM in 250 µL 1x RNAase free siRNA buffer (Qiagen). Concentration 
of siRNA was verified using the Nanodrop spectrometer system (ThermoFisher 
Scientific) and 1 in 100 dilution aliquots were prepared to limit the number of freeze-
thaw cycles.  Cells were counted and centrifuged to give 3 X 106 cells per tube. Jurkat 
cells were resuspended in 200 µL HEPES buffered electroporation solution (HEPES 20 
mM, NaCl 137 mM, KCl 5 mM, Dextrose 6 mM, Na2HPO4 0.7 mM, pH 7.5) to which 50 
nM siRNA reagents (50 nM scrambled siRNA as negative control) was added into each 
respective 0.2 cm transfection cuvettes (Sigma Aldrich) before electroporated at the 
relevant setting (X-005 for Jurkat cells). 500 µL of simple RPMI was added to the 
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mixture in the cuvette and the contents are incubated at room temperature for 10 
minutes. The solution was removed with a pipette and transferred to pre-incubated 9.5 
mL T-25 flasks (Corning) containing relevant growth media. Cells were incubated for 
48 hours before assessment of transfection and experimental procedures.  
 
2.7. Chemical transfection 
 
2.7.1. Chemical transfection of plasmid DNA  
 
1 X 105 MCF-7 cells were seeded in 24-well plate in 1 mL of growth medium 24 hours 
before transfection to ensure optimal confluency of 70 – 90%. 2 µg of respective DNA 
was diluted in 100 µL of simple DMEM. 4 µL of Turbofect transfection reagent 
(ThermoFisher Scientific) was added to the diluted DNA and mixed immediately by 
pipetting or vortexing. Mixture was then incubated at room temperature for 20 
minutes before 100 µL of the transfection reagent/ DNA mixture was added drop-wise 
to each well in the 24-well plate. The plate was then gently rocked to achieve even 
distribution of the complexes immediately before the plate was incubated at 37oC, 5% 
CO2. The plate was then be analysed after 24 hours using an inverted Leica DMII 
fluorescence microscope with GFP filter cube to ensure effective transfection and to be 
used for different assays. In wound healing assays, transfection efficiency was measured 
by counting an area of cells in overlay of fluorescence images, taken with the GFP filter 
cube, in the bright-field images. Transfection efficiency was then quantified by 
fluorescence cells divided by total cells in the area and multiply by 100%.  In calcium 
flux and transwell migration assays, transfection efficiency was gauged by measuring 
fluorescence at excitation/ emission of 485/520 nm using BMG Labtech Fluorostar 
Optima plate reader (BMG Labtech, Germany).  
 
2.7.2. Chemical transfection of siRNA  
 
Scrambled siRNA (Dharmacon) was used as a negative control and it has the same 
nucleotide composition but not the same sequence as the test siRNA. PKCα and PKCζ 
siRNA (Qiagen) were prepared and diluted to working concentrations in RNAase free 
water (Qiagen). Concentration of siRNA was verified using the Nanodrop spectrometer 
system (ThermoFisher Scientific). MCF-7 cells were counted and centrifuged to give 2 
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X 105 cells per well in 24-well plates. Cells were transfected using Lipofectamine 
RNAiMax reagent (ThermoFisher Scientific). Diluted 50 nM of PKCα and PKCζ siRNA 
(Qiagen) were added to dilute the Lipofectamine RNAiMax reagent (ThermoFisher 
Scientific) in a 1:1 ratio. Mixture was then incubated for 5 minutes at room temperature. 
The siRNA-lipid complex was then added to cells and cells were incubated for 48 hours 
before assessment of transfection and experimental procedures.  
 
2.8. Calcium flux 
 
Adherent cell lines were harvested by addition of PBS containing 2.5 mM EDTA. THP-
1 cells were collected, centrifuged at 1800g for 5 minutes. All cells were re-suspended 
in calcium flux buffer (137 mM NaCl, 5 mM KCl, 2 mM MgCl2, 1.5 mM CaCl2, 10 mM 
HEPES pH 7.4, 25 mM D-glucose). Cells were spun down and washed twice more in 
calcium flux buffer before resuspension in 1 mL of calcium flux buffer to give a 
concentration of 1 X 106 cells/mL. Cells were then treated with the relevant 
concentrations of inhibitor and loaded with the membrane permeable 
acetoxymethylester conjugated form of Fura-2 (Invitrogen). Fura-2 AM is a cell 
permeant, intracellular calcium indicator. Fura-2 AM ester is a non-polar calcium 
insensitive compound that freely crosses the cell membrane. Once inside the cell, 
ubiquitous cellular esterases hydrolyse the compound to a calcium ion sensitive 
negatively charged moiety, Fura-2. Due to its anionic charge, Fura-2 can no longer 
cross the cell membrane and is essentially trapped within the cell. Fura-2, upon binding 
to Ca2+, exhibits a shift in its absorption or excitation peak from 338 nm to 366 nm. 
 
2 µM of Fura-2 AM was added to all cell samples before incubation at 37oC, 5% CO2 for 
30 minutes. Cells were then centrifuged at 1800g and washed three times with 1 mL 
calcium flux buffer. 100 µL of cell was added to each well of a black, opaque reader 
plate (ThermoFisher Scientific) before calcium flux assessment by addition of different 
agonist injected directly into the wells using BMG Labtech Fluorostar Optima plate 
reader (BMG Labtech, Germany). Changes in calcium release were determined by 
ratiometric analysis of alteration in fluorescence sequentially stimulated by 340 nm 
and 380 nm light detected at a fixed emission frequency of 510 nm. Data were recorded 
and analysed using BMG Optima software and were represented as ratio of the 
fluorescence detected, which is directly related to the amount of intracellular calcium. 
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The change in fluorescence was calculated as the difference between the pre-
stimulated 340 nm/ 380 nm ratio and the peak value after stimulation.  
 
2.9. Migration assays  
 
2.9.1. Chemotaxis migration assay using ChemoTX plate  
 
Chemotaxis assays for Jurkat cells were carried out in ChemoTX 5 µm pore chemotaxis 
plates (Neuroprobe Inc, USA). Wells to be used in the chemotaxis plate were blocked 
with 30 µL blocking buffer (1% BSA in simple RPMI) for at least 30 minutes at room 
temperature. Chemokine solutions were prepared at 1 – 10 nM, depending on assay 
requirements, in working buffer (0.1% BSA in simple RPMI). Jurkat cells were micro-
centrifuged at 5000g for 5 minutes, washed once in simple RPMI and resuspended in 
39 µL working buffer to give 25 X 104 cells per well with two wells worth of cells per 
sample for stimulated and unstimulated runs. Relevant treatments or vehicle control 
were added before an incubation for 30 minutes at 37oC, 5% CO2. The blocking buffer 
was removed from the plate and replaced with 31 µL of the relevant chemokine solution 
(working buffer for unstimulated samples). The membrane was attached and 20 µL of 
cell suspension was added onto the top surface of the membrane. The plate was then 
incubated in a fully humidified chamber for 5 hours before membrane was dried and 
removed. The cells in each well were then counted with a haemocytometer.  
 
2.9.2. Transwell migration assay 
 
Adherent cells were cultured until around 90% confluence was reached and detached 
by incubation with PBS with 2.5 mM EDTA for 5 minutes. Cells were washed in PBS 
and re-suspended in 12 mL growth medium of growth medium at a density of 3 X 105 
cells per mL. Cells were pipetted into 6 well plates (2 mL per well) and incubated at 
37oC, 5% CO2 for 24 hours to allow adherence. Cells were then chemically transfected 
with relevant DNA plasmids (refer to section 2.7.1; page 56) and analysed using an 
inverted Leica DMII fluorescence microscope using GFP filter cube to see if there was 
effective transfection. Cells were then removed by incubation at 37oC, 5% CO2 with PBS 
with 2.5 mM EDTA for 15 minutes until most cells were suspended in solution. In a 
sterile 24 well plate, 600 µL of 0.2% BSA/DMEM were added in each well and relevant 
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chemokine was added into positive wells. In these chemotaxis assays, 8 µm pore 
Greiner Bio-One inserts (PETMembrane) were used and inserted in each well. Cells 
were counted at a density of 1 X 106 per mL and washed gently with 5 mL PBS and re-
suspended with 0.2% BSA/DMEM. 200 µL of cells were added in each insert and plate 
was incubated at 37oC, 5% CO2 for 24 hours. Inserts were removed and added onto a 
new, sterile 24 well plate. Cells were then gently removed from inserts by incubating 
with 0.25% Trypsin EDTA (Gibco) at 37oC, 5% CO2 for 30 minutes. 200 µL cells were 
added to each well of a black, opaque reader plate (ThermoFisher Scientific) before 
assessment at excitation/ emission of 485/520 nm using BMG Labtech Fluorostar 
Optima plate reader (BMG Labtech, Germany).  
 
2.9.3. Wound healing assay 
 
Sterile 12 well plates were prepared by marking the outside of the bottom surface with 
two parallel lines with indelible marker per well which forms the reference points for 
wound healing quantification. This procedure was done before the addition of cells. 
Adherent cells were cultured until around 90% confluence was reached and re-
suspended by incubation with PBS with 2.5 mM EDTA for 5 minutes. Cells were washed 
in PBS and re-suspended in 24 mL of growth medium at a density of 3 X 105 cells per 
mL. Cells were pipetted into pre-marked 12 well plates (2 mL per well) and incubated 
at 37oC, 5% CO2 for 24 hours to allow adherence and spreading of the cells. Scratches 
were made in the cell layer perpendicular to the reference lines using a 200 µL pipette 
tip drawn along the side of the plate lid. The growth medium was then removed, and 
the cells washed gently twice in PBS to remove loosened and suspended cells. 200 µL 
of simple DMEM was then placed in each well and the wounds were imaged in 
duplicate using an inverted Leica DMII fluorescence microscope in bright-field mode 
at 10X magnification in such a way that the horizontal reference line was visible in all 
images. The relevant chemokines and inhibitors were added into respective wells at 
working concentration (tables 2.1, 2.3) Images were then collected at 24 hours 
(timepoint 24) after addition of treatments. Wound healing was quantified using 
Microsoft Powerpoint by aligning the horizontal reference line to vertical and then 
aligning vertical guides to the midpoint of the cell which was closest to the centre of 
the scratch but part of the confluent monolayer. The perpendicular width between the 
two edges of the scratch could then be determined. For timepoint images, the 
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transformation setting used for the t=0 (timepoint 0) images were used, and 
perpendicular width re-determined as described (figure 2.1).  
 
 
Figure 2.2: Image representative of wound healing assay on MCF-7 cells. A scratch was made 
on a cell monolayer and images were captured at timepoint 0, before addition of chemokine, and at 
timepoint 24 to assess migration of cells. The perpendicular width (arrowed line) between the two 
edges of the scratch were measured. Quantification of migration of cells into the wound was 
calculated as ratio of woundwidth at timepoint 24 to woundwidth at timepoint 0. A value of 1 denotes 
no migration occurred, whereas a value < 1 denotes cell migration.  
 
2.10. Imaging techniques 
 
2.10.1. Phalloidin actin stain  
 
CHO.CCR5 or transfected MCF-7 cells (refer to section 2.7.1; page 56) were split at 
around 95% confluence with 4mL PBS with 2.5 mM EDTA and 200 µL of cells were 
placed over washed coverslips in a 12 well plate. Cells were incubated for 24 hours to 
allow cells adherence. Once 95% confluence was reached, the inhibitors were added at 
working concentrations and left for 30 minutes. Ligands were then added to relevant 
wells at working concentration (100 nM CCL3 and 10 nM CXCL12) and plates were 
incubated at 37oC, 5% CO2 for 1 hour. Cells were washed twice in PBS and fixed by 
adding 300 µL 4% paraformaldehyde solution for 10 minutes. Cells were gently washed 
twice in PBS and then treated with 300 µL 0.1% Triton X-100 (FisherBioTech) solution 
for 5 minutes for cell permeabilization. Cells were washed twice in PBS and then 2 µL 
of Alexa Fluor 488 tagged phalloidin (Invitrogen) was added to 200 µL PBS or 300 µL 
of diluted Phalloidin CruzFluor 594 Conjugate (1 in 2000 in 1 % BSA/PBS) (Santa Cruz) 
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was placed onto the slides before incubation at 4oC in the dark for 30 minutes. Cells 
were gently washed twice with PBS and coverslips with cells were mounted onto glass 
slides with DPX mountant (ThermoFisher Scientific), which contains an anti-oxidant 
that inhibits stain fading. Cells were analysed immediately using an inverted Leica 
DMII fluorescence microscope with a filter setting suitable for the fluorophore used.  
 
2.10.2. CCR5 receptor internalisation 
 
Cells were seeded overnight onto coverslips. Once 95% confluence was achieved, the 
inhibitors were added to respective wells at working concentrations and plates were 
incubated at 37oC, 5% CO2 for 30 minutes. Cells were then stimulated with 100 nM 
CCL3 and plates were incubated at 37oC, 5% CO2 for 1 hour. Cells were gently washed 
once with PBS and HEK/1/85a/7a (1:100) in 1 mL simple DMEM (1 mL PBS as negative 
control) was placed onto the cells which were then incubated at 4oC for 1 hour. Cells 
were gently washed three times with PBS before fluorescently tagged secondary 
antibody (1:1000) was added in 1 mL PBS and incubated at 4oC for 1 hour. Cells were 
washed three times in PBS and coverslips were mounted onto glass slides with DPX 
mountant (ThermoFisher Scientific). Cells were analysed immediately using an 
inverted Leica DMII fluorescence microscope with a filter setting suitable for the 
fluorophore used.  
 
2.10.3. CXCR4 receptor internalisation 
 
Adherent cells were seeded overnight onto coverslips. Once 95% confluence was 
achieved, the inhibitors were added at working concentrations and incubated at 37oC, 
5% CO2 for 30 minutes. Cells were then stimulated with 10 nM CXCL12 and incubated 
at 37oC, 5% CO2 for 1 hour. Cells were washed twice with PBS and stained with CXCR4 
mAB 12G5 (Santa Cruz Biotechnology) (1:100) in 1 mL PBS (1 mL PBS as negative 
control) which were then incubated at 4oC for 1 hour. Cells were washed three times 
with PBS before fluorescently tagged secondary antibody (1:1000) was added in 1 mL 
PBS and incubated at 4oC for 1 hour. Cells were gently washed twice with PBS and 
coverslips were mounted onto glass slides with DPX mountant (ThermoFisher 
Scientific). Cells were analysed immediately by an inverted Leica DMII fluorescence 
microscope with a filter setting suitable for the fluorophore used.  
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For suspension cells’ staining, the procedure above was followed although cells were 
prepared in suspension in 1.5 mL tubes with cell density of 5 X 106 per mL in PBS and 
centrifuged between treatments and washes. Mounting of the cells was achieved by 
resuspending pelleted cells in 50 µL of glycerol mounting mixture (90% glycerol in 
PBS) then pipetting 20 µL of the resulting suspension into a glass cover slip. These 
coverslips were dried at 4oC overnight and analysed using an inverted Leica DMII 
fluorescence microscope with a filter setting suitable for the fluorophore used.  
 
2.10.4. Microscopy 
 
Fluorescently stained slides and transfected cells with EGFP were imaged using Leica 
wide field fluorescence microscope fitted with 10, 40, 63X inverted air objectives fitted 
with a colour CCD camera. Leica images were captured and analysed using the Leica 
Imaging Suite software (overlays represent true colours). Micrographs of cells shown 
in this thesis were captured in 10X, 40X or 63X magnification. All immunofluorescence 
was validated by testing for non-specific secondary antibody binding.  
 
2.11. Internalisation assay and flow cytometry analysis  
 
Transfected Jurkat cells (refer to section 2.6.1; page 55) (untransfected cells as negative 
control) were re-suspended in 1 mL of 0.5% BSA/PBS to give cell density of 1 X 106 per 
mL. Cells were washed with 0.5% BSA/PBS twice and re-suspended with 300 µL of 
0.5% BSA/PBS. Cells were activated with 15 nM CXCL12 at 37oC for 15 minutes or left 
untreated as negative control. Cells were then washed with ice-cold 0.5% BSA/PBS 
twice and were re-suspended in anti-h CXCR4 antibody (R&D systems) (1 in 2000) at 
4oC for 1 hour (resuspension with 0.5% BSA/PBS as negative control). Cells were gently 
washed twice in ice-cold 0.5% BSA/PBS and then incubated at 4oC for 1 hour with 
secondary antibody goat anti-Mouse IgG (H+L), F(ab’)2 fragment, CF 647 (Sigma 
Aldrich) (1 in 200). Stained cells were gently washed twice with 0.5% BSA/PBS and 
gated to exclude dead cells. Differences in cellular fluorescence were then determined 
and quantified using BD FACSCalibur (BD Biosciences) and data analysed using 
CellQuest software version 3.1 (Becton Dickinson, San Jose, CA).  
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2.12. Western blotting 
 
2.12.1. Sample preparation 
 
5 X 105 cells were spun down at 1800g for 5 minutes and the supernatant was removed. 
Cells were then either frozen as a pellet for later analysis or used immediately. On the 
day of analysis, the pellet was defrosted (where necessary) and 40 µL of lysis/ sample 
buffer (Mammalian Protein Extraction Buffer, GE Healthcare Life Sciences) was added 
and mixed until a homogenous consistency was reached. Mixture was incubated in ice 
for at least 30 minutes to promote cell lysis. The lysis mixture was then immediately 
spun down at 14000g for 10 minutes. The supernatant was removed in preparation for 
gel electrophoresis and the pellet was discarded. Protein concentration of samples were 
then measured by the Nanodrop spectrometer system (ThermoFisher Scientific). The 
lysed sample was placed in boiling water for 5 minutes to denature proteins further 
before use for SDS-PAGE.  
 
2.12.2. SDS-PAGE sample separation 
 
SDS-PAGE gels consisted of a stacking phase for sample loading (0.1089g Tris, SDS 2% 
pH 8.8, 4.5% acrylamide v/v, 0.1% ammonium persulphate w/v, 0.01% TEMED v/v) 
which constituted the top 20% gel and a 12% acrylamide running phase (0.67155g 
Tris/SDS 2% pH 8.8, 12% acrylamide v/v, 0.1% ammonium persulphate w/v, 0.01% 
TEMED v/v). 20 µL of sample was loaded into the stacking phase wells with a Hamilton 
microsyringe along with 5µL Pierce pre-stained protein MW marker (ThermoFisher 
Scientific) as ladder. Unused wells were loaded with 20µL loading buffer (4% SDS, 
0.02% bromophenol blue, 20% glycerol, 80 mM Tris, pH 6.8) to allow identification 
of the elution front. Gels were run at a constant 30 mA until the elution front reached 
the running gel when the current is increased to 50 mA constant until the elution front 
ran off the gel, at which point electrophoresis was complete.  
 
2.12.3. Protein transfer  
 
The gel plates were removed from the clamp assembly and separated so that the gel 
remained intact on one plate. The gel was then transferred to a nitrocellulose 
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membrane (Whatman) pre-soaked with transfer buffer. The membrane and gel were 
placed between sheets of (Whatman) filter paper pre-soaked in transfer buffer (25 mM 
Tris, 192 mM glycine, 10% methanol, pH 8.3), sufficient sheets were used to allow a 
good contact between electrodes of the transfer plate in the semi-dry blotter kit 
(Sigma-Aldrich). The transfer was undertaken at 15 volts constant for 45 minutes. 
Successful protein transfer was evaluated by the transfer of the protein marker to the 
nitrocellulose membrane.  
 
2.12.4. Immunostaining and imaging 
 
After protein transfer was verified the nitrocellulose membranes were initially blocked 
for non-specific binding with PBS-T (0.5% v/v Tween-20 in PB) containing 5% w/v 
low-fat milk powder (Marvel) for 1 hour at room temperature. Blocking buffer was then 
removed and the relevant primary antibody (table 2.4) was diluted in blocking buffer 
before overnight rolled-agitation at 4°C. The following day the primary antibody was 
removed, and the membrane washed 3 times for 5 minutes with PBS-T before addition 
of the relevant secondary peroxidase tagged Ab was added at 1:5000 in 10 mL blocking 
buffer. After 1-hour roller-agitation, the secondary antibody solution was removed, and 
the membrane was washed 3 times for 5 minutes in a tray with gentle shaking to 
facilitate flattening. Proteins were visualised by addition of Pierce ECL Western 
Blotting Substrate (ThermoFisher Scientific) after which the membrane was 
sandwiched between 2 acetate sheets and imaged using the G-Box imaging system 
(Syngene, UK) set to automatically calculated exposure. Images were captured using 
Gene-snap software (Syngene, UK).  
 
2.12.5. Membrane stripping 
 
Antibodies were removed from the membrane before a second stain by incubation with 
Millipore Stripping Solution (Millipore, Temecula California) at room temperature for 
15 minutes before blocking and re-probing for immunostaining as described previously 
(section 2.11.4).  
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2.13. Bioluminescence Resonance Energy Transfer (BRET) 
 
Cells were transfected with plasmids DNA CXCR4-RLuc3 (donor) and h-arrestin3-
GFP10 (acceptor) and also maintained as described previously (refer to section 2.6.1; 
page 55). Transfected cells were then seeded in 96-well plates (with clear bottoms that 
had been treated with poly-D-lysine) (Corning) and left in culture for 24 hours before 
being processed for BRET assay. Transfection was assessed by visualising localisation 
of fluorescent h-arrestin3-GFP10 in cells using Leica DMII fluorescence microscope 
with GFP filter cube. Luciferase substrate solution, coelenterazine 400a (DeepBlueC) 
(Biotium), stock was reconstituted in ethanol for BRET assay and EnduRen (Promega) 
stock was reconstituted in DMSO. For routine BRET measurements, cells were washed 
with BRET buffer (PBS, 0.5 mM MgCl2, 0.01% BSA) 24 to 48 hours after transfection 
and luciferase substrate solution, DeepBlueC (Biotium) or EnduRen (Promega) was 
added to a final concentration of 5 µM or 60 µM respectively in BRET buffer (PBS, 0.5 
mM MgCl2, 0.1% glucose). DeepBlueC (Biotium) was added just before detecting 
emission from that well and EnduRen (Promega) was added to live cells at least 1.5 
hours before BRET detection. Readings were then collected using Clariostar 
Monochromator (BMG Labtech) measuring signals detected in the 410±40 nm and 
515±15 nm windows for luciferase and GFP10 light emissions. The BRET signal is 
determined by calculating the ratio of the light intensity emitted by the h-arrestin3-
GFP10 over the light intensity emitted by CXCR4-RLuc3. The values were corrected by 
subtracting the background BRET signal detected when the CXCR4-RLuc3 construct 
was expressed alone. To assess the effects of ligands, CXCL12 was added at the 0.01 nM, 
0.1 nM, 1 nM, 5 nM and 10 nM and incubated at 37oC for 5 minutes before the addition 
of luciferase substrate solutions and BRET reading. For acquisition of full BRET spectra, 
cells were transfected as described above with different amounts of h-arrestin3-GFP10 
for a given quantity of CXCR4-RLuc3 (0.1µg). Cells were detached and re-suspended in 
BRET buffer (PBS, 0.5 mM MgCl2, 0.01% BSA).  200,000 cells were seeded in 100 µL 
of BRET buffer (PBS, 0.5 mM MgCl2, 0.01% BSA) in a 96-well plate with a clear bottom 
(Corning), and BRET scan was performed in FLUOstar Optima (BMG Labtech) by 
reading luminescence between 480 – 520 nm after addition of DeepBlueC for cells 
expressing [acceptor]/[donor] ratios.  
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2.14. Curve prediction and statistical analysis  
 
All data were analysed using GraphPad Prism 6 and represent at least 3 independent 
experiments (unless stated otherwise). All concentration response sigmoidal curves 
used to calculate EC50 and IC50 values were fitted assuming a Hill coefficient of 1. 
Statistical significance was determined using unpaired student t-tests where applicable 
or one-way ANOVA analysis of variance followed by Bonferroni or Dunnett’s multiple 
comparison as post-tests where 3 or more data sets were to be analysed. A significant 
value of 95% was used with p values indicated as follows p≤0.05 = *, p≤0.01 = **, 
p≤0.001 = ***. P values above 0.05 were therefore considered as not significant (ns). 
All error bars represent standard error of the mean value (S.E.M).  
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CHAPTER 3: Characterisation of CXCR4 activation  
 
3.1. Introduction  
 
Chemokines are chemotactic cytokines, a superfamily of small secreted cytokines that 
were initially characterised through their ability to prompt the migration of leukocytes. 
Chemokine receptors and their ligands were shown to be interesting therapeutic 
targets due to their involvement in various immune-related diseases, including 
rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, chronic 
obstructive pulmonary disease, HIV-1 infection and cancer [1,270]. Attention has been 
focused on the chemokine receptors expressed on cancer cells as distinct patterns of 
chemokine/receptor expression are linked to many diseases, including the progression 
of cancer and cancer cell migration which show similarities to leukocyte trafficking [9]. 
Emerging evidence has shown that chemokines are involved in cancer progression 
through specific chemokine/chemokine receptor pairing in tumour metastasis and the 
shaping of tumour microenvironment in favour of tumour growth and metastasis [3,11]. 
Involvement of chemokines in chemokine receptor signalling also contributes to the 
survival and proliferation of cells, which is important for cancer cells to adapt to foreign 
environments [11]. The chemokine receptor CXCR4 is most commonly found on human 
and murine cancer cells, and it is primarily activated by the chemokine CXCL12 [2,11]. 
This ligand can induce intracellular signalling through several divergent pathways 
initiating signals related to chemotaxis, cell survival, and/or proliferation, increase in 
intracellular calcium and gene transcription. Interactions between CXCR4 and CXCL12 
have a crucial role in the migration and patterning of many embryonic cell lineages, 
the mobilisation of HSCs and the migration of naïve lymphocytes [1]. The expression 
of CXCR4 on malignant epithelial and hematopoietic cells suggests that 
CXCR4/CXCL12 pathway may influence the biology of cancer and play an important 
role in directing the metastasis of CXCR4+ tumour cells to organs that express CXCL12 
[2]. It is essential to study the network of chemokines and their receptors as they 
influence the development of primary tumours and metastases but due to its 
complexity, it is still not yet fully understood.  
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3.2. Chapter aims  
 
Hypothesis: We hypothesised that different chemokines illicit different signalling 
pathway responses in different cell types.  
 
Aims: The aim of this chapter is to characterise CXCR4 activation using different 
chemokine ligands and to identify a ‘route’ by which activated CXCR4 receptors 
transduce signals to chemotaxis. Most chemokines bind to multiple receptors and the 
same receptor may bind to more than one chemokine, suggesting further studies of 
CXCR4 and its activation with variety, including chemically modified chemokines 
would be interesting. There is accumulating evidence that chemokines may display 
their own pattern of activation of signalling pathways, suggesting that different 
chemokines can play different roles [270]. Ultimately, this would aid in mapping the 
chemokine network and the signalling events upon chemokine ligand binding on 
CXCR4 activation. This will allow relation of observations to specific signalling axis and 
allow comparison to the relevant literature. By understanding the involvement of 
chemokines and their receptors in migration of cells, novel therapeutic targets to stop 
cancer metastasis may be discovered.  
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3.3. Results 
 
3.3.1. Expression of chemokine receptors in MCF-7 cells 
 
MCF-7 cells are adherent, non-invasive breast carcinoma cells, and they have been 
shown to express chemokine receptors, such as CXCR4, by quantitative RT-PCR 
analyses  [4,192]. High levels of CXCR4  expression in human breast cancer correlates 
with metastasis to tissues, such as lymph nodes, bone marrow, liver and lung, that 
secrete CXCL12 [4,8]. CXCL12 is a homeostatic chemokine, and the major function is 
to regulate hematopoietic cell trafficking and secondary lymphoid tissue architecture 
[2].  
 
MCF-7 cells were harvested and washed with calcium flux buffer (refer to section 2.8; 
page 57). MCF-7 cells were incubated with Fura-2 AM, which can pass through the cell 
membrane and fluoresce upon binding to calcium. This makes it a useful tool in the 
quantification of calcium signalling occurring upon receptor activation. CXCL12 was 
demonstrated to induce calcium responses from MCF-7 cells in a dose-dependent 
manner, with an EC50 of 93.61 nM (assuming Hill coefficient of 1) (figure 3.1).  
 
 
Figure 3.1: Concentration response curve for MCF-7 cells upon CXCL12 activation. Data is expressed 
as changes in fluorescence ratio (340nm/380nm) where the basal fluorescence, prior to the addition 
of CXCL12, is subtracted from peak fluorescence following addition of CXCL12. Data represent mean 
± SEM from at least three independent experiments.  
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To confirm that MCF-7 cells are suitable to study the CXCR4/CXCL12 signalling axis, 
we did preliminary experiments to confirm cell surface expression of different 
chemokine receptors on MCF-7 cells by activating them with a variety of chemokines. 
In this study, we used CCL3, CXCL8 and CXCL12.  
 
CCL3, also known as MIP-1α, is a cytokine belonging to CC chemokine family with 
inflammatory and chemokinetic properties [271]. They are known to be involved in the 
acute inflammatory state in the recruitment and activation of leukocytes [272,273]. 
CCL3 binds to the receptors CCR1 and CCR5 [271]. CCL3 plays an important role in the 
pathogenesis of various inflammatory diseases and conditions that exhibit bone 
resorption, resulting in good diagnostic potential for the detection of several 
inflammatory diseases such as rheumatoid arthritis [273]. CCL3 is one of the 
chemokines that is most widely studied because it has been shown that it is one of the 
major HIV-suppressive factors produced by CD8+ T-cells [271,274].  
 
CXCL8, also known as IL-8, is a chemokine that attracts neutrophils, basophils, and T-
cells but not monocytes [275]. It has been shown to be involved in neutrophil activation 
[276]. CXCL8 is released from several cell types in response to an inflammatory 
stimulus, including epithelial cells, airway smooth muscle cells and endothelial cells 
[276–279]. CXCL8 initially is produced as a precursor peptide of 99 amino acids which 
then undergoes cleavage to create several active CXCL8 isoforms [275]. CXCL8 
receptors that could contribute to CXCL8-mediated tumorigenic and angiogenic 
responses include CXCR1 and CXCR2 [275], and since there are different CXCL8 
isoforms, it has been shown that CXCL8 (7-77) has a higher affinity for receptors CXCR1 
and CXCR2 as compared to CXCL8 (1-77) [278].  
 
CXCL12, also known as SDF-1, is produced in two forms; CXCL12a (SDF-1α) and 
CXCL12b (SDF-1β), by alternative splicing of the SDF-1 gene [280,281]. In our 
laboratory, the isoform that we usually use in our assays is SDF-1α. CXCL12 is a 
chemoattractant, and it activates CXCR4 to induce a rapid and transient rise in the 
level of intracellular calcium and chemotaxis [282,283].  
 
Figure 3.2 demonstrates that CCL3, CXCL8 and CXCL12 are all capable of inducing a 
release of intracellular calcium response upon activation of their chemokine receptors 
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in MCF-7 cells. The literature suggests that these signalling pathways could occur 
through receptors CXCR1 and CXCR2 upon CXCL8 activation; CCR1 and CCR5 upon 
CCL3 activation; and CXCR4 upon CXCL12 activation. Mueller et al. (2001) reported 
that MCF-7 cells express upregulated levels of CCR5, CXCR2 and CXCR4 through flow 
cytometric analyses and quantitative RT-PCR analyses [4]. This explains the 
intracellular calcium signalling observed upon activation of chemokine receptors in 
MCF-7 cells in figure 3.1. This data shows that we can perform specific chemokine 
receptor studies using these different chemokines in MCF-7 cells to study downstream 
signalling cascades, which may result in chemokine-induced migration of these cell 
types. 
 
 
Figure 3.2: Comparison of intracellular calcium response upon activation of different chemokine 
receptors by different chemokines in their working concentrations. Data is expressed as changes in 
fluorescence ratio (340nm/380nm) where the basal, before addition of chemokine, is subtracted from 
peak fluorescence after addition of chemokine. Data represent mean ± SEM from at least three 
independent experiments.  
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3.3.2. CXCL12 N-His Tag binding to CXCR4 promotes intracellular calcium response 
in MCF-7 cells but not chemotaxis in suspension leukemic T-lymphocytes, Jurkat 
cells 
 
As discussed previously, Mueller et al. (2001) confirmed expression of CXCR4 was 
markedly upregulated and that there is strong cell-surface expression of CXCR4 on 
MCF-7 cells [4]. CXCR4 is a receptor for CXCL12 that transduces a signal by increasing 
intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation and finally 
chemotaxis [257,284]. The binding of CXCL12 to CXCR4 induces intracellular 
signalling through several divergent pathways initiating signals related to chemotaxis, 
cell survival and/or proliferation, increase in intracellular calcium and gene expression 
[2,280,285].  
 
Chemokines are characterised by the presence of four conserved cysteines, which form 
two disulphide bonds [11]. The CXCL12 proteins belong to a group of CXC chemokines, 
whose initial pair of cysteines are separated by one intervening amino acid [5].  CXCL12 
is strongly chemotactic for lymphocytes and has been implicated as an important cell 
co-ordinator during development [82,283]. In a collaboration with Professor K. 
Schmitz (TU Darmstadt), we were given some CXCL12 N-His Tag and wanted to 
investigate if it can induce intracellular signalling via CXCR4. The recombinant human 
CXCL12 consists of 83 amino acids and predicts a molecular mass of 9.83 kDa (figure 
3.3). 
73 
 
 
Figure 3.3: Amino acid sequence of (a) CXCL12, containing 68 amino acid residues (marked blue) and 
(b) CXCL12 N-His Tag, containing 83 amino acid residues. Difference between the two recombinant 
human SDF-1α is the 15 amino acids His-Tag (marked red) that was fused at the N-terminus in CXCL12 
N-His Tag, which makes this protein have a molecular mass of 9.83 kDa compared to the molecular 
mass of CXCL12 of 8.0 kDa.  
 
MCF-7 cells were incubated with Fura-2 AM at 37oC and intracellular calcium response 
stimulated by different concentrations of CXCL12 N-His Tag vs 10 nM CXCL12 positive 
control was measured after 60 minutes of incubation. Binding of CXCL12 N-His Tag to 
CXCR4 in MCF-7 cells was demonstrated to promote intracellular calcium signalling. 
CXCL12 N-His Tag EC50 for calcium release was calculated as 274 nM (assuming Hill 
coefficient of 1) (figure 3.4a). Calcium signalling increases as the concentration of 
CXCL12 N-His Tag increases (figure 3.4a). MCF-7 cells were treated with 10 nM CXCL12 
as positive control to show that cells were able to signal. Calcium flux was quantified 
and this increase in intracellular calcium suggested that there was chemokine activity 
upon binding. It is hypothesised that this is achieved via the Gβγ subunit. This then 
triggers PLC activation and formation of IP3 and DAG, which results in mobilisation of 
calcium from intracellular stores [70]. Figure 3.4b confirmed that there was calcium 
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signalling in MCF-7 cells upon CXCR4 activation by varying concentration of CXCL12 
N-His Tag when compared to 10 nM CXCL12 positive control.  
Figure 3.4: CXCL12 N-His Tag binds to CXCR4 to induce intracellular calcium response.                                
(a) Concentration response curve for MCF-7 cells upon CXCL12 N-His Tag activation. (b) Calcium flux 
response: MCF-7 cells upon CXCL12 activation in presence of different concentrations of CXCL12 N-
His Tag as antagonist vs positive control 10 nM CXCL12. Data is expressed as changes in fluorescence 
ratio (340nm/380nm) where the basal fluorescence prior to the addition of CXCL12 is subtracted from 
peak fluorescence following addition of CXCL12. Data represent mean ± SEM from at least three 
independent experiments (One-way ANOVA, Bonferroni multiple comparison, ns = not significant, 
p>0.05).  
 
Since our group has previously shown that chemotaxis can occur independently of 
intracellular calcium release [142] and that there is differential regulation of signalling 
75 
 
in different cell lines [286], we wanted to investigate if the binding of CXCL12 N-His 
Tag and CXCR4 could also induce migration in Jurkat cells using chemotaxis assays.  
 
Jurkat cell line is an immortalised T lymphocyte cell line that was originally obtained 
from the peripheral blood of a boy with T cell leukaemia [287]. One of the reasons why 
Jurkat cell line has been widely used is due to the expression of various chemokine 
receptors, susceptible to viral entry, particularly HIV, where it was identified that HIV 
receptor (CD4) and the co-receptors (CXCR4 and CCR5) HIV binding to susceptible 
target cells [257,271].  
 
Jurkat cells were treated with different concentrations of CXCL12 N-His Tag and 
CXCL12 as positive control, and chemotaxis assays were analysed after 5 hours of 
incubation. Figure 3.5a shows that CXCL12 N-His Tag has no chemotactic activity on 
Jurkat cells compared to the positive control of 1 nM CXCL12, even at high 
concentrations.  
 
Since CXCL12 N-His Tag showed that they may have binding activity on CXCR4 as they 
induced intracellular calcium signalling (figure 3.4a), we would like to investigate if 
they had an effect on CXCR4/CXCL12 signalling axis. Even though CXCL12 N-His Tag 
showed no chemotactic activity on Jurkat cells, it would be interesting to see if they 
have a role in binding of chemokine CXCL12 to chemokine receptor CXCR4. At 
increasing concentrations, CXCL12 N-His Tag seems to act as an antagonist that blocks 
CXCR4-mediated chemotaxis induced by the endogenous ligand, CXCL12 (figure 3.5b).  
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Figure 3.5: CXCL12 N-His Tag does not induce CXCR4-mediated chemotaxis and it acts as an inhibitor 
in CXCL12-induced chemotaxis in Jurkat cells. (a) Concentration response plot of Jurkat migration 
towards 0, 0.01, 0.1, 10, 50, 100 and 500 nM CXCL12 N-His Tag vs positive control 0, 0.01, 0.1, 1 and 
10 nM CXCL12. (b) Migration of Jurkat cells was induced in the presence or absence of CXCL12 N-His 
Tag, which was made to concentrations stated in mixture with 1 nM CXCL12. Data represent mean ± 
SEM from at least three independent experiments (One-way ANOVA, Bonferroni multiple comparison, 
* = p ≤ 0.05). 
 
Figure 3.5a shows that the optimal dose of CXCL12 is 1 nM. There was reduced 
chemotactic activity when Jurkat cells were treated with more than 1 nM CXCL12 in a 
dose-dependent manner (figure 3.5a).  
 
Figure 3.5b shows that when cells were incubated with both 1 nM CXCL12 and 
increasing concentrations of CXCL12 N-His Tag, there was a trend towards inhibition 
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of cell migration in a dose dependent manner, which was significant at 100 nM CXCL12 
N-His Tag.  
 
3.3.3. Characterisation of chemokine-mediated chemotaxis in Jurkat cells  
 
Here, we have chosen the Jurkat cell line to characterise chemotaxis signalling in 
response to different chemokines. As discussed previously, Jurkat cells have been 
widely used in chemokine research as they express various chemokine receptor.  
 
Chemokines that were used in our lab to perform chemotaxis assays in Jurkat cells were 
CCL1, CCL2, CCL3, CCL5, CCL8, CCL23, CXCL11 and CXCL12. These are summarized 
in table 3.1. 
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Table 3.1: Chemokines  
 
Chemokines  Description Receptors  Refs 
CCL1 (I-309) • chemotactic cytokine for monocytes, NK cells and immature B cells and dendritic cells but not neutrophils 
• a small glycoprotein secreted by activated T cells 
CCR8 [288–
290] 
CCL2 (MCP1) • recruits monocytes, memory T cells and dendritic cells, but not neutrophils or eosinophils to the sites of 
inflammation produced by either tissue injury or infection 
• ability to bind to receptors on the surface of leukocytes targeted for activation and migration  
CCR2 [286–
288] 
CCL3 (MIP-
1α) 
• useful as a biomarker as it performs various biological functions such as recruiting inflammatory cells, 
wound healing, inhibition of stem cells, and maintaining effector immune response 
CCR1, 
CCR5 
[273] 
CCL5 
(RANTES) 
• chemokine for T cells, eosinophils and basophils, and plays an active role in recruiting leukocytes into 
inflammatory sites 
• has been demonstrated to have a critical role in T-lymphocyte activation and as one of the major HIV-
suppressive factors produced by CD8+ T cells 
CCR1, 
CCR3, 
CCR5 
[294–
297] 
CCL8 (MCP2)  • uses multiple cellular receptors to attract and activate human leukocytes 
• has been shown to act as a potent inhibitor of HIV-1 due to its high-affinity binding to the receptor CCR5, 
which is known as one of the major co-receptors for HIV 
CCR2, 
CCR5 
[1,295,
298] 
CCL23 (MIP-
3) 
• highly chemotactic for resting T cells and monocytes, and slightly chemotactic for neutrophils, but not for 
activated lymphocytes 
CCR1 [295] 
CXCL11 (IP-9) • chemotactic for interleukin-activated T-cells 
• has been shown to exhibit effects on its target cells by interacting with CXCR3, with a higher affinity than 
CXCL9 and CXCL10 
CXCR3 [300,3
01] 
CXCL12  
(SDF1-α) 
• has been chemokine of interest as CXCR4/CXCL12 signalling axis is involved in numerous cancers. CXCL12 
plays a key role in several aspects of tumour progression including angiogenesis, metastasis and survival.  
CXCR4, 
ACKR3 
[55,30
2–
305] 
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Figure 3.6: Comparison of migration of Jurkat cells in different chemokines in chemotaxis assays 
after 5 hours of incubation. (a) Migration of Jurkat cells measured in the presence or absence 1 nM 
CCL3, 10 nM CCL23 and 1 nM CCL8 (b) Migration of cells measured in the presence or absence 1 nM 
CCL3, 10 nM CCL1 and 10 nM CXCL12 (c) Concentration response plot comparing migration of cells 
observed towards 0.01, 1, 10, 50, 100, 150 nM CCL2 to positive control 1 nM CXCL12. Note: positive 
control stimulated migration is 10-fold lower than expected (d) Concentration response plot of Jurkat 
comparing migration towards 0.01, 0.1, 1, 10, 50, 100 nM CCL5 and CXCL11 to positive control 1 nM 
CXCL12. Data represent mean ± SEM from at least three independent experiments. Note: Experiments 
were performed by visiting students in our laboratory.  
 
Jurkat cells were treated with different chemokines at their working concentrations in 
chemotaxis assays and analysed after 5 hours incubation (refer to section 2.9.1; page 
58). Figure 3.6 shows that Jurkat cells did not migrate towards CCL1, CCL2, CCL3, 
CCL5, CCL8, CCL23 or CXCL11.  There may be several explanations for these 
observations. The first explanation is that Jurkat cells may not express these chemokine 
receptors on their cell surface. Secondly, it may be that these interactions do not induce 
chemotactic activity in this cell type. GPCRs are key mediators of intracellular 
signalling, initiating signals elating to chemotaxis, cell survival and/or proliferation, 
increase in intracellular calcium and gene transcription, but these are cell-type, 
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receptor-type and ligand-type dependent interactions [27,306]. Hence, there might be 
activation of receptors by these ligands in the cells, but it doesn’t induce intracellular 
signalling to chemotaxis. To confirm if this is the case, further experiments of 
immunofluorescence staining of primary antibodies should to be done to ensure the 
expression of the receptors that interact with the chemokines, and that the effects of 
the signalling are due to activation of the receptors by the chemokines.  
 
The third explanation to this observation may be due to the use of inappropriate 
concentration of chemokines. Chemokine induced cell migration usually generates a 
bell-shaped chemotactic dose-response curve [307]. There might be a possibility that 
the concentration of chemokines used were not within the range to induce chemotactic 
signalling. Increasing concentration of chemokine could have been done but that 
would have been too expensive to continue.  
 
These results have shown that the CXCR4/CXCL12 signalling axis can be studied using 
Jurkat cell lines, and that Jurkat cell lines are not suitable to study downstream 
migratory signalling cascades of other chemokine receptors.  
 
3.3.4. CXCL14 acts as an inhibitor of CXCL12-induced chemotaxis in Jurkat cells  
 
CXCL14, also known as breast and kidney-expressed chemokine (BRAK), is a 
homeostatic chemokine with unknown chemokine receptor selectivity and is expressed 
in epithelial cells in normal tissue in the absence of inflammatory stimuli [308]. Its 
expression is usually downregulated in inflammatory setting, which suggests that 
CXCL14 plays an important role in the maintenance of tissue homeostasis and that it is 
a highly selective monocyte chemoattractant [309].  
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Figure 3.7: CXCL14 does not induce migration of Jurkat cells. Concentration response plot of Jurkat 
cells migrating towards 0, 0.001, 0.01, 0.1, 1, 5, 10, 50, 100 nM CXCL14 vs 0, 0.001, 0.01, 0.1, 1, 10 nM 
CXCL12 as positive control. Data represent mean ± SEM from at least three independent experiments. 
 
There was no substantial migration of Jurkat cells towards increasing concentrations 
of CXCL14 compared to increasing concentrations of CXCL12 which acted as positive 
control (figure 3.6). This can be due to CXCL14 not binding and activating CXCR4, but 
in recent years, studies have shown that CXCL14 specifically binds to CXCR4 with high 
affinity [310,311], therefore, this result cannot be explained by that hypothesis. 
Alternative hypothesis of the data suggests that CXCL14 is not a chemotactic cytokine 
for this cell type as intracellular signalling events can be cell-type specific [286,312,313]. 
Despite the potential clinical significance of CXCL14, the molecular mechanisms 
behind the physiological functions of CXCL14 are poorly understood.  
 
Collins et al. (2017) have shown that epithelial chemokine CXCL14 synergises with 
CXCL12 via allosteric modulation of CXCR4 [308]. Since we have shown that there is 
differential regulation of cell migration in different chemokine receptors in different 
cell types [286,314] in our previous studies, it is useful to investigate the role of CXCL14 
in CXCL12-induced migration as CXCL14 binds specifically to CXCR4 as discussed 
previously [310,311].  
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In studying the relationship between CXCL14 and CXCL12, we tried to establish if there 
was crosstalk between them in the CXCR4-mediated downstream signalling response.  
Figure 3.8: CXCL14 does not induce migration and doesn’t have a synergistic effect with CXCL12 in 
CXCR4-mediated migration of Jurkat cells.  (a) Migration of Jurkat cells was induced in the presence 
or absence of 0.1 nM CXCL12, 100 nM CXCL14 and combination mixture of 0.1 nM CXCL12 and 100 
nM CXCL14. (b) Migration of Jurkat cells was induced in the presence or absence of 0.1 nM CXCL12, 
300 nM CXCL14 and combination mixture of 0.1 nM CXCL12 and 300 nM CXCL14. Data represent mean 
± SEM from at least three independent experiments. 
 
Here, we have lowered the concentration of CXCR4 endogenous ligand, CXCL12 and 
carried out chemotaxis assays of Jurkat cells with 0.1 nM CXCL12 instead of working 
concentration, 1 nM CXCL12. Since there was evidence of synergy between CXCL12 and 
CXCL14 [308], we wanted to investigate the relationship between CXCL14 and CXCL12 
with different combinations of chemokine concentrations. This would determine if 
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CXCL14 would co-operate with CXCL12 to produce an additive effect in the induction 
of cell migration.  
 
Figure 3.8 shows that Jurkat cells do not migrate towards 0.1 nM CXCL12, 100 nM 
CXCL14 or 300 nM CXCL14 independently, or in assays induced with combination 
mixture of 0.1 nM CXCL12 and 100 nM CXCL14, or 0.1 nM CXCL12 and 300 nM CXCL14 
(figure 3.8). We expected to observe no migration towards 0.1 nM CXCL12 and also 
with both 100 nM and 300 nM CXCL14, as demonstrated previously in figure 3.7. 
However, in contrast to a previous study [308], we observed no migration of cells in 
either combination mixtures of 0.1 nM CXCL12 and 100 nM CXCL14; or 0.1 nM CXCL12 
and 300 nM CXCL14.  Currently, this data suggests the lack of synergistic effect 
between CXCL14 and CXCL12, or the concentrations of CXCL12 and/or CXCL14 were 
not enough.  
Figure 3.9: CXCL14 does not induce migration and had inhibitory effect towards CXCL12-induced 
migration of Jurkat cells. Migration of Jurkat cells was induced in the presence or absence of 1 nM 
CXCL12, 300 nM CXCL12 and combination mixtures of 1 nM CXCL12 & 300 nM CXCL12 in chemotaxis 
assays after 5 hours of incubation. Data represent mean ± SEM from at least three independent 
experiments. (One-way ANOVA, Bonferroni multiple comparison, *** = p ≤ 0.01). 
 
The concentration of CXCL12 was then increased from 0.1 nM to 1 nM to observe any 
additive effect of cell migration due to the synergistic relationship between CXCL14 
and CXCL12. Instead of synergy effects observed as demonstrated in previous study 
[308], we observed significant inhibition of CXCL12-induced chemotaxis of Jurkat cells 
when treated with 300 nM CXCL14 compared to the positive control of 1 nM CXCL12. 
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Analysis of these data suggests that CXCL14 acts as an antagonist to CXCL12 for the 
chemokine receptor CXCR4 in Jurkat cells.  
 
3.4. Discussion 
 
Chemokines are small proteins that function as chemotactic cytokines by directing 
cellular migration, and therefore have been shown to have a role in helping leukocytes 
and other migratory cells to find their way in the body [37]. Chemokines have been 
widely studied due to their involvement in physiology and homeostasis as well as in 
the pathogenesis of tumours and their metastasis [12]. Studying the roles of 
chemokines and their chemokine receptors shows promising potential as appropriate 
targeted therapy in numerous inflammatory diseases and cancers [4,303–305,315]. 
Plerixafor (AMD3100) is an example drug that has been approved for clinical 
treatment, which directly blocks the CXCR4 receptor, showing that it is a very efficient 
inducer of hematopoietic stem cell mobilisation in both animal and human studies 
[316–318]. It has also been shown to be associated with Warts, 
Hypogammaglobulinemia, Immunodeficiency and Myelokathexis (WHIM) syndrome 
[319,320]. WHIM syndrome is caused by mutations in CXCR4 that result in increased 
agonist-dependent signalling. McDermott et al. (2011) have shown that plerixafor 
increased absolute lymphocyte, monocyte and neutrophil counts in blood to normal 
and it can correct panleukopenia, which is an acute usually fatal epizootic disease 
especially of cats that is caused by parvovirus that causes destruction of white blood 
cells [320]. Their studies showed that that panleukopenia in WHIM syndrome is 
caused by CXCR4/CXCL12 signalling-dependent leukocyte sequestration [320].  
 
Infiltrating leukocytes are not the only cells that respond to chemokine gradients in 
cancers; cancer cells can express chemokine receptors and respond to chemokine 
gradients [4,10]. Organ-specific metastasis might be governed by interactions between 
chemokine receptors on cancer cells with metastatic potential and chemokine 
gradients in target organs, showing that chemokines play a significant role in organ-
selective cancer metastasis (figure 3.10) [9,28,86]. 
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Figure 3.10 (adapted from Koizumi et al. [9]) : Schematic illustrate showing cancer cell migration 
and metastasis share many similarities with leukocyte trafficking. (a) Chemokine receptors 
expressed on cancer cells in cancer metastasis, causing it to migrate to organs releasing specific 
chemokines. (b) Chemokines derived from cancer cells in cancer progression, creating an ideal 
microenvironment for tumour growth [9].  
 
Many cancer types have upregulated expression of chemokines and chemokine 
receptors leading to vast chemokine receptor signalling and expression [12]. However, 
the chemokine receptor that is most commonly found on human and murine cancer 
cells is CXCR4, and CXCL12 is the only host chemokine ligand for CXCR4 [1,9]. CXCR4 
expression is low on normal breast, ovarian and prostate epithelia [4,5,13], and 
therefore,  implies that expression of CXCR4 is a characteristic of malignant epithelial 
cells and on cells from several hematopoietic malignancies [2]. This suggests that the 
CXCR4/CXCL12 pathway may influence the biology of cancer and plays an important 
role in directing metastasis of CXCR4+ tumour cells to organs that express CXCL12, 
including lymph nodes, lungs, liver or bones [9,28].  
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Figure 3.11: Simple overview of chemokine receptor signalling. Calcium release and PKC activation 
downstream of PLC play an important role in mediating migration [321]. GRK phosphorylation of the 
C-terminus of chemokine receptors allows arrestins to bind, leading to receptor desensitisation and 
internalisation. However, arrestin binding also leads to the activation of several proteins including 
MAPK [11].  
 
As mentioned previously, the binding of CXCL12 to CXCR4 initiates different 
downstream signalling cascades (figure 3.11), which can result in biological responses 
such as chemotaxis, cell survival and/or proliferation, increase in intracellular calcium 
and gene transcription [2]. Activation of GPCRs triggers production of second 
messenger molecules and activating downstream signalling cascades. Once GPCRs are 
stimulated, PLC are activated and cleaves PIP2 into DAG and IP3. DAG remains 
membrane bound and IP3 is released into the cytosol where it binds to specific IP3 
calcium channel receptors in the endoplasmic reticulum (ER) [322].  
 
Since the nature of these pathways may be tissue-dependent, triggers of signalling 
pathways may also differ in cell types [2,286,313]. There was intracellular calcium 
release upon CCL3, CXCL8 and CXCL12 binding in MCF-7 cells (figure 3.2), suggesting 
the expression of CCR5, CXCR2 and CXCR4 receptors on breast cancer cells, MCF-7. 
Since chemotaxis can occur independently of calcium signalling [18,142], investigating 
chemokine-mediated migration in different cell lines is useful and imperative.  
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CXCL12 N-His Tag showed an EC50 value that was three times higher than CXCL12 (274 
nM vs 93.61 nM respectively) (figures 3.1a and 3.4a). CXCL12 N-His Tag exhibited 
intracellular calcium signalling (figure 3.4a) but no chemotactic activity in Jurkat cells 
(figure 3.5a), suggesting that there was binding of CXCL12 N-His Tag to the receptor 
CXCR4 which induces signalling but not chemotaxis. Figure 3.5a also shows that there 
was reduced chemotactic activity when Jurkat cells were treated with more than 1 nM 
CXCL12. This may be due to loss of directional cues for the cells to migrate towards as 
discussed in introduction (refer to section 1.7; page 42). As difference in chemokine 
gradient no longer exists at high chemokine concentrations, cells would stop moving 
because there is a loss of chemotactic guidance.  
 
These observations may also be due to the dimerization of CXCL12. A migrating cell 
will move towards a higher concentration gradient, and at higher concentrations, 
CXCL12 starts to dimerize, and dimers elicit different signals from the monomers 
[18,323]. At lower concentrations, CXCL12 monomers are able to promote arrestin 
recruitment and elicit arrestin-dependent signals such as actin assembly and 
chemotaxis, but at higher concentrations, CXCL12 starts to dimerize, leading to 
chemotactic signals being dampened [18].  
 
Previous studies [142,286] have shown that intracellular signalling can occur 
independently of each other as downstream effectors could be activated differently as 
intracellular signalling could occur via G-protein-dependent or arrestin-dependent 
signalling [20,26].  At higher concentrations, CXCL12 N-His Tag acts as inhibitor to 
CXCL12-induced migration (figure 3.5b), suggesting that CXCL12 N-His Tag has a role 
as an antagonist in CXCR4/CXCL12 signalling axis. At 100 nM, CXCL12 N-His Tag 
significantly inhibits CXCL12-induced migration of Jurkat cells. Chemokine ligands 
exist as a mixture of monomeric and higher order species, and the changes in the 
oligomeric state of CXCL12 dictates the migratory outcome, where monomers, but not 
dimers, induce cellular migration [324]. Drury et al. (2011) has demonstrated that 
oligomeric states of CXCL12 mediate distinct biological effects through the same 
receptor, and dimeric CXCL12 exhibits receptor interactions, downstream signalling 
and migration responses distinct from the monomeric CXCL12 [323]. From the data 
reported by others [18,325,326], we hypothesise that CXCL12 N-His Tag may have the 
same function as the dimeric form of CXCL12, where it acts as a partial agonist of 
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CXCR4, thereby stimulating calcium mobilisation, but showing no chemotactic 
activity. So, at increasing concentrations, the hypothesis is that it starts to bind to the 
receptors more readily than the endogenous ligand, and hence causing a significant 
reduction in CXCL12-induced migration in Jurkat cells [324,325]. 
 
These data imply that modification to the CXCL12 by adding 15 amino acids of 
polyhistidine Tag in N-terminus causes these effects. Crump et al. (1997) has shown 
that modification to Lys-1 and Pro-2 resulted in loss of activity but generates potent 
SDF-1 antagonists [327]. They have also reported that the first 8 residues of SDF-1 is 
important for activation. Hence, addition of amino acid residues at the N-terminus of 
CXCL12 N-His Tag may abrogate the ability of CXCL12 to fully bind to chemokine 
receptor CXCR4 to induce chemotactic signalling but it can still activate other 
signalling events such as calcium mobilisation [326]. By shifting the relative positions 
of N-terminal amino acids of SDF-1, it seems to affect the binding ability of CXCL12 to 
CXCR4, which results in different signalling events. The interaction between CXCL12 
and CXCR4 has been proposed to occur through a two-step process [66,270,328]. The 
binding between 12-17 residues of CXCL12 and 2-36 residues of CXCR4 results in a 
conformational change and this change would then facilitate interaction between the 
first 8 amino acid residues of CXCL12 and a revealed binding pocket in CXCR4, which 
have been previously discussed as an important interaction for activation 
[257,327,329].  
 
CXCL12 can be converted into a potent antagonist of CXCR4 by as little as a single N-
terminal amino acid substitution (P2G) [327]. Recently, Qin et al. (2015) has provided 
insights into CXCR4 interactions with CXCL12, where the structure revealed that there 
is a more extensive binding interface than anticipated from the previously described 
two-site model [330]. Chemokines interact via their globular core with the receptor N-
terminus (chemokine recognition site 1) and via their N-terminus with the receptor TM 
pocket (chemokine recognition site 2) [270]. In complex with vMIP-II, a high affinity 
antagonist of CXCR4, Qin et al. (2015) showed that the binding pocket of CXCR4 is 
open and negatively charged and can be separated into a major and minor subpocket 
[330,331]. The binding of chemokine recognition site 1 is dominated by ionic 
interactions between positively charged residues in the chemokine and negatively 
charged amino acids at N-terminus and extracellular surface of the receptor, including 
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sulfonated tyrosines [270,326]. CXCR4 is a rare CXC receptor that possesses a 
sulfotyrosine in the proximal N-terminus, which may explain its unique ability to 
engage vMIP-II via its basic N- or β2-β3 loops, which is important for vMIP-II and 
CXCL12 recognition [330]. While engaging a conserved set of binding determinants, 
Qin et al. (2015) [330] showed that ligands may occupy different regions of the binding 
pocket, which may explain the ability of CXCL12 N-His Tag binding to CXCR4, but has 
a different mechanism and acts as an antagonist to CXCR4/CXCL12 binding.   
 
Another possible hypothesis for these results is that CXCL12 N-His Tag may act as a 
negative allosteric modulator, where it binds in an allosteric site which leads to a 
conformational change to the receptor CXCR4 and thus, decreasing the affinity for 
CXCL12 binding at active sites. At higher concentrations, there would be more binding 
of CXCL12 N-His Tag to the allosteric sites of available CXCR4 in Jurkat cells, and thus 
causing conformational changes, reducing CXCL12 binding to CXCR4 and migration of 
Jurkat cells in chemotaxis assays. Allosteric regulation is the process associated to 
conformational and functional transitions in protein structures by binding of an 
effector at a site other than the protein’s active site [306]. Planesas et al. (2015) 
proposed that CXCR4 has a minimum of 2 allosteric binding sites in distinct domains 
(figure 3.12) attending to the allosteric functionality, such as antagonists to inhibit 
inflammation and cancer or agonists to enhance angiogenesis in tissue regeneration 
[306]. The mechanism of action of allostery is very complex, however, they may 
represent a novel drug target. Hence, the identification and studying of allosteric 
residues is useful and important [332–334].  
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Figure 3.12: Studying the binding interactions in allosteric sites of the CXCR4 receptor. There is a 
possibility that CXCL12 N-His Tag binds to allosteric sites of CXCR4 causing negative allosteric effects 
in CXCL12-induced migration via CXCR4 in Jurkat cells [306].  
 
Collins et al. (2017) [308] identified that there is a synergistic relationship between 
CXCL14 and CXCL12 via allosteric modulation of CXCR4. However, the results (figures 
3.8 and 3.9) obtained in this chapter contradicts their findings. Contrary to expected 
increase in CXCL12-induced migration of Jurkat cells by CXCL14, these results showed 
that CXCL14 significantly decreased the migration of Jurkat cells when treated in 
combination with 1 nM CXCL12 (figures 3.8 and 3.9). Chemokines, upon activation of 
their corresponding receptor, induce intracellular signalling cascades that result in cell 
activation and motility. This includes G-protein-mediated and -independent pathways, 
such as arrestin-dependent signalling and MAPK/ERK signalling, however, this is 
dependent on cell-type, ligand-type and receptor-type to generate different 
intracellular responses [20,312,313]. CXCR4 is widely expressed in primary cells, 
including tissues and peripheral blood mononuclear cells (PBMCs). Collins and his 
group isolated T, B and NK cells that uniformly expressed CXCR4 [335]. One of their 
investigations involved experiments with lymphocytes, where they have demonstrated 
robust cell migration by combining subactive concentrations (0.1 nM or 1 nM) of 
CXCL12 with increasing concentrations of CXCL14, which peaked at 300 nM CXCL14. 
By using CXCR4 antagonist, AMD3100, they managed to show that the synergy 
response was indeed depend on CXCR4 [308]. Collins and his group concluded that 
the underlying mechanism of synergism between CXCL14 and CXCL12 correlates with 
conformational changes induced by CXCL14 and/or dimer formation of cell-surface 
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CXCR4 [308]. In their studies, they used PBMCs and transfected murine pre-B-cell line 
300.19 while in our studies, we used Jurkat cells, human leukemic T-lymphocytes. This 
may be the possible explanation to this rather contradictory result and showing that 
this signalling is cell-type specific.  
 
Even though our findings differ from what was reported by Collins et al. [308], the 
results of this chapter are consistent with what was reported by Tanegashima et al. 
(2013) [310]. Tanegashima and his group have demonstrated that CXCR4 is the ligand 
binding receptor for CXCL14 and that CXCL14 acts as a natural inhibitor of the 
CXCR4/CXCL12 signalling axis. Since the activity of CXCL14 is analogous to the CXCL12 
dimer, it is suggested that the underlying mechanism may be related to dimerization 
of CXCL14 since there was a complex between CXCL14 and CXCR4 detected. CXCL14 
could suppress the tumour growth via specific inhibition of the CXCR4/CXCL12 
signalling [310]. Despite the potential clinical significance of CXCL14, it remains 
unclear whether CXCL14 modulates CXCR4/CXCL12 signalling physiologically.  
 
Despite the potential clinical significance of CXCL14 in various diseases, molecular 
mechanisms behind physiological functions of CXCL14 are still poorly understood. 
CXCL14 has been implicated in the maintenance of tissue macrophages, cancer 
progression and metabolic regulation [336]. CXCL14 possesses chemoattractive activity 
for activated macrophages, immature dendritic cells and natural kill cells [336]. CXCR4 
is the first chemokine receptor identified that binds CXCL14 with high affinity and 
specificity [310]. In this chapter, we demonstrated that CXCR4 is the ligand binding 
receptor for CXCL14. However, from observations in figure 3.7, CXCR4 alone is not 
sufficient for driving the CXCL14-induced chemotaxis, since Jurkat cells, which express 
CXCR4, showed no response in chemotaxis assays when treated with CXCL14 
compared to positive control CXCL12. There are suggestions that CXCL14 receptor and 
signal transduction pathways may be different from those of conventional CXC-type 
chemokines [336] and that CXCL14 could be implicated in CXCR4/CXCL12 axis to 
modulate important physiological processes in immunological development and stem 
cell maintenance [308,310,337].  
 
Overall, this chapter has shown that MCF-7 and Jurkat cells may be ideal cells for 
studying CXCR4/CXCL12 signalling axis, and that CXCL12 is the most appropriate 
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chemokine to study the biology of CXCR4 in downstream signalling cascades leading 
to migration of cells.  
 
CXCL12 N-His Tag and CXCL14 seem to have an effect in CXC12/CXCR4 signalling axis 
but further work is required to establish the roles of these chemokines in this signalling 
network. There is room for further progress in determining the involvement of other 
chemokines and its receptors and their relationships in modulating physiological 
processes in development, cell maintenance and immune responses.  
 
Since these findings showed migration of cells in CXCR4/CXCL12 signalling, we would 
like to study the roles of two proteins that we believe are involved in initiating 
downstream signalling cascades, leading to migration of cells. The two proteins of 
interest are Protein Kinase C (PKC) and arrestins, which will be discussed in chapters 
4 and 5 (figure 3.12).  
 
Figure 3.13: A simple schematic overview of chemokine receptor signalling to show proteins that 
may be involved in migration of cells towards CXCL12. The two proteins of interest, PKC and arrestins 
have been circled in red.  
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3.4. Chapter conclusions 
 
The final conclusions to be drawn from this chapter are:  
 
1. CXCR4/CXCL12 signalling axis initiates intracellular calcium signalling in 
MCF-7 cells and chemotaxis in Jurkat cells.  
2. The binding of CXCL12 N-His Tag to CXCR4 induces intracellular calcium 
signalling in MCF-7 cells but not chemotaxis in Jurkat cells. This indicates the 
importance of N-terminal residues in CXCL12 in chemotaxis. The data also 
suggests that there may be allosteric regulation of CXCR4 by CXCL12 N-His 
Tag.  
3. The findings of this chapter suggest that CXCL14 acts as an inhibitor in 
CXCR4/CXCL12 signalling axis, and these findings were supported by previous 
studies that showed high affinity binding of CXCL14 to CXCR4 receptors 
[310,336]. However, these interactions are cell-type specific as there were other 
studies showing that is synergy relationship between CXCL12 and CXCL14 on 
CXCR4 receptors in PBMCs [308].  
4. Results indicate that MCF-7 and Jurkat cells could be the ideal cells as model 
systems for studying CXCR4/CXCL12 signalling axis, and CXCL12 is the most 
appropriate chemokine to study the biology of CXCR4 as investigations with 
other chemokines did not show any significant results.  
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CHAPTER 4: Determination of the role of PKC in CXCL12-
induced migration of different cancer cell types  
 
4.1. Introduction  
 
Activation of protein kinase C (PKC) is one of the earliest events in the cascade of signal 
transduction pathways leading to a variety of cellular responses. It has been shown that 
PKC inhibitors do not affect CCL3-induced cell migration in THP-1 cells [142] but 
according to recent studies, different chemokine receptor signalling networks are 
regulated in different ways, in particular, there is a difference in CC- and CXC- receptor 
families [314]. Some PKC isoforms has also been shown to be implicated directly in 
migration of cancer cells via chemokine receptors [338–341].  Several groups have 
shown that receptor desensitisation  is not necessarily based only on phosphorylation 
of agonist- occupied receptors by G-protein coupled receptor kinases (GRK); it can also 
be caused by phosphorylation of receptors by second messenger-activated kinases such 
as PKC, to attenuate receptor interaction with G-proteins [66,342]. Oppermann et al. 
(1999) [343] have shown the equivalence in importance of both GRK and second 
messengers PKC in phosphorylation of  CCR5, a chemokine receptor. Second 
messenger-activated kinases, Protein Kinase A (PKA) and PKC potentially 
phosphorylate both the ligand bound GPCR and multiple other receptors in a 
heterologous manner [141]. The complexities and reversals in PKC pharmacology have 
led to difficulties in understanding the current status of pharmacological activities of 
PKC [136] and determining whether these observations are receptor- or cell-type 
specific is not possible from literature alone. For a more in-depth investigation of 
CXCL12-induced cell migration to be possible, it is important to identify the key points 
in downstream signalling axis. These points will allow comparisons to be made in 
CXCL12-induced cell migration of different cancer cell types and hence, drawing a 
distinct and clearer picture in difference in signal transduction in different cellular 
background. 
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4.2. Chapter aims 
 
Hypothesis: We hypothesised that PKC phosphorylation contributes to CXCL12-
induced migration in different cell types.  
 
Aims: The primary aim of this chapter is to investigate the molecular mechanisms of 
CXCL12-induced cell migration, and the importance of PKC activation in this system. 
This approach should give us a pharmacological insight in the role of PKC in cell 
migration and also, to verify specific signalling pathways in different cell settings. This 
will allow future observations to be related to a specific signalling axis and allow 
comparison to relevant literature.  
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4.3. Results 
 
4.3.1. PKC inhibition has no effect on the internalisation of CCR5 receptors or 
actin polymerisation upon CCL3 activation  
 
Figure 4.1: CCR5 internalisation in CHO.CCR5 cells upon CCL3 activation. Micrographs of CHO.CCR5 
monolayers (a) before and (b) after treatment with 100 nM CCL3. Cells were stained with primary 
antibody, HEK/1/85a/7a rat monoclonal and secondary antibody anti-rat-FITC and fixed with 4% 
paraformaldehyde before imaging. Images representative of population. Acquired with Leica imaging 
suite with 40X magnification.  
 
Basal 
Basal + CCL3  
a  
b  
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PKC has been shown to have central roles in signalling in response to many 
extracellular ligands and can influence many aspects of cell behaviour [344]. As 
discussed in this chapter’s introduction, pan-isotype PKC inhibition does not inhibit 
migration of THP-1 cells [142], but the involvement of specific isoforms has not been 
particularly well characterised. Pre-treatment of CHO.CCR5 cells with 5 µM 
GF109203X and 4 µM Rottlerin for 30 minutes didn’t seem to affect CCR5 
internalisation upon 100 nM CCL3 activation as loss of CCR5 receptors on the surface 
(figure 4.2) was observed after incubation of the cells with CCL3 for 30 minutes. Figure 
4.2 shows no obvious difference in CCR5 internalisation compared to control 
experiments (figure 4.1).  
 
Figure 4.2: PKC inhibitors, GF109203X and Rottlerin, do not affect CCR5 internalisation in CHO.CCR5 
cells upon CCL3 activation. Micrographs of CHO.CCR5 monolayers treated with 100 nM CCL3 and PKC 
inhibitors, (a) GF109203X and (b) Rottlerin. Cells were stained with primary antibody, HEK/1/85a/7a 
rat monoclonal and secondary antibody FITC and fixed with 4% paraformaldehyde before imaging. 
Images representative of population. Acquired with Leica imaging suite with 40X magnification.  
 
 
GF109203X GF109203X + CCL3 
Rottlerin  Rottlerin + CCL3 
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GF109203X is a potent, highly selective, pan-isotype PKC inhibitor 
bisindolylmaleimide. GF109203X does not inhibit PKC through the regulatory domain 
of the kinase and it has an IC50 of 0.02 µM. It is a conventional PKC inhibitor that 
inhibits isoforms α, βI, βII and γ with similar potency [148]. Rottlerin is Mallotoxin, 
which is isolated from Mallotus philippinesis. Rottlerin has been widely used as a 
selective inhibitor of PKCδ at IC50 of 3 – 6 µM though its role as a specific PKCδ 
inhibitor has been questioned. Rottlerin has recently been described as a promiscuous 
inhibitor, and therefore it is not valid any longer to describe Rottlerin as a selective 
inhibitor of PKCδ, since there are biological and biochemical processes that are PKCδ- 
independent that may affect results [152,345].  
 
These results supports the observations made by Cardaba et al. [142], which showed 
that PKC inhibitors do not affect CCL3 induced migration in THP-1 cells. Figure 4.2 
showed no effects of CCR5 internalisation upon CCL3 activation, therefore, it is 
unlikely that the PKC inhibitors will affect CCL3 induced migration via the chemokine 
receptor CCR5.  
 
Fluorescence microscopy was used to determine if the PKC inhibitors, GF109203X and 
Rottlerin, disrupt cytoskeleton using Alexa-488 Phalloidin stained CHO.CCR5 cells. 
CHO.CCR5 cells were used in these experiments, as they are large cell lines and allow 
for easier identification of cellular structures. These cells were grown as monolayer on 
coverslips to high confluence (refer to section 2.10.1.; page 60) and were treated for 30 
minutes with 5 µM GF109203X or 4 µM Rottlerin and then 100 nM CCL3 for 1 hour 
prior to fixing and staining. Cells were stimulated with 100 nM CCL3 for 1 hour prior 
to fixing and staining. 
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Figure 4.3: Actin polymerisation in CHO.CCR5 cells. Micrographs of CHO.CCR5 monolayers (a) before 
and (b) after treatment with 100 nM CCL3. Cells were fixed and stained with Alexa-488 Phalloidin actin 
stain (green). Images representative of population. Acquired with Leica imaging suite with 63X 
magnification.  
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Figure 4.4: PKC inhibitors, GF109203X and Rottlerin, do not disrupt actin polymerisation in 
CHO.CCR5 cells. Micrographs of CHO.CCR5 monolayers treated with 100 nM CCL3 and PKC inhibitors, 
(a) GF109203X and (b) Rottlerin. Cells were fixed and stained with Alexa-488 Phalloidin actin stain 
(green). Images representative of population. Acquired with Leica imaging suite with 63X 
magnification. 
 
Actin filaments observed were clearly not disrupted in both basal and pre-treated PKC 
inhibitors CHO.CCR5 cells (figures 4.3, 4.4) and it could be seen that the distribution 
of actin was uniform. Through fluorescence microscopy, it can be concluded that PKC 
inhibitors did not disrupt the actin cytoskeleton upon CCL3 activation and the 
presence of stress fibres were evident.  
 
Alexa-488 Phalloidin binds to actin filaments much more tightly than to actin 
monomers, and this leads to a decrease in the dissociation rate of actin subunits from 
filament ends, essentially stabilising actin filaments through the prevention of filament 
depolymerisation. Upon CCL3 activation, there were visible actin stress fibres observed 
in stained CHO.CCR5 cells with Alexa-488 tagged phalloidin (figure 4.3). There was no 
difference observed between CCL3 activated basal CHO.CCR5 and pre-treated PKC 
GF109203X GF109203X + CCL3  
Rottlerin  Rottlerin + CCL3  
a  
b  
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inhibitors CHO.CCR5 cells. These observations agree with results that were published 
before, where PKC inhibitors do not affect CCL3 induced migration via chemokine 
receptor CCR5 [142] and unsurprisingly, no obvious disruption of the actin 
cytoskeleton was observed.  
 
4.3.2. PKC inhibitors do not have any effects on CXCL12-induced calcium release in 
MCF-7 cells 
 
In the literature, it has been suggested CC- and CXC- chemokine receptor signalling 
networks are regulated in different ways in cellular migration activation [313,314,346]. 
As discussed in chapter 3, MCF-7 cells have been widely used in CXCR4/CXCL12 
research as they have been shown to highly express receptor CXCR4 when stained with 
the anti-CXCR4 12G5 mAB [4,8,286]. With that information, it shows us that they are 
a good model system to study the role for CXCR4 and its signalling axis in the 
progression to metastasis.  
 
MCF-7 cells were treated with different PKC inhibitors at their working concentrations 
(refer to table 1.2) to target different PKC isoforms. This would allow the roles of 
phosphorylation by different PKC isoforms in migration of cells to be assessed 
individually.  
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Figure 4.5: PKC inhibitors do not reduce calcium release in MCF-7 cells. (a, b, c) Pre-treatment for 30 
minutes with 5 μM GF109203X, 4 μM Rottlerin, 10 nM Staurosporine do not significantly affect 
intracellular calcium flux in MCF-7 cells after stimulation with 10 nM CXCL12. (d, e, f) Representative 
tracers showing calcium mobilisation in MC7-cells (10 nM CXCL12). Results represent the mean ± SEM 
of at least 3 independent experiments (Unpaired t-test, ns = not significant, p>0.05) 
 
Pre-treatment of MCF-7 cells with 5 μM GF109203X, 4 μM Rottlerin and 10 nM 
Staurosporine for 30 minutes had no significant effect on the levels of calcium release 
observed (figure 4.5). Staurosporine is an antibiotic that is isolated from Streptomyces 
staurosporeus. It is a potent cell-permeable PKC inhibitor and has a similar structure 
as GF109203X. It has an IC50 of 2.7 nM with regards to block the enzyme from rat brain 
[347]. 
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This indicates that CXCL12-induced calcium release is not PKC-dependent, and since 
migration of cells can occur independently of intracellular calcium release, migration 
of cells via CXCR4/CXCL12 signalling axis should be investigated individually to see if 
PKC activation is needed.  
 
4.3.3. Inhibition of PKC blocks migration of MCF-7 cells in wound healing assays 
 
Figure 4.6: Wound healing assay on MCF-7 cells in the presence or absence of Rottlerin or 
GF109203X. Cell migration was induced with 10 nM CXCL12 and measured after 24 hours. Images are 
representative of 3 independent experiments.  
 
CXCR4 and its ligand CXCL12 have been shown to play an important role in regulating 
metastasis of breast cancer to specific organs in the body via a CXCL12-CXCR4 
chemotactic gradient [192]. There are a variety of studies that show that PKC isoforms 
are also important for cancer cell migration [348,349]. Here, we investigated whether 
PKC is implicated in CXCL12-induced migration in adherent breast cancer MCF-7 cells 
by blocking the PKC enzymes with the pan-isotype PKC inhibitors, GF109203X, 
Rottlerin and Staurosporine.   
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Figure 4.7: Quantification of migration of MCF-7 cells into the wound in the presence or absence of 
PKC inhibitors, GF109203X or Rottlerin. A value of 1 denotes no migration occurred whereas a value 
< 1 denotes cell migration. Pre-treatment for 24 hours with PKC inhibitors have significant inhibitory 
effect on MCF-7 cells migration towards 10 nM CXCL12 vs control in wound healing assays. All results 
represent the mean ± SEM of 3 independent experiments (One-way ANOVA, Bonferroni multiple 
comparison, *= p≤0.05, **= p≤0.01).  
 
Figure 4.7 showed that PKC may be involved in CXCL12-induced migration in MCF-7 
cells as there was a significant inhibition in migration of cells into the wound after 24 
hours treatment with PKC inhibitors, GF109203X (**=p≤0.01) and Rottlerin 
(*=p≤0.05).  
 
For further determination if PKC activation is needed in CXCL12-induced migration in 
MCF-7 cells, another pan-isotype PKC inhibitor, Staurosporine was used.  
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Figure 4.8: Quantification of migration of MCF-7 cells into the wound in the presence or absence of 
PKC inhibitor, Staurosporine. A value of 1 denotes no migration occurred whereas a value < 1 denotes 
cell migration. Pre-treatment for 24 hours with PKC inhibitor shows trends of inhibitory effect on MCF-
7 cells migration towards 10 nM CXCL12 vs control in wound healing assays. All results represent the 
mean ± SEM of 3 independent experiments (One-way ANOVA, Bonferroni multiple comparison, ns = 
not significant, p>0.05).  
 
Pre-treatment with Staurosporine had no significant effect but it showed trends of 
inhibitory effect on MCF-7 cells migration towards 10 nM CXCL12 in wound healing 
assays (figure 4.8).  
 
These results (figures 4.7, 4.8) show that PKC activation is needed in CXCL12-induced 
migration of MCF-7 cells via CXCR4. siRNA knockdown of PKCα and PKCζ proteins in 
MCF-7 cells confirmed the importance of PKC for migration in these cells (figure 4.9), 
where Mills et al. (2016) [286] showed that the loss of conventional isoform, PKCα, and 
atypical isoform, PKCζ, completely abolishes any migration towards CXCL12.  
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Figure 4.9: PKCα and PKCζ siRNA knockdown experiments showed significant loss of CXCL12-
induced migration in chemically transfected MCF-7 cells. (a) Wound healing assay on MCF-7 cells 
after transfection with 50 nM scrambled siRNA as control or PKCα siRNA. Cell migration was induced 
with 10 nM CXCL12 and measured after 24 hours. (b) Western blot analysis of PKCα expression in 
MCF-7 cells after siRNA knockdown, where β-actin acts as loading control. (c) Wound healing assay on 
MCF-7 cells after transfection with 50 nM scrambled siRNA as control or PKCζ siRNA. Cell migration 
was induced with 10 nM CXCL12 and measured after 24 hours. (d) Western blot analysis of PKCζ 
expression in MCF-7 cells after siRNA knockdown, where β-actin acts as loading control. Quantification 
of migration of cells into the wound. A value of 1 denotes no migration occurred whereas a value < 1 
denotes cell migration. All results represent the mean ± SEM of 6 independent experiments (One-way 
ANOVA, Bonferroni multiple comparison, **= p≤0.01, ***= p≤0.001). Note: Collaboration with Shirley 
Mills in the laboratory [286].  
 
MCF-7 cells were chemically transfected with scrambled siRNA as control, PKCα or 
PKCζ siRNA via Turbofect for 24 hours. Transfected MCF-7 cells were treated with 10 
nM CXCL12 for another 24 hours before wound healing assay analysis (refer to section 
2.9.3.; page 59). There is a significant loss of migration in chemically transfected PKCα 
and PKCζ siRNA MCF-7 cells, and therefore, confirms the importance of PKC activation 
for migration in these cells (figures 4.9a and 4.9c). The success of knockdown was 
confirmed by western blot analysis as shown in figures 4.9b and 4.9d.  
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4.3.4. Inhibition of PKC has no effect on Jurkat cell migration  
 
As discussed in this chapter’s introduction, pan-isotype PKC inhibition does not inhibit 
migration of THP-1 cells [142], but the involvement of specific isoforms has not been 
well characterised particularly as there is some evidence that atypical PKCζ is directly 
involved in CXCL12 signalling in immature human CD34+- enriched cells and in 
leukemic pre-B Acute Lymphocytic Leukaemia (ALL) G2 cells [339].  
 
As further confirmation to see if PKC activation is needed in CXCL12-induced 
migration, leukemic Jurkat cells were used as they have been shown to express CXCR4 
[286] and they are good model system that are frequently used to study 
CXCR4/CXCL12 signalling axis.   
 
CXCL12-induced cell migration depends on certain intracellular proteins, which need 
to be activated to allow the cell to move towards the chemokine stimulus [11], hence it 
is important to study different signalling cascades and see whether they are implicated 
in CXCR4 migration in suspension cells compared to adherent cells.  
 
Pre-treatment of suspension leukemic T-lymphocytes, Jurkat cells, with different PKC 
inhibitors have shown that they have no significant inhibitory effects in chemotaxis 
towards 1 nM CXCL12 in chemotaxis assays (figure 4.10). 
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Figure 4.10: PKC and PKD inhibitors have no significant inhibitory effect on CXCL12-induced 
migration in suspension Jurkat cells. (a) Cell migration towards 1 nM CXCL12 in untreated control 
cells or GF109203X pre-treated cells. (b) Cell migration towards 1 nM CXCL12 in untreated control 
cells or Rottlerin pre-treated cells.  (c) Cell migration towards 1 nM CXCL12 in untreated control cells 
or Staurosporine pre-treated cells. (d) Cell migration towards 1 nM CXCL12 in untreated control cells 
or CID755673 pre-treated cells.  All results represent the mean ± SEM of 4 independent experiments 
(One-way ANOVA, Bonferroni multiple comparison, * = p≤ 0.05, ns = not significant).  
 
This observation is different from what was seen in adherent MCF-7 cells but agrees 
with the results that were seen in CCL3 induced migration of suspension cell line    
THP-1, where PKC activation is not essential [142]. Pan-isotype GF109203X, Rottlerin 
and Staurosporine not only did not have inhibitory effects in migration of cells but 
showed trends of increasing number of cells migrating (figure 4.10a, b, c). Pre-
treatment of Jurkat cells with Rottlerin showed significant increased migration of 
Jurkat cells (figure 4.10b).  
 
Pre-treatment of Jurkat cells with 5µM GF109203X showed high number of cells 
migrating, even in mean basal control GF109203X. This suggests that GF109203X 
might have directly or indirectly induced cell activation, which leads to cell migration. 
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However, these observations contradict with studies from other groups, as they have 
shown that GF109203X is a potent and selective inhibitor of PKC [138,148]. 
Alternatively, PKC has a role in receptor desensitisation, and hence slowing or stopping 
basal cell migration. In these experiments, activation of PKC was inhibited by 
GF109203X. This might cause reduced activation of PKC, resulting in continued 
activation of receptor and therefore, migration of cells.  
 
To confirm that PKC activation is not essential in CXCL12-induced migration in Jurkat 
cells, a more specific protein kinase D (PKD) inhibitor, CID755673, was used. PKD is a 
serine/threonine kinase with three isoforms; PKD1-3 [350]. It was previously thought 
to be PKC isoform, PKCµ, but catalytic domain homology has since distinguished PKD 
as a member of calcium calmodulin-dependent kinase (CaMK) family [154]. Figure 
4.10d shows that there was no inhibition in migration of Jurkat cells when cells were 
treated with CID755673.  
 
siRNA knockdown experiments were also undertaken to confirm the importance of 
PKC for CXCL12-induced migration in Jurkat cells.  
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Figure 4.11: PKCα and PKCζ siRNA knockdown experiments showed significant loss of CXCL12-
induced migration in electroporation transfected Jurkat cells. (a) Cell migration towards 1 nM CXCL12 
in Jurkat cells after transfection with scrambled siRNA as control or PKCα siRNA. (b) Cell migration 
towards 1 nM CXCL12 in Jurkat cells after transfection with scrambled siRNA as control or PKCζ siRNA. 
(c) Western blot analysis of PKCα expression in Jurkat cells after siRNA knockdown, where β-actin acts 
as loading control. All results represent the mean ± SEM of 6 independent experiments (One-way 
ANOVA, Bonferroni multiple comparison, ***= p≤0.001). Note: Collaboration with Shirley Mills in 
laboratory [286]. 
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Jurkat cells were transfected with scrambled siRNA as control, PKCα or PKCζ siRNA by 
electroporation transfection using AMAXA Nucleofector for 24 hours prior to 
chemotaxis assays (refer to section 2.6.2.; page 55). siRNA knockdown of PKCα and 
PKCζ proteins in Jurkat cells allow us to differentiate between the use of different PKC 
isoforms. PKCα knockdown leads to a significant loss of about half the migratory 
response (figure 4.11a), whereas PKCζ knockdown has less, but still significant, impact 
(figure 4.11b). In figures 4.11a and 4.11b, there are still a robust number of cells migrating 
but when compared to migration of control cells (transfected with 50 nM scrambled 
siRNA), the migration of PKCα and PKCζ siRNA transfected Jurkat cells is significantly 
lowered. The success of knockdown was confirmed by Western blot analysis (figure 
4.11c).  
 
4.4. Discussion  
 
The aim of this chapter was to determine the role of PKC in CXCL12-induced migration 
of different cancer type of cells through different assays.  
 
PKC is a family of protein kinases enzymes that are involved in controlling the function 
of other proteins through the phosphorylation of hydroxyl groups or serine and 
threonine residues on these proteins. PKC isoforms transduce a wide range of 
extracellular signals that result in the generation of DAG, therefore regulating diverse 
cellular behaviours such as survival, growth and proliferation, migration and apoptosis 
[344]. Hence, it is important to investigate the downstream signalling cascades that 
leads to migration of cells after PKC activation as dysregulation can be associated with 
a plethora of pathophysiologies [136]. PKCs were famously discovered and studied due 
to its role as direct signal transducers for phorbol esters [351], a class of plant-derived 
tumour-promoting compounds, which potently mimics the function of endogenous 
ligand, DAG [134].  
 
As discussed in introduction, Oppermann et al. (1999) [343] have shown that 
phosphorylation of the receptors by GRK and PKC are both equally important in 
activating downstream signalling cascades upon ligand activation but the involvement 
of specific isoforms has not been well characterised.  
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Figure 4.12: Overview of signalling cascade. Schematic overview of signalling cascades involved in the 
migration of cells towards CXCL12.  
 
Figure 4.12 shows an overview of cascade, and the potential intracellular signalling 
proteins that are involved in CXCR4/CXCL12 signalling axis. The chemokine receptor 
CXCR4 has been of interest for a number of years, as it has been shown to be up-
regulated in several cancers and its activation can lead to cancer cell metastasis 
[192,286,352]. Although numerous studies have investigated cell migration of cells over 
the years, there are still questions that remain unanswered as to which downstream 
effector proteins are important to contribute in the movement of cells. Furthermore, 
there is conflicting evidence in the literature about the importance or involvement of 
downstream signalling partners in different systems [78,338,339,353]. Characterisation 
of the signalling molecules is usually carried out specifically. Since there are so many 
different cell types or read out systems and approaches, it is unsurprising that some of 
the data may contradict each other. Therefore, studying the main signalling molecules 
that are thought to be of importance in CXCL12-induced migration in adherent cells 
versus suspension cells can give us a clearer picture of CXC-system in different cell 
types.  
 
One of the findings in this chapter is that there are indeed differences in which 
signalling molecules are important for cell migration in leukemic cells compared to 
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adherent breast cancer cells. Both Jurkat and MCF-7 cells do express CXCR4 and 
migrate towards CXCL12, however the signalling molecules between the two cell types 
show some intriguing differences [286].  
 
Small molecule inhibitors were used in experiments to investigate the importance of 
PKC activation in migration of cells. Studies have shown that all PKC inhibitors possess 
some degree of promiscuity, but conventional and novel PKCs have been shown to 
somewhat have lower levels of selectivity, with approximately 5-10% of compounds in 
screen hitting their isoforms [231,354–356].  
 
There are a variety of studies that show that PKC isoforms are also important for cancer 
cell migration [341,348]. Pan-isotype inhibitors, GF109203X and Rottlerin, completely 
blocks breast cancer cell migration towards CXCL12 (figures 4.7); however, at the same 
concentration of the inhibitors, there is no inhibitory effects on the migration of the 
leukemic suspension cells towards CXCL12 (figures 4.10a, 4.10b). Instead, it seems like 
GF109203X and Rottlerin lead to an increase in migration of the suspension Jurkat cells 
(figures 4.10a, 4.10b). This result agrees with previous studies, where PKC inhibitors do 
not block the migration of suspension THP-1 cells [314], as discussed above.  
 
To put into context, PKC activation may be required to activate MAPK-induced 
migration in adherent MCF-7 cells but in suspension Jurkat cells, it is implied that PKC 
may have a role in desensitisation of CXCR4 receptor. If PKC activation is inhibited and 
resulting in absence of phosphorylation via PKC, signal termination may not be able to 
occur. Hence, it can be hypothesised that the increase in CXCL12-induced migration of 
Jurkat cells is due to PKC causing a prolonged desensitisation of the receptor. These 
observations suggest that there are differential effects of PKC-mediated desensitisation 
in different cell types, which leads to different cellular responses.  
siRNA approach was used to further confirm the results obtained with the small 
molecule inhibitors and it showed that knockdowns of PKCα and PKCζ in MCF-7 cells 
completely blocks movement of the cells in wound healing assays (figures 4.9a, 4.9c) 
[286], confirming the results acquired from inhibition of PKC using small molecule 
antagonists (figures 4.7, 4.8). However, knockdown of these PKC isoforms in 
suspension Jurkat cells generated a different and more complicated picture as 
knockdowns of PKCα and PKCζ has contradicted with observations with small 
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molecule antagonists. Knockdown of PKCα and PKCζ result in a significant loss of 
migratory cells (figures 4.11a, 4.11b), which is very different from the observations seen 
in PKC inhibition studies with small molecular antagonists (figure 4.10). Hence, it is 
speculated that there is a difference in the usage of PKC in CXCL12-induced migration 
of these two cell types [286].  
 
As discussed previously, the structure of all PKCs consists of a regulatory domain and 
a catalytic (also known as kinase) domain, which are joined together by a hinge region 
[357]. The catalytic region is highly conserved among the different isoforms, and this 
is the region that allows for different functions to be processed [131]. Another feature 
of the PKC catalytic region that is essential to the viability of the kinase is its 
phosphorylation. The conventional and novel PKCs have three phosphorylation sites; 
the activation loop, the turn motif and the hydrophobic motif; while atypical PKCs are 
phosphorylated only on the activation loop and the turn motif [357]. These 
phosphorylation events are essential for the activity of the enzyme, except for 
phosphorylation of the hydrophobic Ser660/Thr729 motif as it has been shown to be 
unnecessary by the presence of glutamic acid which acts as a negative charge and 
similar to a phosphorylated residue [130,358,359].  
 
Based on the observations from these experiments, it can be speculated that MCF-7 
cells need the catalytic activity of PKC and so small molecule antagonists as well as 
knockdown prevents migration of cells, whereas Jurkat cells may not need the kinase 
activity of PKC, which is implicated in cell migration, but it may depend on the 
functionality of the other PKC isoforms domains. It has been shown that PKCs can be 
cleaved by caspases, generating a catalytically active kinase domain and a freed 
regulatory domain fragment that can act both as an inhibitor of the full-length enzyme 
and as an activator of certain signalling responses [132]. 
 
Overall, the data in Jurkat cells is more complex, but they show a difference towards 
use of PKC in MCF-7 cells and so further investigations should be carried out. To draw 
a clearer picture, it is important to investigate downstream signalling cascades 
following phosphorylation of receptors. Arrestins, another group of proteins that have 
been known to play a role in desensitisation and migration of cells, bind to 
phosphorylated receptor. Hence, studying arrestins is the way forward to further 
115 
 
characterise the role of PKC and, to understand the role of arrestins in different cell 
types as difference in usage of PKC in two different cell systems was observed.  
 
 
 
 
 
 
  
116 
 
4.5. Chapter conclusions 
 
The final conclusions to be drawn from this chapter are: 
 
1. PKC activation is essential in adherent breast cancer cells, MCF-7 cells as 
inhibition of PKC blocks MCF-7 cell migration. This result was further 
confirmed by siRNA knockdown experiments, where it was shown that 
knockdown of conventional PKCα and atypical PKCζ, abrogates movement of 
cells.  
2. Inhibition of PKC has no inhibitory effects on suspension leukemic Jurkat cells 
migration but knockdown of PKCα and PKCζ result in a significant loss of 
migratory cells. This suggests that there is a difference in the usage of PKC 
isoforms domains in different cell types.  
3. This chapter concludes that the cellular background may be important for 
distinct signalling pathways used by the CXCR4 receptor and therefore a 
generalisation of how CXCR4 induces migration in different cell types and 
species should be avoided.  
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CHAPTER 5: Role of arrestins in CXCR4/CXCL12 signalling axis 
 
5.1. Introduction  
 
Over the past decade, significant efforts have been made to unravel the regulatory 
properties and molecular mechanisms that control arrestins’ interactions with GPCRs. 
One of arrestins’ roles involve selectively binding to the active phosphorylated forms 
of their cognate GPCRs, which mediate receptor desensitisation  by blocking G-protein 
coupling [163]. In addition to their ‘classical’ function in desensitisation  and 
internalisation, arrestins are important for regulating GPCR signal transduction 
[108,109]. Currently, there are four known arrestin subtypes; arrestins 1 and 4 have been 
shown to be expressed in photoreceptor cells and are known as the two visual subtypes 
while arrestins 2 and 3 (also known as β-arrestins-1 and -2) are non-visual arrestins, 
which are expressed ubiquitously in all cells and tissues. Arrestins 2 and 3 not only have 
a function in the desensitisation of most GPCRs, but they also serve as multifunctional 
adaptors and scaffolds of GPCR signalling [80,81]. All these insights have shed some 
light on the complexity involving GPCR-arrestin interactions and to help researchers 
understand arrestins’ role in development of cancer and tumour metastasis through 
chemotaxis [81,171]. Over the years, various signalling molecules that are involved in 
CXCR4 triggered migration have been identified, however, there is still some 
uncertainty about which pathways are directly involved in cell migration. The 
requirement of arrestins for chemotaxis in the downstream signalling networks of 
multiple receptors implicates that arrestins play a key role in mediating cell migration 
[81,246,360]. Studies on chemokine receptors suggest that receptor desensitisation and 
recycling are important for cell polarisation during chemotaxis [80,81]. Furthermore, 
arrestins facilitate the activation of numerous effector pathways, such as MAPKs and 
Akt, and acts as a scaffold for specific components of the MAPK signalling cascade 
[185,361]. As mediators of receptor desensitisation, arrestins contribute to cell polarity 
during chemotaxis by quenching the signal at the trailing edge of the cell. An 
alternative theory is that arrestins scaffold signalling molecules that are involved in 
cytoskeletal reorganisation to promote localised actin assembly events leading to the 
formation of leading edge [362–365]. The involvement of arrestins in chemokine 
release as well as actin reorganisation suggests that they play multiple roles in the in 
vivo chemotactic process. More extensive studies that evaluate the speed and distance 
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of migration, as well as more in vivo studies that demonstrate immune cell infiltration, 
cancer metastasis, wound healing, and other cellular responses, are necessary to fully 
elucidate the role of each pathway [183].   
 
5.2. Chapter aims 
 
Hypothesis: We hypothesised that arrestins is important in CXCL12-induced 
migration in different cell types.  
 
Aims: The primary aim of this chapter is to investigate the role and importance of 
arrestin 2 and arrestin 3 in CXCL12-induced migration and whether they are involved 
either in cell polarisation or act as potential scaffolds in this system.  This approach 
should give us some pharmacological insights into the role of arrestins in cell migration 
and help us to understand the interactions of arrestins with different signalling 
molecules, such as PKC, within different cellular settings. This will allow future 
observations to be related to a specific signalling axis and allow comparison to relevant 
literatures.  
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5.3. Results  
 
5.3.1. Investigation of the role of arrestins in non-invasive adherent breast cancer 
cells, MCF-7 cells via CXCR4 upon CXCL12 activation 
 
Recent findings indicate that most signalling pathways do not function in isolation, but 
rather as components of larger signalling networks. It is no surprise that several recent 
studies showed that arrestins mediate various forms of crosstalk between receptor 
signalling systems due to arrestins’ position in cells as discussed previously 
[81,261,366]. However, while most studies have focused on roles of arrestins at the 
plasma membrane and in the cytoplasm, emerging evidence suggests additional 
functions in the nucleus, specifically in regulating transcription [366]. Both arrestins 
contain nuclear localisation signals, but only arrestin 3 contains a nuclear export signal. 
Thus, whereas arrestin 3 is found exclusively in the cytoplasm, arrestin 2 is present in 
both cytoplasm and the nucleus [193].  
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Figure 5.1: Micrographs of MCF-7 monolayers treated with 10 nM CXCL12. MCF-7 cells were (a) mock 
transfected (basal) as negative control and (b) chemically transfected with 2 μg plasmid DNA coding 
non-functional pEGFP.C2 as a control for 24 hours. Cells were fixed with 4% paraformaldehyde before 
imaging. Images representative of population. Acquired with Leica imaging suite with 63X 
magnification.   
 
 
 
 
 
Basal  Basal + CXCL12  
pEGFP.C2 pEGFP.C2 + CXCL12 
a  
b  
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Figure 5.2: Overexpression of arrestins in MCF-7 cells upon CXCL12 activation. Micrographs of      
MCF-7 monolayers treated with 10 nM CXCL12. MCF-7 cells were chemically transfected with 2 μg 
plasmid DNA coding for (a) EGFP tagged arrestin 2 (pArr2.EGFP), (b) EGFP tagged arrestin 3 
(pArr3.EGFP) and (c) EGFP tagged arrestin 2-mutant (pA2-Mut.EGFP), for 24 hours. Cells were fixed 
with 4% paraformaldehyde before imaging. Images representative of population. Acquired with Leica 
imaging suite with 63X magnification.   
 
Figure 5.1 shows control experiments and figure 5.2 shows successful transient 
transfection of EGFP tagged arrestins 2,3 and arrestin 2-mutant in MCF-7 cells.  
Overexpression of arrestins 2 and 3 in transfected pArr2.EGFP and pArr3.EGFP MCF-7 
cells can be found mainly in the cytoplasm. There is a distinct difference in terms of 
pArr2.EGFP  pArr2.EGFP + CXCL12 
pArr3.EGFP pArr3.EGFP + CXCL12 
pA2-Mut.EGFP pA2-Mut.EGFP + CXCL12 
a  
b  
c  
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localisation of these proteins compared with the pA2-Mut.EGFP transfected MCF-7 
cells, where the mutated arrestins 2 found spread between the cytoplasm and nucleus 
of the cells but mostly located within the nucleus of the cell. It appears that point 
mutation of the protein arrestin 2 changes the location of its accumulation within the 
cell. This is different when compared to wildtype (WT) arrestin 2, where it can be 
observed that most of the arrestins were located in the cytoplasm of MCF-7 cells (figure 
5.2).  
 
These results (figures 5.1, 5.2) also show the differences in movement of arrestins upon 
CXCL12 activation via CXCR4 receptors in MCF-7 cells. Arrestins are well known 
negative regulators of GPCR signalling [366]. Upon GPCR activation, arrestins have 
been shown to translocate to the cell membrane and bind to the phosphorylated 
agonist-occupied receptors which will lead to uncoupling of these receptors from G-
proteins  and promote the internalisation of these receptors, which attenuates 
signalling [367]. In MCF-7 cells that have been transiently transfected with pArr3.EGFP 
plasmids, a clear movement of arrestin upon CXCL12 activation is visible, compared to 
cells which were transfected with pArr2.EGFP and pA2-Mut.EGFP plasmids (figure 
5.2). This movement leads to visible change of fluorescence localisation in the cell, 
where arrestin 3 has clustered together in defined little spots after CXCL12 treatment, 
showing that arrestin 3 may be involved in CXCR4 activation.  
 
The binding of CXCL12 to CXCR4 induces intracellular signalling through several 
divergent pathways, which leads to downstream events such as chemotaxis, cell 
survival, and/or cell proliferation, increase in intracellular calcium and gene 
transcription [2]. Ligand stimulation can result in an increase in intracellular calcium 
and this change is usually used as a measure of the chemokine activity [2,142].  
 
Non-visual, arrestins 2 and 3, are known to function either as terminators of receptor 
signalling and clathrin adaptor proteins by mediating GPCR desensitisation and 
internalisation, or independently as scaffolds for signalling, where they act as 
multifunctional adaptor/scaffold proteins that dynamically assemble a wide range of 
complexes in response to stimulation of most 7 TMRs [171,179]. The hypothesis is that 
overexpression of arrestins can either enhance homologous GPCR desensitisation or 
enhance arrestin-dependent signalling. To determine if CXCR4-mediated calcium 
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release is arrestin-dependent, MCF-7 cells were transfected (refer to section 2.7.1.; page 
56) with pArr2.EGFP, pArr3.EGFP and pA2-Mut.EGFP plasmids DNA. Control cells 
were transfected with pEGFP.C2 plasmids, which leads to an expression of green 
fluorescent protein but no signalling function.  
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Figure 5.3: pArr3.EGFP and pA2-Mut.EGFP transfected MCF-7 cells seem to slightly increase calcium 
release. (a) Fluorescence assays using 2 μg plasmids DNA coding for different EGFP tagged arrestin 
subtypes compared to mock transfected MCF-7 cells. (b) Calcium release of MCF-7 cells transfected 
with 2 μg plasmid DNA coding for different EGFP tagged arrestin subtypes upon 10 nM CXCL12 
activation with pEGFP.C2 as control. (c) Ratio of calcium flux of transfected MCF-7 cells vs expression 
levels of arrestins in transfected MCF-7 cells. Results represent the mean ± SEM of at least 3 
independent experiments (One-way ANOVA, Dunnett’s multiple comparison, ns = not significant, 
p>0.05). 
 
a 
b 
c 
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Figure 5.3a shows successful transient transfection of different EGFP tagged arrestins 
subtypes in MCF-7 cells using fluorescence assays. In figure 5.3b, MCF-7 cells that have 
been transiently transfected with pArr3.EGFP and pA2-Mut.EGFP plasmids showed a 
trend of increase, though not significant, in calcium release upon stimulation by 10 nM 
CXCL12 compared to control pEGFP.C2 transfected MCF-7 cells. An increase in 
calcium signalling when there was an overexpression of arrestin 3 and mutated arrestin 
2 suggest that CXCR4-mediated calcium release in MCF-7 cells may not have occurred 
via ‘classical’ G-protein signalling, in which arrestin acts as a desensitising protein.  
 
Quantification by ratio in relative fluorescence unit (figure 5.3c) accounts for the 
difference in calcium release of transfected MCF-7 cells to expression levels of different 
arrestins’ subtypes and the results showed that there was a trend towards an increase 
in calcium release comparative to an increase in the level of arrestin 3 expression. 
Though the results were not significant, they suggest that arrestin 3 play a role in 
calcium release via CXCR4 upon CXCL12 activation, but not arrestin 2 as pArr2.EGFP 
and pA2-Mut.EGFP overexpressed cells didn’t show any difference in calcium release. 
Analysis of the data suggested that arrestins not only mediate desensitisation  of G-
protein signalling, but may also act as signal transducers themselves [109].  
 
5.3.2. Arrestin 3 overexpression slightly increase MCF-7 cells migration in wound 
healing assays via CXCR4 receptor upon CXCL12 activation 
 
Classically, arrestins terminate receptor signalling. After receptor activation, arrestins 
desensitise phosphorylated GPCRs, blocking further activation and initiating receptor 
internalisation.  Arrestins are required for the desensitisation of several chemokine 
receptors, including CCR2, CXCR1, CXCR2, CCR5 and chemokine receptor of interest, 
CXCR4, which is primarily activated by CXCL12 [14,81,246,284,368,369]. It has been 
shown that arrestins are required in CXCR4-mediated lymphocyte chemotaxis [182] 
but the precise role of arrestins in leukocyte chemotaxis has not been fully defined. 
Aberrant expression of CXCR4 in human breast cancer correlates with the metastasis 
to tissues secreting CXCL12, and recently arrestins have emerged as key regulators of 
migration of cells. However, the involvement and role of arrestins in migration of these 
cancer cells has not yet been established. Here, we investigated the role of arrestins in 
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by chemically transfecting MCF-7 cells and using wound healing assays to assess 
migration of cells as shown in figures 5.4 and 5.5.  
 
 
Figure 5.4: Wound healing assay of chemically transfected MCF-7 cells. MCF-7 cells were transfected 
with 2 μg plasmids DNA coding (a) non-functional pEGFP.C2 as a control and (b) pArr2.EGFP for 24 
hours, overexpressing arrestin 2. After 24 hours of transfection, cell migration was induced with 10 
nM CXCL12 and measured after 24 hours. Acquired with Leica imaging suite with 10X magnification. 
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Figure 5.5: Wound healing assay of chemically transfected MCF-7 cells. MCF-7 cells were transfected 
with 2 μg plasmids DNA coding (a) pArr3.EGFP and (b) pA2-Mut.EGFP for 24 hours, overexpressing 
arrestin 3 and mutated arrestin 2. After 24 hours of transfection, cell migration was induced with 10 
nM CXCL12 and measured after 24 hours. Acquired with Leica imaging suite with 10X magnification. 
 
Pre-treatment for 24 hours with 10 nM CXCL12, pArr3.EGFP MCF-7 cells show a trend 
of increase of migration of cells into the wound (figure 5.5). Arrestin 3 overexpression, 
though not significant, appeared to increase MCF-7 migration slightly. This further 
indicate that both calcium release and migration of MCF-7 cells does not occur via 
‘classical’ G-protein signalling as there was an increase in calcium release and migration 
of MCF-7 cells overexpressing arrestin 3, suggesting that arrestin 3 plays a role in 
CXCR4/CXCL12 signalling pathway of MCF-7 breast cancer cells.  
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Figure 5.6: Quantification of migration of chemically transfected MCF-7 cells into the wound in the 
presence or absence of CXCL12. A value of 1 denotes no migration occurred whereas a value < 1 
denotes cell migration. MCF-7 cells were chemically transfected for 24 hours using 2 μg plasmids DNA 
coding for pArr2.EGFP, pArr3.EGFP and pA2-Mut.EGFPand also pEGFP.C2 as a control. Pre-treatment 
with 10 nM CXCL12 for 24 hours before data analysis. All results represent the mean ± SEM of at least 
3 independent experiments (One-way ANOVA, Bonferroni multiple comparison, ns = not significant, 
p>0.05).  
 
Figure 5.6 show representative results from chemically transfected MCF-7 cells in 
wound healing assays; pArr3.EGFP transfected MCF-7 cells’ migration show a small, 
but not significant, trend of increase compared to control pEGFP.C2 cells, but not 
pArr2.EGFP and pA2-Mut.EGFP transfected cells. This implies that arrestin 3 is the 
important arrestin subtype in CXCR4/CXCL12 signalling axis in MCF-7 cells. However, 
it is difficult to say with certainty that the role of arrestins in this assay when the 
positive control was not robust, which may be due to loss of cells at the end of the 
experiment. Since the transfection efficiency was low and variable, transient 
transfected MCF-7 cells do not provide a reliable test system. As mentioned previously, 
we also observed a loss of cells during the timeframe of the experiment (figures 5.4 and 
5.5), which predominantly seemed to affect the transfected cells. The reason for this 
could be that after 72 hours of incubation, these cells are more mobile after transfection 
and therefore more likely to come off the plastic well. However, it confirms that this 
method is not reliable enough to understand the function of arrestins in cell migration. 
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Figure 5.7: Quantification of migration of chemically transfected MCF-7 cells using Boyden Chamber 
migration assay and fluorescence was measured after 24 hours in the presence or absence of 
CXCL12. MCF-7 cells were chemically transfected for 24 hours using 2 μg plasmid DNA coding for 
pArr2.EGFP, pArr3.EGFP and pEGFP.C2 as a control (a) Micrographs of transfected MCF-7 monolayers 
with pArr2.EGFP, pArr3.EGFP, and pEGFP.C2 as control. Images representative of population. Acquired 
with Leica imaging suite with 10x and 63X magnifications. (b) Relative fluorescence unit measured 
after pre-treatment with 10 nM CXCL12 after 24 hours. All results represent the mean ± SEM of at 
least 3 independent experiments (One-way ANOVA, Bonferroni multiple comparison, ns = not 
significant, p>0.05).  
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As described previously, there was high variability and inconsistency in the wound 
healing assays, hence alternative cell migration assays can be considered. The most 
widely accepted cell migration technique is the Boyden chamber assay. We therefore 
used this experimental set-up on the transiently transfected MCF-7 cells. The chamber 
was suspended over a larger well which contain medium as control and 10 nM CXCL12 
as the chemotaxis-inducing agent (refer to section 2.9.2.; page 58).   
 
Fluorescence images shown in figure 5.7a demonstrated that there was effective 
chemical transfection of MCF-7 cells, but looking at figure 5.7b, there was a variability 
between different experiments. However, even with these variations in experiments, a 
trend of an increase in migration of transfected pArr3.EGFP cells compared to 
pArr2.EGFP transfected cells was observed, which agreed with data shown in figure 5.6. 
This data further implies that arrestin 3 is the important arrestin subtype that plays a 
role in CXCR4/CXCL12 pathway in migration of MCF-7 cells. This trend, however, was 
not significantly different to the control.  
 
There is limited literature that supports efficiency of chemical transfection of MCF-7 
cells which indicates that MCF-7 cells may be difficult to be transfected effectively. 
Overall, the MCF-7 cells did not migrate very well at all under these conditions and are 
therefore, not a good model system to investigate the influence of arrestin on 
migration.  
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5.3.3. Overexpression of arrestin has no obvious disruptive effect on MCF-7 cells’ 
actin polymerisation upon CXCL12 activation 
 
 
Figure 5.8: Arrestin 2 overexpression has no obvious effect on actin polymerisation in MCF-7 cells. 
Micrographs of MCF-7 monolayers chemically transfected for 24 hours using 2 μg plasmids DNA 
coding for pArr2.EGFP (green) and pEGFP.C2 (green) as a control and then treated with 10 nM CXCL12 
for 15 minutes. Cells were fixed with 4% paraformaldehyde and stained with Phalloidin CruzFluor 594 
(red). Images representative of population. Acquired with Leica imaging suite using 10X magnification.  
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Actin filaments staining with fluorescent phalloidin is a useful imaging tool to 
investigate the distribution of F-actin in cells. Here, we investigated the effects of 
arrestin on actin cytoskeleton of MCF-7 cells. Phalloidin CruzFluor 594 conjugate is a 
deep red fluorescent conjugate that binds to actin filaments, stabilising actin filaments 
through the prevention of filament depolarisation. Actin is used by the cell for 
mechanical processes such as growth, scaffolding of the cytoskeleton, and movement. 
Therefore, there is importance in investigating actin as disruption of the actin 
equilibrium destroys cellular functioning and blocks migration [370,371].  
 
Fluorescence microscopy was used to determine if actin cytoskeleton was disrupted by 
overexpression of arrestins 2 and 3. By transfecting MCF-7 cells with pArr2.EGFP and 
pArr3.EGFP plasmids compared to control pEGFP.C2 MCF-7 cells and staining the cells 
with Phalloidin Cruzfluor 594 (red fluorescent conjugate), we could see if changes in 
levels of arrestins expression would have an obvious effect on actin cytoskeleton upon 
CXCL12 activation. These cells were grown as a monolayer on coverslips to high 
confluence (refer to section 2.10.1.; page 60) and chemically transfected for 24 hours 
and then were stimulated with 10 nM CXCL12 for 1 hour prior to fixing with 4% 
paraformaldehyde and staining.   
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Figure 5.9:  Arrestin 3 overexpression has no obvious effect on actin polymerisation in MCF-7 cells. 
Micrographs of MCF-7 monolayers chemically transfected for 24 hours using 2 μg plasmids DNA 
coding for pArr3.EGFP (green) and then treated with 10 nM CXCL12 for 15 minutes. Cells were fixed 
with 4% paraformaldehyde and stained with Phalloidin CruzFluor 594 (red). Images representative of 
population. Acquired with Leica imaging suite using 10X magnification. 
 
Arrestin 2 and 3 overexpression did not have an obvious effect on actin polymerisation 
in MCF-7 cells (figures 5.8, 5.9). Although actin stress fibres were not widely evident 
due to the low magnification of images and the small sized MCF-7 cells, the distribution 
of actin was uniform. There was not any obvious disruption to actin localisation and 
uniformity of actin.  
 
MCF-7 cells are rather small in size; hence it is very difficult to identify cellular 
structures. MCF-7 cells also tend to grow on top of each other, instead of forming a 
uniform monolayer, so it can be difficult to observe and identify cellular structures 
clearly. MCF-7 cells have been proven to have high level of CXCR4 expression, but the 
inability to clearly observe actin stress fibres across the cells was disappointing. The 
majority of actin fibres are situated along the plasma membrane surrounding the cells 
and neither stimulation by CXCL12 nor overexpression of arrestins showed an obvious 
change in the localisation of the actin fibres.  
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5.3.4. Investigation of the role of arrestins in leukemic T lymphocytes, Jurkat cells  
Figure 5.10: Flow cytometry. (a) G1 gated population was used, to show transient transfection of 
Jurkat cells by electroporation transfection in the presence or (b) absence (mock) of DNA plasmids 
coding (c) pArr2.EGFP, (d) pArr3.EGFP and (e) pA2-Mutant.EGFP. (f) Quantification of mean of 
fluorescence intensity based on gated population of Jurkat cells, G1. Results represent the mean ± 
SEM of 3 independent experiments. (One-way ANOVA, Dunnett’s multiple comparison, * = p≤0.05, ** 
= p≤0.01) 
 
Since non-invasive adherent breast cancer cell lines were difficult cell lines to work 
with and had low transfection efficiency, Jurkat cells (leukemic T-lymphocytes) were 
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an alternative cell line to work with to investigate CXCR4/CXCL12 signalling axis. As 
discussed previously, Jurkat cells have been proven to express high levels of CXCR4, 
and also have been widely studied in the group as a model system to look at CXCR4 
function [286]. There is literature suggesting that cellular background can be 
important for distinct signalling pathways [286] used by the CXCR4 receptor, hence it 
is important to establish the roles of arrestins in a different cell line, and to use another 
cell line to define CXCR4/CXCL12 signalling axis.  
 
Transfection of these suspension cells was different from adherent breast cancer cells, 
since Jurkat cells were not transfected with a chemical agent but by using 
electroporation transfection, Amaxa Nucleofector programme X-005. Nucleofection is 
an electroporation-based transfection method which enables transfer of nucleic acids 
such as DNA or RNA into cells by applying a specific voltage and reagents. Jurkat cells 
were transfected with pArr2.EGFP, pArr3.EGFP and pA2-Mut.EGFP and also pEGFP.C2 
as non-functional control (refer to section 2.6.1.; page 55), using appropriate 
Nucleofector programme X-005 for high expression level. This particular programme 
has 84%±3 efficiency rate and 75%±11 viability with 2 μg DNA and 1 X 106 cell count 
according to literature and optimised protocol provided by Amaxa, Lonza [372,373]. 
With Nucleofection, even hard-to-transfect cell lines can be transfected with high 
efficiency, which would allow us to study the role of arrestins in CXCR4/CXCL12 
signalling in Jurkat cells more in-depth.  
 
Jurkat cells were transfected for 24 hours and activated with 15 nM CXCL12 for 1 hour. 
Arrestin transfected cells showed a significant increase in fluorescent intensity 
compared to mock transfected control cells as determined by flow cytometry (figure 
5.10f) using the forward/side scattered plot, marked by G1 population (figure 5.10a). 
Flow cytometry is a useful tool to analyse transfection efficiency in electroporated 
transfected Jurkat cells as it allows rapid, accurate and simple of collection of data 
related to many parameters from a heterogenous fluid mixture containing live cells. 
Figures 5.10b – 5.10e showed that there was a difference between mock transfected and 
arrestins transfected cells and since the mean fluorescence values obtained in mock 
transfected cells was significantly lower than in the EGFP-arrestin transfected cells 
(figure 5.10f), we have shown that there was effective transient transfection of Jurkat 
cells. However, there was a lower transfection efficiency rate than what is stated in 
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literature, concluding that Jurkat cells are not easily transfected. As enough viable cells 
were still available, further experiments to determine the role of arrestins in Jurkat cell 
line in CXCL12-induced migration via CXCR4 receptor were undertaken.  
 
Figure 5.11 shows flow cytometry of CXCR4 internalisation after electroporation 
transfection of Jurkat cells with different EGFP tagged arrestin subtypes and induction 
with 15 nM CXCL12. 
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Figure 5.11: Flow cytometry of arrestin transfected Jurkat cells. Flow cytometry analysis was carried 
out following electroporation transfection of Jurkat cells in the presence or (a) absence (mock) of DNA 
plasmids coding (b) pEGFP.C2 as non-functional control, (c) pArr2.EGFP and (d) pArr3.EGFP.  
Electroporation transfection was conducted 24 hours before the induction of CXCR4 internalisation 
with 15 nM CXCL12. The percentage of cells is shown in each quadrant.  
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Figure 5.12: Comparison of percentage CXCR4 expression in the presence or absence (mock) of DNA 
plasmids coding pArr2.EGFP and pArr3.EGFP and also pEGFP.C2 as non-functional control. This data 
represents percentage of CXCR4 surface expression in transfected cells in the absence of CXCL12. 
Preliminary data represent one experiment. 
Figures 5.12 and 5.13 show the comparison of percentage CXCR4 expression in the 
presence of DNA plasmids coding pArr2.EGFP, pArr3.EGFP and pEGFP.C2 as non-
functional control vs mock transfected Jurkat cells. From these data, we can start to 
investigate whether overexpression of arrestins does affect the expression of CXCR4 on 
the cell surface. Preliminary data shows that overexpression of arrestins did not affect 
CXCR4 cell surface expression in Jurkat cells.  
 
The relative CXCR4 surface expression was calculated as a percentage using the 
following: 100 x (mean channel of fluorescence [stimulated])/ (mean channel of 
fluorescence [medium]). The preliminary experiment of staining CXCR4 in arrestin 
transfected cells on ice (in either the presence or absence of 15 nM CXCL12) has shown 
that there was no difference in internalisation rate between mock transfected cells and 
arrestin transfected cells upon CXCL12 stimulation.  
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Figure 5.13: Preliminary data showed that arrestins may not be required for CXCL12-induced 
internalisation of CXCR4. CXCL12-induced internalisation of CXCR4 in Jurkat cells as deduced by flow 
cytometry following electroporation transfection in the presence or absence (mock) of 2 μg plasmids 
DNA coding pEGFP.C2 as non-functional control, pArr2.EGFP and pArr3.EGFP to overexpress arrestins 
2 and 3. The relative CXCR4 surface expression of transiently transfected Jurkat cells following 
incubation with 15 nM CXCL12 or buffer alone. Preliminary data represent one experiment.  
 
In the ‘classical’ model of GPCR regulation when receptor is activated and 
phosphorylated, CXCR4 signalling is rapidly desensitised after ligand binding by 
receptor internalisation. This is achieved by the binding of arrestins, which sterically 
block further interactions between GPCR and G-proteins , which would then mediate 
receptor internalisation  through clathrin coated pits [2,69,142].  
 
Transfected Jurkat cells were activated with 15 nM CXCL12 for 1 hour before treatment 
with anti-CXCR4 primary antibody for 1 hour and then stained with anti-mouse IgG 
(H+L) 647 secondary antibody for 1 hour before analysing in flow cytometry (refer to 
section 2.11.; page 62). The preliminary data may suggest that internalisation of CXCR4 
is not arrestin-dependent as there was not any increase of internalisation rate in 
overexpression of arrestins. However, since the data was based on one experiment with 
a high internalisation rate in mock transfected, any further conclusion should be 
avoided. It is difficult to observe differences in internalisation rate from these 
experiments when there could be other factors affecting internalisation  rates, such as 
the carboxyl-terminus of the receptor, the type of ligand, the cell type and the 
140 
 
phosphorylation status of CXCR4 receptor in cells [313]. Therefore, exploring other 
different methods to show the effects of arrestin overexpression on CXCR4 receptor in 
Jurkat cells via CXCL12 signalling transduction is important. 
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5.3.5. Investigation of overexpression of arrestins in migration of leukemic T 
lymphocytes, Jurkat cells via CXCR4 upon CXCL12 activation  
 
Arrestins are required for the desensitisation of several chemokine receptors, including 
CXCR4, and so there is importance in studying the role of arrestins and how they affect 
CXCL12-induced migration via CXCR4 – through receptor desensitisation or localised 
scaffolding of cytoskeletal signalling molecules [14,284]. Furthermore, the mechanism 
by which arrestins mediate migration may differ with cell and receptor type [81].  
 
In addition to regulating receptor stimulated G-protein signalling, arrestins are also 
capable of initiating distinct signalling patterns. These patterns are often both spatially 
and temporally distinct from G-protein mediated signalling which result in cellular 
consequences, including migration of cells [108,193]. 
Figure 5.14: Arrestin 3 overexpression significantly increase migration of Jurkat cells via CXCR4 upon 
CXCL12 activation. Jurkat cells were transiently transfected by electroporation transfection with 2 μg 
plasmids DNA coding pEGFP.C2 as non-functional control, pArr2.EGFP, pArr3.EGFP and pA2-
Mutant.EGFPto overexpress arrestin 2, 3 and mutated arrestin 2. Cells were transfected for 24 hours. 
Cell migration towards 1 nM CXCL12 in pEGFP.C2 control cells or overexpressed arrestin 2, 3 and 
mutated arrestin 2 Jurkat cells. All results represent the mean ± SEM of at least 3 independent 
experiments (One-way ANOVA, Bonferroni multiple comparison, * = p≤0.05). 
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Transfected Jurkat cells were incubated for 5 hours with 1 nM CXCL12 in chemotaxis 
assays before cells were counted and data analysed (refer to section 2.9.1.; page 58). We 
observed a significant increase in migration of cells that was transfected with plasmids 
DNA coding pArr3.EGFP (figure 5.14) in CXCR4 signalling axis upon 1 nM CXCL12 
activation. This indicated that arrestin 3 may play a role in migration of Jurkat cells, 
but not arrestin 2 subytype as there was not much difference in migration between 
control pEGFP.C2, pArr2.EGFP and pA2-Mut.EGFP cells. These results indicate that 
arrestin 3, and not arrestin 2, is required in migration of cells is supported by studies 
performed by Fong et al. (2002) where they have shown that CXCR4-mediated 
lymphocyte chemotaxis was defective in arrestin 3 and G-protein coupled receptor 
kinase 6 (GRK6)- knockout mice [145]. Investigations of knockdown arrestins in Jurkat 
cells using small interfering RNA (siRNA) was then undertaken to confirm the role of 
arrestins in CXCL12-induced migration in Jurkat cells.  
 
siRNA was electroporation transfected to knockdown arrestins in Jurkat cells. siRNA-
mediated gene knockdown (Dharmacon, USA) is a powerful tool that has been used to 
identify gene function and to map out biological pathways. Scrambled siRNA is used 
as a negative control siRNA, as they are designed to have no known target in the cells 
and are important in distinguishing sequence-specific silencing from non-specific 
effects in the RNAi experiment. Jurkat cells were electroporated transfected with 
siRNAs (refer to section 2.6.2.; page 55) for 48 hours before stimulation with 1 nM 
CXCL12 in chemotaxis assays for 5 hours. Electroporation transfection was the method 
chosen for siRNA delivery because suspension cells are not compatible with lipid-
mediated transfection.  
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Figure 5.15: Arrestin 3 plays a role in migration of Jurkat cells via CXCR4 upon CXCL12 activation. 
Jurkat cells were transiently transfected by electroporation transfection with (a) 50 nM Arrestin 2 
siRNA (Arr2 siRNA), Arrestin 3 siRNA (Arr3 siRNA) and 50 nM scrambled siRNA as non-functional 
control to knockdown arrestins 2 and 3 in Jurkat cells (b) 100 nM scrambled siRNA and combination 
of 50 nM Arr2 and Arr3 siRNAs. Cell migration towards 1 nM CXCL12 in scrambled siRNA control cells 
or knockdown arrestins 2 and 3 in Jurkat cells. All results represent the mean ± SEM of at least 3 
independent experiments (One-way ANOVA, Bonferroni multiple comparison, * = p≤0.05,                      
*** = p≤0.001) 
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In Jurkat cells with knockdown arrestin 3, there was a significant reduction in migrating 
cells compared to negative scrambled siRNA (figure 5.15a). This data confirmed that 
CXCL12-induced migration might be arrestin 3-dependent signalling. Another 
experiment was done to see if there was a cumulative effect when both arrestin 2 and 
3 were knocked down with electroporation transfection and incubated for 48 hours 
before analysis (figure 5.15b). Results showed that upon CXCL12 activation in 
chemotaxis assay for 5 hours, half of the migratory cells were significantly reduced, 
which was very similar to the data where only arrestin 3 was knocked down.  There was 
no indication of cumulative effect from combination knockdown of arrestins 2 and 3. 
Hence, these data imply that the reduction in migration of cells is due to arrestin 3 
subtype and that CXCL12-induced migration via CXCR4 in Jurkat cells is arrestin 3-
dependent signalling.  
 
siRNA knockdown technique is useful to assess the function of a protein within cells as 
they are involved in the RNA interference (RNAi) pathway. To assess the results from 
the knockdown experiments, we used the western blot technique (refer to section 2.12.; 
page 63), which usually indicates the presence or absence of proteins. Different 
antibodies with different epitope specificities (table 5.1) were used to observe if there 
was a knockdown of arrestins in samples.  
 
Table 5.1: Different primary antibodies from Santa Cruz Biotechnology 
 
Antibodies used for arrestin 2/3 
Western Blot 
Source 
β-Arrestin-1/2 Antibody (H-290): sc-
28869 
• Rabbit polyclonal IgG 
• Epitope corresponding to amino acids 
7-290 mapping at the N-terminus of β-
arrestin-1 (arrestin 2) of human origin 
β-Arrestin-1/2 Antibody (21-B1): sc-53781 • Mouse monoclonal IgG1 
• Raised against β-arrestin-1 (arrestin 2) 
of human origin 
β-Arrestin-1/2 (A-1): sc-74591 • Mouse monoclonal IgG1 (kappa light 
chain) 
• Raised against amino acids 7-290 
mapping at the N-terminus of β-
arrestin-1 (arrestin 2) of human origin 
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Unfortunately, we did not manage to observe any bands, even in the untreated control 
Jurkat cells where arrestin band should be visible at molecular weight of 55 kDa. We 
have done numerous changes to the method and followed different optimised 
protocols, including changing the primary antibodies, but only the western blot 
loading control, beta actin, was visible on the blot, whereas arrestin was never detected 
reliably (figure 5.16). One reason for this is that the antibodies commercially available 
for detecting arrestins are not very reliable. Another approach that could be used is 
real-time PCR (RT-PCR) to check for the presence of the mRNA, which is a very 
sensitive method, but doesn’t give an accurate prediction of expected protein levels. 
Unfortunately, we were not able to use the RT-PCR approach in the preparation of this 
thesis. 
 
Figure 5.16: Western blot analysis of arrestin expression in Jurkat cells after knockdown, where β-
actin acts as loading control. Primary antibody, β-Arrestin-1/2 (21-B1) mouse monoclonal (1:500 
dilution) and secondary antibody anti-mouse pox (1:5000 dilution) were used in arrestin2/3 western 
blot.  
 
It is disappointing that we could not show that there definitely was a knockdown of 
arrestins triggering mRNA degradation and suppression of gene expression for arrestin 
which contributed to the reduction of migratory cells. However, by combining the data 
from overexpression and knockdown of arrestins in Jurkat cells, they are consistent in 
suggesting that arrestin 3 plays a role in CXCL12-induced migration via CXCR4 in 
Jurkat cells.  
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5.3.5. Investigation of overexpression of arrestin 3 in MAPK and PKC signalling 
cascades upon CXCL12 activation via CXCR4 receptor in Jurkat cells 
 
PKC family members regulate numerous cellular responses including gene expression, 
protein secretion, cell proliferation, and the inflammatory response [126]. When cells 
are stimulated, PKC is transiently activated by diacylglycerol which is produced in the 
membrane during signal-induced turnover of inositol phospholipids [130]. Activation 
of chemokine receptors can lead to phosphorylation of the receptor via GRK and PKC 
[141,142,343]. Classically, G-protein stimulation via second messenger effectors like 
PKC and protein kinase A (PKA) promotes ERK1/2 phosphorylation and nuclear 
translocation for modulating transcription [374].  
 
Recently, it has become evident that arrestins serve as molecular scaffolds for 
numerous signalling proteins [80], but the consequences of these signalling events are 
still poorly understood. Numerous receptors which require arrestins for migration also 
promote arrestins’ dependent association with MAPKs [169,170,180,182,375]. It is 
important to study the MAPK pathway and to understand its downstream signalling 
cascades as many extracellular growth factors and stresses converge on MAPKs for 
regulating cellular processes, such as cell proliferation, survival and differentiation 
[171].  
 
The ERK MAPK signalling pathway is the model for arrestin mediated signalling, 
whereby GPCRs activate MAPK through the G-protein subunits upon agonist 
stimulation [376,377]. Arrestins scaffold the MAP kinase signalling molecules, 
including MAP kinase (MEK1) and MAP kinase (ERK), leading to phosphorylation and 
activation of ERK1/2 [179]. An association with arrestin-dependent ERK activation has 
been described in previous researches but how arrestins affect these downstream 
signalling effectors is still not fully understood [179].  
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Figure 5.17: Effects of overexpression of arrestin 3 in chemotaxis assays on PKC and MAPK signalling 
pathways. Jurkat were transiently transfected by electroporation transfection, in the (a) absence 
(mock) or presence of 2 μg plasmids DNA coding (b) pArr3.EGFP to overexpress arrestin 3. Cells were 
incubated in the absence and presence of 10 μM SB203580 (selective p38 MAPK inhibitor), 25 μM 
(MEK1/2 inhibitor) and 4 μM Rottlerin (non-selective PKC inhibitor) for 30 minutes and cell migration 
towards 1 nM CXCL12 in overexpressed arrestin 3 Jurkat cells vs control mock transfected Jurkat cells 
analysed after 5 hours. All results represent the ± SEM of at least 3 independent experiments (One-
way ANOVA, Bonferroni multiple comparison, * = p≤0.05, *** = p≤0.001, ns = not significant). 
 
Since we have shown that arrestin 3 plays a role in CXCL12-induced migration via 
CXCR4 receptor activation in Jurkat cells, it would be worthwhile to investigate the 
effects of overexpression of arrestin 3 in MAPK and PKC signalling pathways as the next 
step. Jurkat cells were transfected with DNA plasmids coding pArr3.EGFP for 24 hours 
and treated with inhibitors for 30 minutes before stimulated in chemotaxis assays for 
5 hours (refer to section 2.6.1.; page 55).  
 
ERK1/2 and p38 MAPK are associated with canonical Gβγ signalling to chemotaxis [75] 
and are also used more generally as markers or receptor mediated protein activation 
associated with Gβγ and arrestin-dependent signalling. p38 MAPKS are members of 
the MAPK family which are activated by a variety of environmental stresses and 
inflammatory cytokines. SB203580 is a selective inhibitor of p38 MAPK. The data 
showed that in overexpressed arrestin 3 Jurkat cells, there was significantly less 
inhibition of cells via p38 MAPK pathway when comparing migration of treated 
pArr3.EGFP cells (figure 5.17b) to treated mock transfected Jurkat cells (figure 5.17a) 
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with 10μM SB203580. This observation suggests that arrestin 3 plays a role in p38 
MAPK signalling cascade that results in migration of cells.    
 
PD98059 is a small molecule inhibitor of MKK/ MEK in MAPK cascade and it acts by 
binding to the inactivated form of MEK. The results showed that ERK1/2 MAPK 
pathway may not be arrestin 3-dependent signalling as there was no difference in 
migration of pArr3.EGFP cells (figure 5.17b) vs mock transfected Jurkat cells (figure 
5.17a) when treated with 25μM PD98059. We observed significant inhibition of cell 
migration towards 1 nM CXCL12 in both conditions.  
 
Figure 5.17 also showed a possible relationship between PKC and arrestin 3 in CXCL12-
induced chemotaxis as there was a difference observed between mock transfected and 
pArr3.EGFP transfected Jurkat cells after PKC inhibition by 4 μM Rottlerin, a non-
selective PKC inhibitor. Overexpression of arrestin 3 in Jurkat cells did not significantly 
increase migration of cells treated with Rottlerin (figure 5.17b), unlike in mock 
transfected Jurkat cells where PKC inhibition significantly increased migration of cells 
(figure 5.17a). However, in both conditions, there was no inhibition of migration 
observed and the difference in numbers of migratory cells between the two conditions 
were insignificant for us to conclude that there definitely is a link between arrestin 3 
and PKC. Since there wasn’t any inhibition of migration of cells observed, this further 
confirmed that CXCL12-induced migration of CXCR4 is not PKC-dependent as 
discussed in chapter 4.   
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5.4 Discussion 
 
Canonical signalling by 7TMRs involves ligand binding which induces a change in 
receptor conformation that causes the activation of heterotrimeric G-proteins, leading 
to second messengers’ generation and downstream signalling. Desensitisation  occurs 
when GRKs phosphorylate the activated receptor and promotes the binding of 
arrestins, which act sterically to block further G-protein activation [374].  
 
However, in recent years, the roles of arrestins has evolved to become distinct 
transducers of 7TMR that signals independent of G-proteins and to facilitate the 
activation of numerous signalling pathways, including MAPKs, c-Src and Akt by acting 
as multiprotein binding scaffolds [80,109,261]. These diverse downstream signalling 
cascades involving arrestin mediated signalling results in cellular responses such as 
chemotaxis [81], cardiomyocyte contractility [378], and the prevention of apoptosis 
[186]. Chemotaxis mediated by CXCR4 plays a key role in lymphocyte homing and 
haematopoiesis. Chemokine receptors are GPCRs that mediate chemotaxis in response 
to inflammatory chemokines released at sites of injury [379]. 
 
Arrestins are small family of proteins that are important for regulating signal 
transduction at GPCRs. Arrestins exist in the cytoplasm in multiple forms; free 
monomers, free oligomers and microtubule-associated arrestins [380]. Mammalian 
arrestin family can be broadly classified into visual and non-visual groups [164]. The 
visual arrestins, arrestin 1 (rod arrestin) and arrestin 4 (cone arrestin) are expressed 
only in photoreceptors while the non-visual receptors, arrestin 2 and arrestin 3 exist 
ubiquitously in most cells and interacts with hundreds of GPCRs [164,380]. A 
prominent difference between arrestin 2 and arrestin 3 is their subcellular localisation  
[381]. While arrestin 3 appears to be almost exclusively extranuclear, arrestin 2 is found 
both in the cytoplasm and nucleus [381]. This might clarify why mutated arrestin 2 
protein has been observed to be primarily located in the nucleus of the cell (figure 5.2). 
As discussed previously, there are several recent studies that have found that arrestins 
mediate various forms of crosstalk between receptor signalling systems due to their 
position in cells, and this may be due to the fact that most signalling pathways have 
been found to function as components of larger signalling networks [261].  
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Arrestins are well known to terminate receptor signalling, and after receptor activation, 
arrestins desensitise phosphorylated GPCRs, blocking further activation and initiating 
receptor internalisation [80]. In addition to arrestins’ involvement in the 
internalisation of receptors, arrestins can also function as signal transducers by directly 
activating pathways such as Akt, MAPK and PI3K, but their role as mediators of 
receptor desensitisation, scaffolding or as direct signalling modulators to these 
pathways are still poorly understood [18,81]. Our aim is to study how non-visual 
arrestins are involved in migration of cells, and also, to see if different cell types have 
different usage of arrestins leading to migration of cells.  
 
Calcium release upon CXCL12 activation via CXCR4 signalling in MCF-7 cells may not 
be arrestin-dependent signalling in both ‘classical’ and ‘scaffold’ settings, but in 
migration of MCF-7 cells, arrestin 3 did seem to play an important role, suggesting that 
cellular migration occurs via arrestin-dependent signalling. Data analysis confirms that 
migration of cells can occur independently of calcium release as discussed in chapter 4 
[142].  
 
Arrestins have recently been described by literature as essential regulators of cell 
migration either towards or in the presence of a chemical ligand by interacting with a 
cell-surface receptor. Their role in migration of cells is poorly understood; whether 
their role in migration of cells reflects receptor desensitisation or localised scaffolding 
of cytoskeletal signalling molecules (figure 5.18) [18,81]. 
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Figure 5.18 (adapted from DeFea et al. (2007) [81]): Localised actin assembly versus receptor 
desensitisation. Receptors at the front of the cell are exposed to a higher concentration of 
chemokines. Arrestins may preferentially uncouple receptors from their cognate G-protein in the back 
of the cell while G-protein signalling simultaneously persists in the front. Another theory is that 
arrestins may also scaffold cytoskeletal proteins at the front of the cell, leading to localised actin 
assembly events.  
 
Actin cytoskeletal reorganisation and cell migration require arrestins to regulate 
downstream signalling, which eventually lead to these two processes [81]. By regulating 
receptor internalisation  and by scaffolding of signalling molecules, arrestins facilitate 
gradient sensing and cytoskeletal reorganisation which leads to cell migration [18], 
suggesting that arrestins use these two functions to orchestrate cellular response to 
chemotactic signals. Actin polymerisation from monomers is a spontaneous but slow 
process and has been shown to be the driving force behind directed cell movement and 
can be regulated by various proteins [18,81]. Based on visual assessment, arrestins did 
not seem to have an obvious effect on actin polymerisation in MCF-7 cells. Further 
experiments could be done to confirm the involvement of arrestins in actin 
polymerisation upon CXCL12 activation via CXCR4 receptors such as quantifying 
fluorescence in flow cytometry or using different and larger sized cells to visualise 
changes in actin upon CXCL12 activation.  
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The internalisation of chemokine receptors occurs after the ligand binds to the 
receptor, so depending on the percentage of receptors being activated, internalisation  
may reduce the level of receptor expression at the membrane and therefore change 
functionality [313]. Based on arrestins ‘classical’ role, previous literature has indicated 
that they are mediators of receptor desensitisation  and internalisation  [80,81,380], 
but this doesn’t mean that role of arrestins in chemokine receptor signalling can be 
generalised as each receptor may utilise arrestins differently in the process of 
chemotaxis [18]. Based on our preliminary data, overexpression of arrestins did not 
have an effect on internalisation of CXCR4 receptors upon 15 nM CXCL12 stimulation. 
There are two explanations for this: receptor turnover and differential signalling in 
response to ligand multimers. CXCL12 monomers and dimers elicit different signalling 
where CXCL12 monomers have the ability to promote arrestin recruitment and evoke 
arrestin-dependent signals, whilst the dimers do not [18]. Therefore, in addition to 
simply promoting receptor turnover, arrestins may mediate signalling at lower CXCL12 
concentrations while at higher concentrations, their signal may be dampened. This 
could explain why there was not an increase in internalisation of CXCR4 receptors 
upon CXCL12 stimulation in Jurkat cells overexpressing arrestins. However, it is 
difficult to draw a conclusion from this data at this stage as more experiments are 
needed to confirm the reliability and reproducibility of these results.  
 
MAPK networks are critical for the transmission of extracellular signals into 
appropriate intracellular responses. Once activated, MAPKs can phosphorylate a wide 
array of intracellular targets that include cytoskeletal elements, membrane 
transporters, nuclear pore proteins, transcription factors and other protein kinases 
[80,382] . Arrestins have been shown to serve as scaffolds for numerous signalling 
networks; arrestin-dependent signalling was distinct from its role in internalisation 
and is thought to be responsible for ligand-biased signalling observed through GPCRs 
[81].  
 
Overexpression of arrestin 3 resulted in an increase in cellular migration, which was 
further confirmed by siRNA knockdown of arrestin 3 expression, proving that arrestin 
3 is the important arrestin subtype that may be involved in migration of cells. 
Knockdown of arrestins via siRNA is a useful investigative tool and clearly shows the 
importance of different arrestin subtypes in CXCL12-induced migration via CXCR4. 
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Simultaneous knockdown of arrestin 2 and arrestin 3 further confirmed that arrestin 3 
is the main subtype in CXCL12-induced migration as there was not further reduction 
in the number of migrating cells when both arrestins’ subtypes were knocked down. 
This data supports previous findings, where arrestin 3 is critically involved in CXCR4-
mediated chemotaxis [145,182], and according to literature, this is mediated by its 
enhancement of p38 MAPK activation [182]. However, we could not show that there 
definitely was a knockdown of arrestins due to the lack of availability of reliable arrestin 
antibodies. Other methods should be considered for future work, which includes RT-
PCR to check for the presence of the mRNA. 
 
The potent MEK1/2 inhibitor, PD98059, was used to investigate if ERK1/2 
phosphorylation is needed for migration or a consequence of scaffold formation that is 
unrelated to migratory responses. The data suggested that CXCL12-induced migration 
via CXCR4 activation is sensitive to ERK1/2 inhibition and that migration of cells via 
ERK1/2 MAPK pathway is not arrestin-dependent. This data does not support the 
theory of arrestin as a scaffold for ERK1/2 MAPK pathway since there weren’t any 
differences between mock transfected cells and Jurkat cells that overexpressed arrestin 
3, but this might only mean that arrestin 3 and GPCR scaffold complex is not applicable 
in downstream ERK1/2 MAPK signalling that results in CXCL12-induced migration.  
 
However, there were different effects observed between mock and pArr3.EGFP 
transfected Jurkat cells when SB203580, a potent p38 MAPK inhibitor was used. We 
observed that overexpression of arrestin 3 in Jurkat cells had less inhibition of 
migration of cells, which meant there were more cells migrating in pArr3.EGFP 
transfected cells compared to the control mock transfected Jurkat cells. This data 
suggests that arrestin-mediated signalling occurred, and this can be interpreted as 
evidence to support arrestin scaffold signalling. It is implied that when there was an 
overexpression of arrestin 3 in Jurkat cells, there are more arrestin 3-CXCR4 receptors 
complexes formed to scaffold p38 MAPK activation cascades [382]. The p38 MAPK has 
been associated with α-chemokine receptor mediated arrestin-dependent signalling 
[383]. Therefore, it is important to determine the effect of p38 inhibition in CXCR4 
mediated chemotaxis on Jurkat cells. The effects of p38 inhibition clearly show that in 
CXCL12-induced migration via CXCR4, these proteins are activated by arrestins and 
that their kinase function is required in CXCR4 mediated chemotaxis. 
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Figure 5.19: An overview of chapter 5 results. Cellular signal transduction involves highly 
coordinated cascades of events. Data indicated that arrestins may be involved in p38 MAPK 
pathway, and that they may act as signal transduction scaffolds or is dependent on arrestin 
signalling.  
 
These results outline a picture of CXCL12-induced migration via CXCR4 and from 
them, it was demonstrated that arrestin 3 is the subtype that is most likely involved 
in migration of cells (figure 5.19). It is important to identify which signalling proteins 
further downstream are shared with canonical migratory signalling, as there is a 
unique signalling axis, dependent on both chemokine receptor and cell type. In order 
to develop drugs targeting chemokine receptors, it is important to consider biased 
signalling and understand which residues are important for ligand binding and 
subsequent receptor interaction with different intracellular effector molecules. Biased 
signalling, which results in activation of one of several different pathways, should be 
considered and it can be divided into three distinct forms – ligand bias, receptor bias, 
and tissue or cell bias [260]. Most biased signalling is differentiated into G-protein 
dependent and arrestin-dependent signalling.  
 
The presented data supports a role for arrestin-dependent signalling; however, it is 
still unclear the exact nature of arrestin in signal transduction, and there is a need to 
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study these relationships clearly at recruitment and signalling level. These 
observations leave unanswered questions: the relationship and associated machinery 
between activated receptor and arrestin as well as the mechanism of arrestin-
dependent assembly with different downstream effector molecules. Hence, further 
studying and understanding how GPCR signalling molecules engage in signal 
transduction and activate signalling pathways is important.  
 
Another factor that should have been considered in these experiments is the presence 
atypical chemokine receptor, ACKR3 (also known as CXCR7) receptor in Jurkat cells. 
ACKR3 is also a CXCL12-binding receptor. ACKR3 functions as a scavenger receptor 
for CXCL12 and it has been shown that ACKR3 suppresses processes, including 
tumour growth, survival and proliferation of breast cancer cells, in multiple organs 
and tissues [384,385]. Melo et al. (2014) has demonstrated that ACKR3 is highly 
expressed in Jurkat cells and that it can potentiate CXCR4 response to CXCL12 [386]. 
Their studies suggested that the presence of ACKR3 may be important in potentiating 
the migration induced by CXCR4/CXCL12 signalling and this may be due to the 
heterodimerization of both receptors [386]. In the case of the CXCR4-ACKR3 
heterodimer, it has been hypothesised that there is an increase in arrestin-dependent 
signalling, which resulted in enhanced cell migration [387]. In co-expression of 
CXCR4 and ACKR3, the CXCR4-ACKR3 heterodimer complex recruits arrestins, 
which resulted in biased signalling towards arrestin-dependent signalling over G-
protein signalling [387,388]. The presented data in this chapter did not take into 
account the presence of ACKR3, hence further work is needed to be done to establish 
the relationship between CXCR4 and ACKR3 in CXCL12-induced signalling before 
drawing up definite conclusions.  
 
Bioluminescence resonance energy transfer (BRET) can represent a useful 
investigative tool for future work; to understand the role of arrestins more in-depth 
in terms of structure and relationship of arrestins with other different effector 
components in downstream signalling pathway. Arrestins can interact with 
downstream effectors in different modes, so structural studies are important in 
understanding how arrestins transmit signals encoded in the receptor to these 
effector molecules [193].  
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Identifying and mapping the pathways that are involved would be crucial to 
understanding downstream signalling that leads to migration of cells, and which 
components are important for signal transduction.  
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5.5. Chapter conclusions 
 
The final conclusions to be drawn from this chapter are:  
 
1. The role of internalisation and calcium release may be arrestin-independent, 
but this is not the case in studying the role of arrestins in CXCL12-induced 
migration of cells. Changes in level of arrestin expressions seems to affect 
migration of cells.  
2. Arrestin 3 is required in CXC12-induced migration of cells, showing that 
arrestin 3 seems to be important for migration in both suspension Jurkat cells 
and adherent MCF-7 cells.  
3. p38 MAPK pathway may be arrestin 3-dependent signalling upon CXCL12 
activation of CXCR4 receptor.  
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CHAPTER 6: Final discussion and thesis conclusions  
 
6.1. Final discussion 
 
In this thesis, we characterised CXCL12-induced migration via CXCR4 in different cell 
lines with the aim of understanding roles of downstream effectors, particularly of PKC 
and arrestins, in the migration of cells and whether they make useful targets to treat 
CXCR4-mediated chronic immune and metastatic disease. Overall, the conclusions 
from this research are as follows:  
1. MCF-7 and Jurkat cells are good model systems to study the CXCR4/CXCL12 
signalling axis, and CXCL12 is the most appropriate chemokine to study the 
biology of CXCR4 in downstream signalling cascades leading to migration of 
cells.  
2. The N-terminus of CXCL12 is important in initiating signalling events leading 
to migration of cells. The CXCL12 N-His Tag induces intracellular calcium 
signalling but not migration of cells. This suggests that CXCL12 N-His Tag is 
also a partial agonist of CXCR4.  
3. PKC activation is essential for the migration of adherent breast cancer cells, 
MCF-7 cells, as PKC inhibition affects CXCL12-induced migration in MCF-7 
cells antagonistically. This is not true of suspension leukemic T-lymphocytes, 
Jurkat cells, which suggests that there is a difference in the usage of PKC in 
different cell types and that cellular background is important for distinct 
signalling pathways upon CXCR4 activation by CXCL12. Therefore, a 
generalisation of how CXCR4 induces migration in different cell types and 
species should be avoided as there may be presence of bias at tissue level.  
4. Although CXCR4 internalisation and calcium release may be arrestin-
independent, CXCL12-induced migration of cells via CXCR4 depends on 
arrestins, as changes in level of arrestin expressions affects migration of cells.  
5. Arrestin 3 is required for CXCL12-induced migration of cells, but not the 
arrestin 2 subtype, in both MCF-7 and Jurkat cells. The requirement of arrestins 
for cellular migration in downstream of CXCR4 suggests that arrestin 3 plays a 
key role in mediating CXCL12-induced cell migration.  
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6. p38 MAPK pathway may be arrestin 3-dependent in CXCR4/CXCL12 signalling 
axis but a specific role for arrestin-dependent sequestration of MAPKs in 
chemotaxis has not been shown.  
 
As stated in the introduction, the aim of this thesis is to investigate the activation of 
signalling molecules in the downstream signalling cascades in CXC- chemokine 
receptors. This was to identify potential targets to CXCL12-induced migration to by-
pass the problems with receptor redundancy and transactivation. There is a need for 
therapies to block cell migration since there is a major involvement of chemokines and 
chemokine receptors in both chronic inflammatory and cancer metastasis [86,389]. 
GPCRs have been proven to be attractive targets for therapeutically potential in drug 
discovery over the decades, and more than 30% of all prescription drugs are directed 
at fewer more than 50 known receptors [390]. Chemokine receptors are part of the 
GPCR family, and for the last two decades, many pharmaceutical companies have been 
trying to develop drugs blocking specific chemokine receptors. Chemokine receptors 
were considered to be highly promising drug targets for inflammatory and 
immunological diseases but there are only few instances that have reached the approval 
for clinical use; Maraviroc (CCR5 antagonist), Plerixafor (CXCR4 antagonist) and 
Mogamulizmab (anti-CCR4) are amongst the current potential clinical applications of 
individual chemokine receptors [315]. There are several possible reasons why this is the 
case; the intrinsic functional redundancy in the chemokine system, possible cross-talk 
between chemokine receptors and signalling are dependent on cells and species 
specificity may be some of the reasons to why chemokine system as potential drug 
targets still remains unexplored [19,315,391,392].  
 
The interaction between CXCR4 and CXCL12 has been proposed to occur through a 
two-step process [270,327], and the initial interaction between RFFESH motif (residues 
12-17) of CXCL12 and residues 2-36 of CXCR4 are believed to result in a conformational 
change in the receptor [393].  
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Figure 6.1 (adapted from Crump et al. (1997) [327]): A schematic model for interaction of CXCL12 
with CXCR4. (A) Receptor CXCR4 and ligand CXCL12 prior to any interaction between the two.                
(B) Interaction of CXCL12 RFFESH loop (site 1) with the N-terminal segment of CXCR4. The contact 
region is shown in blue. Conformational change of the receptor occurred, exposing the binding groove 
of the receptor (circled in red). (C) N-terminal region (site 2) of CXCL12 bound in groove at the top of 
the helices (shown in orange).  
 
RFFESH motif in the loop region function as a docking site for CXCL12 receptor binding 
[327] and it is important for the initial interaction with CXCR4 in the two-step model 
of chemokine-receptor activation as mutation in this motif significantly decreased 
chemotactic activity [270,394]. The RFFESH formed a receptor binding site and is very 
well defined in CXCL12 [327]. This explains why CXCL12 N-His Tag still induces 
signalling events as initial binding can still occur due to the presence of RFFESH motif 
in CXCL12 N-His Tag and resulting in conformational changes of the receptor, thus 
activating the receptor (figure 6.1B).  
 
In figure 6.1C, the binding of the N-terminal region results in activation of the receptor. 
This conformational change facilitates interaction between the first eight amino acids 
of CXCL12 and an exposed binding pocket in CXCR4 [257,329] (figure 6.1C). Crump et 
al. (1997) demonstrated the importance of first N-terminal 8 residues as they formed 
an important receptor binding site and modification to Lys-1 and Pro-2 resulted in loss 
of activity but generated CXCL12 antagonists [327]. This observation was confirmed by 
conclusion 2, as interaction of CXCL12 N-His Tag (15 amino acids fused at the N-
terminus) with CXCR4 resulted in antagonistic effects at increasing concentrations. 
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This data also indicates CXCL12 N-His Tag may have effects that are analogous to 
CXCL12 dimers. CXCL12 may oligomerize at increasing concentrations and dimeric 
forms have been found to act as a partial agonist, which stimulates calcium 
mobilisation but has no chemotactic effect, and they can also act as a selective 
antagonist that blocks chemotaxis induced by the monomeric form of CXCL12 
[66,324]. It is hypothesised that CXCL12 N-His Tag may be a partial agonist, like 
dimeric CXCL12.   
 
Activation of the receptor by chemokine ligand leads to signalling via heterotrimeric 
G-proteins, which ends with rapid phosphorylation of the receptor via GRK2 [142]. 
Recent studies [125,141,395] have shown that PKC may play a role in phosphorylating 
receptors and therefore lead to the desensitisation  of receptors, triggering binding of 
arrestins and consequently, internalisation of the receptor [66,396]. Oppermann et al. 
(1996) [343] have shown that both GRK and PKC are equally important in 
phosphorylation of receptors. Hence, PKC has the potential to phosphorylate ligand 
bound GPCR and multiple other receptors in a heterologous manner [141].  
 
Turning now to the experimental observations on the role of PKC, PKC activation is 
not essential for the migration of suspension leukemic T-lymphocytes, Jurkat cells, but 
the blockade of PKC activation using small molecules antagonists inhibits migration of 
adherent breast cancer, MCF-7 cells. Instead of inhibiting the migration of Jurkat cells, 
antagonising PKC activation in Jurkat cells seem to have an opposite effect than what 
was observed in MCF-7 cells, resulting to an increase in cell migration instead of an 
inhibition. It is possible, therefore, that PKC has an important role in desensitisation 
of the receptor in Jurkat cells. Hence, when PKC is inhibited, phosphorylation of 
receptor is blocked and causing prolonged activation, which may be the explanation to 
why an increase of migration occurs.  
 
This data, which demonstrates there is a difference in the usage of PKC in different cell 
lines, also supports the hypothesis that signalling is dependent on cells and species 
(conclusion 3). This hypothesis is supported by other literature [19,20,313,315], hence, 
generalisation of how chemokine receptors in different cell types and species should 
be avoided. MCF-7 cells need the catalytic activity of PKC, thus, small molecule 
antagonists as well as knockdown of PKC prevented migration. In Jurkat cells, it seems 
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plausible that it is the functionality of the other PKC domains which is implicated in 
cell migration and not the kinase activity. However, the research did not consider that 
there is a possibility that different PKC isoforms are required in migration of different 
cell lines. The antagonists used inhibit conventional (PKC-α, β1, β2, γ) and novel (PKC-
δ, ε, η, θ) types of PKC isoforms but not atypical PKC isoforms (PKC-ι, ζ). There are 
variety of studies [341,348,397] that demonstrates roles of different PKC isoforms are 
important for cancer cell migration.  
 
After preliminary experiments to establish the role of PKC cell migration, studying the 
role of arrestins is the next step to investigate in the CXCR4/CXCL12 signalling axis as 
arrestins have been shown to be involved in cell migration. Arrestins bind to the 
phosphorylated receptor, and play a role in desensitisation of the receptor, thus 
terminating the cell signalling. Traditionally, arrestins are known to be mediators of 
receptor desensitisation , but recently, arrestins have emerged as key regulators of 
directed cell migration [81]; by directly binding and regulating proteins involved in 
actin reorganisation or by scaffolding signalling molecules involved in cytoskeletal 
reorganisation [18].  
 
CXCL12-induced responses are sensitive to Src [398–400], p38 MAPK, ERK1/2 MAPK 
inhibition [229,286,323,353] and are arrestin 3-dependent (conclusion 6). This 
provides strong evidence that arrestin 3 may be involved in signalling related to the 
migration of cells, supporting the observations from Fong et al. (2002) [191] where 
knockdown of arrestin 3 abrogates migration downstream of CXCR4/CXCL12 
signalling axis. Arrestin 3 may also be involved in the p38 MAPK pathway (conclusion 
7) but not in the MEK/ERK MAPK pathway as increasing expression levels of arrestin 
3 affect p38 MAPK inhibition (by small molecule antagonist, SB203580), resulting in 
significantly less inhibition of cells via the p38 MAPK pathway. Arrestin 3 does not 
seem to be involved in the MEK/ERK MAPK pathway as increased expression levels of 
arrestin 3 in Jurkat cells did not affect the inhibition by PD98059 (MEK inhibitor).  
 
A possible explanation to this observation is that arrestins serve as molecular scaffolds 
for the p38 MAPK pathway (figure 6.2a) and this hypothesis is supported by several 
publications in the current literature, where it has been shown that arrestins act as 
scaffold for numerous signalling proteins including MAPK [81,179]. However, further 
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experiments need to be done to investigate the involvement of other signalling 
molecules in the p38 pathway and to see if there is direct interaction between affected 
signalling molecules and arrestins. With that hypothesis, it is possible that arrestin 3 
acts as a scaffold indirectly to MEK activation (figure 6.2b). Hence, increasing 
expression level of arrestin 3 does not affect MEK inhibition (by PD98059) and that 
there is a significant decrease in migration of Jurkat cells in the CXCR4/CXCL12 
signalling axis.  
 
 
 
Figure 6.2 (adapted from DeWire et al. (2007) [179]): Arrestin scaffolds for signalling. (a) A schematic 
diagram to illustrate arrestin scaffold for p38 activation. There is a possibility that p38 bind arrestin 3 
directly and thus, changes in expression level of arrestin 3 affects p38 inhibition (by SB2032580), 
resulting in reduction of inhibition of cellular migration. Further experiments need to be done to 
investigate other MAPKK signalling molecules that bind to arrestins directly or indirectly (depicted by 
dotted lines). (b) Arrestin scaffold for ERK activation. ERK 1/2 and Raf-1 bind arrestin 3 directly, and 
MEK-1 binds indirectly. It is not known which residues of arrestin 3 bind ERK and Raf-1.  
 
Numerous receptors that require arrestins for migration also promote arrestins’ 
dependent association with MAPKs [180,182,375], but the consequences of these 
signalling events are still poorly understood. These experimental observations 
highlight the potential for inhibitors of well-validated signalling targets, such as PI3K 
and PKC, to be ineffective against certain diseases where CXCR4/CXCL12 signalling 
occurs [286].  
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Arrestin, GRK [146,191] and PKC may be involved in migration but their suitability as 
targets to block migration for therapeutic potential is low due to their ubiquitous 
involvement in GPCR signalling and the high possibility of potential pathological 
signalling by preventing desensitisation of receptors. Identifying players in arrestin-
dependent signalling to migration is likely to offer higher validity targets. It is clear that 
arrestin 3 is involved in CXCR4/CXCL12 signalling axis (conclusion 6) and there is a 
possibility that it may be via MAPK pathway (conclusion 7). However, a specific role 
for arrestin-dependent sequestration of MAPKs in chemotaxis has not been shown.  
 
Table 6.1 lists the protein targets described in this thesis regarding their validity as 
therapeutic agents against CXCL12-induced migration via CXCR4. Recently, an atypical 
second CXCL12 receptor, ACKR3 has been described to be essential in signalling to 
migration by acting as a CXCL12 scavenger to regulate local chemokine availability and 
directly modulating arrestin mediated signalling cascades [401]. This complicates the 
CXCR4/CXCL12 signalling network. Therefore, there is a need to investigate and 
dissect the contributions of CXCR4 and ACKR3 to the different steps of metastasis as 
both CXCR4 and ACKR3 have been found to enhance tumour growth and metastasis 
formation by binding to CXCL12 [402].  
 
Targeting chemokine receptors directly may represent a poor target choice for anti-
migratory therapy but it is advantageous to identify key players amongst signalling 
molecules and understand downstream signalling transduction upon chemokine 
receptor activation to allow successful treatment of patients. Targeting arrestin directly 
does not represent a valid strategy for two reasons. Firstly, all GPCRs require arrestin 
for regulation and inhibiting arrestin may result in a decrease in arrestin-dependent 
signalling, where it occurred, but would also lead to a reduction in desensitisation in 
GPCRs in ‘classical’ G-protein mediate signalling. This could lead to severe negative 
effects physiologically. Secondly, there are no small molecule inhibitors of arrestin at 
present, which adds a further element of complexity with regard to the de novo 
discovery of small molecule arrestin antagonists.  
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Table 6.1: Validity of proteins as targets in CXCL12-induced chemotaxis.  
 
Protein Target 
validity  
Rationale Refs  
CXCR4  Moderate AMD3100 acts as CXCR4 antagonist 
(or partial agonist) and an allosteric 
agonist of ACKR3. Blockade of 
chemokine receptor signalling is 
complex due to signalling 
redundancy and possibility crosstalk 
between receptors. Another 
complexity is that ACKR3 and 
CXCR4 can oligomerize either with 
one another of its own family or each 
other. 
[270,403,404] 
PKC Inconclusive PKC inhibition using pan-isoform 
PKC inhibitors have different effects 
in different cell lines. Further 
experiments need to be done as PKC 
has an unclear role in CXCL12-
induced migration. PKC isoform 
specificity should also be taken into 
account.  
Chapter 4 
Arrestin Moderate, 
but needs to 
be under 
serious 
consideration 
Other than arrestin-dependent 
signalling and arrestin acting as 
molecular scaffolds, arrestin is 
required for desensitisation of all 
GPCRs and therefore, it is most likely 
to impact other GPCR signalling 
adversely.  Arrestin subtype 
specificity would also need to be 
considered.  
Chapter 5 
p38 
MAPK 
Good p38 MAPK inhibition is effective in 
blocking CXCL12-induced migration 
of Jurkat cells but may lack 
specificity between receptor types.  It 
is arrestin 3- dependent but 
involvement of arrestin needs to be 
investigated further.  
Chapter 5 
MEK/ERK 
MAPK 
Good  MEK inhibition is effective in 
blocking CXCL12-induced migration 
of Jurkat cells and is not arrestin 3-
dependent signalling. 
Chapter 5 
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6.2. Future work  
 
As discussed in the introduction (chapter 1), the aim of this thesis is to understand the 
role and interactions of proteins of interest in CXCL12-induced signalling events upon 
CXCR4 activation. This was achieved to a certain extent, but involvement of ACKR3 
was not considered in this thesis. Signalling stimulated by CXCL12 via CXCR4 was 
shown to occur through arrestin-dependent signalling and it seems to also involve p38 
MAPK in migration of cells. There are limitations to the conclusions as there may be 
involvement of ACKR3 on CXCL12/CXCR4 signalling axis and how conformational 
changes in arrestins upon receptor activation contribute to signalling is still poorly 
understood. The conclusions drawn from this thesis allows more in-depth proteomic 
characterisations to be undertaken. Involvement of arrestin 3 in CXCL12-induced 
migration has been established, therefore, the future work based on this thesis falls 
into these areas:  
 
1. Interactions of ACKR3 in CXCR4/CXCL12 signalling axis. 
2. Involvement of ACKR3 in arrestin-dependent signalling in CXCR4/CXCL12 
axis.  
3. Further investigations in different PKC isoforms affecting cell migration. 
4. Investigations in conformational changes in arrestins upon CXCR4 activation 
contribute to its signalling and endocytic functions.  
 
The first two areas will be complex as it involves experiments using ACKR3 antagonists, 
which can only obtained from Chemocentryx and it is not for sale [405]. Another 
approach that could be considered is CRISPR/Cas9 system (Clustered Regularly 
Interspaced Short Palindromic Repeats) [406]. By knocking out ACKR3 gene using 
CRISPR/Cas9 system, it is possible to look at CXCR4 in isolation and to study the 
importance of each receptor in cells.  
 
ACKR3 expression seems to be enhanced during pathological inflammation and 
tumour development [404]. Emerging evidences suggest that ACKR3 can be an 
attractive therapeutic target for autoimmune diseases and cancer [402,407]. There is 
suggestion that ACKR3/CXCR4 heterodimerization, arrestin-mediated signalling and 
modulation of CXCL12 responsiveness by ACKR3 has an impact on understanding the 
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roles of CXCL12 biology in health and disease [404]. Hence, there is an importance in 
understanding the role of ACKR3 in CXCL12/CXCR4 signalling axis. Obtaining ACKR3 
antagonists would allow investigations of relationship between arrestins, CXCR4 and 
ACKR3 and how each component contribute to CXCL12-induced signalling. Area 3 will 
involve further small molecule validation using other inhibitors, and also involve 
additional siRNA experiments to understand the role of different PKC isoforms in 
CXCL12-induced signalling. Investigations using small molecule inhibitors and other 
cell lines can further establish the role of PKC.  
 
Finally, area 4 will involve studying protein-protein interaction in real time using 
bioluminescence resonance energy transfer (BRET). BRET requires proteins of interest 
and suitable controls that are labelled with either a donor or acceptor molecule. BRET 
involves nonradiative (dipole-dipole) transfer of energy from a donor enzyme to a 
suitable acceptor molecule after substrate oxidation [408]. The transfer of excited-state 
energy is inversely proportional to the sixth power of the distance between donor and 
acceptor dipoles, and this distance is comparable to the dimensions of biological 
macromolecular protein complexes [409].  Thus, this makes BRET an appropriate 
method for assessing protein-protein interactions. There are three BRET derivations; 
BRET1, BRET2, and eBRET. The differences between them lies in use of different 
substrates and the donor and acceptor emission peak separation, where the more they 
separate, the easier that the donor and acceptor emissions to be distinguished, thereby 
reducing the background [408].  
 
The BRET technique is most suited to investigate ligand-modulated interactions as 
changes in BRET signal after reagent addition provide good evidence for interaction 
specificity, and changes in BRET signal may represent an increase or decrease in the 
number and/or rate of interactions between the proteins of interest [410]. The proteins 
of interest are genetically fused to the bioluminescent donor or fluorescent acceptor, 
and a suitable substrate is selected for the appropriate combination for BRET assay. 
The BRET technology uses the combination of a 35 kDa Renilla Luciferase (RLuc) as 
energy donor, a 27 kDa variant of GFP as energy acceptor, and appropriate substrate 
for different BRET derivatives. In this case, CXCR4 receptor is fused to RLuc3 as donor 
molecule and human arrestin 3 is fused to GFP10 as acceptor molecule; these plasmid 
constructs were gifted from Professor N. Heveker (University of Montreal). With these 
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constructs, DeepBlueC (coelenterazine 400a) is used as a substrate to perform the 
BRET2 assay. BRET detection after addition of substrate is done with the use of two 
distinct filters; one filter transmits the ‘short-wavelength emission’ that should consist 
of the donor emission of short wavelengths (excluding as much of the acceptor 
emission) and the other filter transmits the ‘long-wavelength emission’ that consists of 
the acceptor emission (if present) in addition to the donor emission of longer 
wavelengths [408]. In BRET2 assay, the example filters of ‘short-wavelength emission’ 
is 370-450 nm and ‘long-wavelength emission’ is 500-530 nm [410]. BRET signal is 
analysed with this formula below:  
 
 
 
We started setting up the necessary experimental set-up in our laboratory and had 
some encouraging preliminary results, but more optimisation is needed to be done as 
we could not obtain clear confirmation that there was a BRET signal between CXCR4-
RLuc3 and h-arrestin 3-GFP10 upon CXCL12 stimulation. A difference in emission 
readings between untransfected, transfected and donor-only controls were detected 
but the BRET signal was not as high as what was obtained in comparable experiments 
published in other labs [410]. Below is a table showing the possible problems and 
solutions to help in optimisation for future work (table 6.2).  
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Table 6.2: Troubleshooting table for BRET2 assays [323,409,410] 
 
Problem Possible reason Solution 
Cells were lost and 
easily detached 
after transfection, 
despite extreme 
care.  
Cells that were usually used in laboratory are MCF-7 
cells and Jurkat cells. These cells were transfected prior 
to BRET assays: 
 
• MCF-7 cells - Chemically transfected and may 
not be sufficiently adherent.  
• Jurkat cells - Electroporation transfected and 
cells are usually more fragile and less viable after 
electroporation transfected.  
• Consider using different plastics or coating wells (e.g. with poly 
(L-lysine)).  
• Consider using different cell lines that are easily transfected, 
such as HEK-293 cells. 
There were low 
relative 
luminescence or 
fluorescence 
counts  
• There is poor protein expression. 
• The cell number is low. 
• Substrate is not viable. 
• Reducing agent present. 
• Instrumentation (CLARIOstar, BMG LABTECH) is 
not functioning correctly, and filters available are not 
suitable. 
• Optimise and consider an alternative transfection strategy. 
• Increase cell concentration and consider changing cell lines. 
• Consider using new aliquot of substrate and ensure dilution of 
substrate stock to a working concentration in assay buffer is 
accurate. 
• Ensure buffers do not include reducing agents such as ascorbic 
acid and also, ensure that it was stored appropriate and made up 
accordingly to perform BRET2 assays.  
• Familiarise the use of instrument with protocols available and 
the help of Clariostar technicians.  
• Check instrument setup and consider recalibration. Ensure that 
suitable filters were available for BRET2 assays.  
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Studying the relationship between chemokine receptor and arrestins upon activation 
would help in understanding the conformational changes in arrestins upon CXCR4 
activation, and the BRET technology would enable us to study protein-protein 
interactions in live cells where they are expressed in a near-physiological environment 
in the correct cellular compartment [410]. Once that has been established, studying 
protein-protein interactions in the presence or absence of small molecule antagonists 
is possible, and hence, further characterising the role of different signalling proteins in 
arrestin-chemokine receptor interaction. As a whole, this future work, in addition to 
the research presented in this thesis, has the potential to enhance productivity in area 
of pharmacology, particularly CXCR4/CXCL12 signalling axis, and has the possibility to 
achieve therapeutic potential.  
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